{"matching_results": 34015, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1271, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1088}, {"key": "negative", "matching_results": 161}, {"key": "neutral", "matching_results": 22}]}]}, {"key": "tickerreport.com", "matching_results": 848, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 772}, {"key": "negative", "matching_results": 76}]}]}, {"key": "wkrb13.com", "matching_results": 815, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 713}, {"key": "negative", "matching_results": 102}]}]}, {"key": "zolmax.com", "matching_results": 813, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 745}, {"key": "negative", "matching_results": 67}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "watchlistnews.com", "matching_results": 811, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 740}, {"key": "negative", "matching_results": 70}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "thelincolnianonline.com", "matching_results": 803, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 711}, {"key": "negative", "matching_results": 91}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "theolympiareport.com", "matching_results": 725, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 619}, {"key": "negative", "matching_results": 103}, {"key": "neutral", "matching_results": 3}]}]}, {"key": "freelancer.com.co", "matching_results": 630, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 565}, {"key": "negative", "matching_results": 57}, {"key": "neutral", "matching_results": 8}]}]}, {"key": "findmarketresearch.org", "matching_results": 583, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 469}, {"key": "negative", "matching_results": 114}]}]}, {"key": "marketscreener.com", "matching_results": 536, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 314}, {"key": "negative", "matching_results": 215}, {"key": "neutral", "matching_results": 7}]}]}]}], "results": [{"id": "IA_kTfdaVOfakwt6LNjD0WmOOPIki-tAZprWYsabdRcDXibLnyWY7FPRBYQNuUHg", "result_metadata": {"score": 38.045483}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0.37081, "label": "positive"}, "text": "Morgan Stanley", "relevance": 0.33, "type": "Person"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Morgan Stanley", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Morgan_Stanley"}], "categories": [{"score": 0.793954, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Morgan Stanley Form", "sentiment": {"score": 0.37081, "label": "positive"}, "relevance": 0.964281}, {"text": "TAKEDA", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.419862}]}, "crawl_date": "2018-11-02T10:36:16Z", "url": "https://www.moneyam.com/action/news/showArticle?id=6192654", "host": "moneyam.com", "text": "(a) Name of exempt principal trader: Morgan Stanley MUFG Securities Co., Ltd.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-02T10:30:00Z", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.753791, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Morgan Stanley MUFG Securities Co.", "relevance": 0.512741, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.461003, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}], "sentiment": {"document": {"score": 0.554031, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" YES - Shire plc 2.", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE EXEMPT PRINCIPAL TRADER If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Morgan Stanley", "relevance": 0.95746, "dbpedia_resource": "http://dbpedia.org/resource/Morgan_Stanley"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.840557, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Offer and acceptance", "relevance": 0.823309, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.758372, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}], "categories": [{"score": 0.535779, "label": "/finance/investing/day trading"}, {"score": 0.49614, "label": "/finance/financial news"}, {"score": 0.468064, "label": "/finance/investing/funds/mutual funds"}], "relations": [{"type": "employedBy", "sentence": "(a) Name of exempt principal trader: Morgan Stanley MUFG Securities Co., Ltd. (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Company Limited (c) Name of the party to the offer with which exempt principal trader is connected: Shire plc (d) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 01 NOVEMBER 2018 (e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?", "score": 0.612341, "arguments": [{"text": "principal trader", "location": [19, 35], "entities": [{"type": "Person", "text": "principal trader"}]}, {"text": "Morgan Stanley MUFG Securities Co., Ltd.", "location": [37, 77], "entities": [{"type": "Organization", "text": "Morgan Stanley MUFG Securities Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "exempt principal trader", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.988172}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.7531}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.745807}, {"text": "Stanley MUFG Securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.74401}, {"text": "offeror/offeree Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.716678}, {"text": "Shire plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.703683}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.69767}, {"text": "possible cash offer", "sentiment": {"score": 0.409607, "label": "positive"}, "relevance": 0.683774}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.613336}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.611139}, {"text": "short positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.609297}, {"text": "Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.608448}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.590309}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.58991}, {"text": "N/A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535479}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531701}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531524}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530941}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522007}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521756}, {"text": "Morgan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519405}, {"text": "Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51909}, {"text": "Ltd.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51907}, {"text": "rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515957}]}, "extracted_metadata": {"sha1": "aa3f13105d101b011cbe61006551c967b917e91b", "filename": "1541154976193.zip-2e413a896162e8072655711f1ea3941c.xml", "file_type": "json"}, "title": "Morgan Stanley Form 8.5 (EPT/NON-RI) - TAKEDA PHARMACEUTICAL", "forum_title": "MoneyAM News"}, {"id": "6bvWZosdZFB8k6iuhkyooUwB2WUBBE2jUdwqFU_b2o-RgiNHFz5_vdvVdWdLyt71", "result_metadata": {"score": 36.72267}, "author": "Market Research Future", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd.", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.462188, "label": "negative"}, "text": "Savient Pharmaceuticals", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Savient Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Savient_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca plc", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": -0.226432, "label": "negative"}, "text": "Merck", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "AstraZeneca", "relevance": 0.865782, "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}, {"text": "Pharmaceutical industry", "relevance": 0.779144, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}], "categories": [{"score": 0.738135, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.460397, "label": "/health and fitness/drugs"}], "relations": [{"type": "employedBy", "sentence": "Gout Market Detail Analysis | Focusing on major Vendors as Takeda Pharmaceutical Company Ltd., Savient Pharmaceuticals, AstraZeneca plc, Merck, etc", "score": 0.449139, "arguments": [{"text": "Vendors", "location": [48, 55], "entities": [{"type": "Person", "text": "Vendors"}]}, {"text": "Takeda Pharmaceutical Company Ltd.", "location": [59, 93], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.927789}, {"text": "AstraZeneca plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.737135}, {"text": "Gout Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.653269}, {"text": "Savient Pharmaceuticals", "sentiment": {"score": -0.462188, "label": "negative"}, "relevance": 0.547548}, {"text": "major Vendors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531303}, {"text": "Merck", "sentiment": {"score": -0.226432, "label": "negative"}, "relevance": 0.296022}]}, "crawl_date": "2018-11-02T08:25:36Z", "url": "https://www.openpr.com/news/1347954/Gout-Market-Detail-Analysis-Focusing-on-major-Vendors-as-Takeda-Pharmaceutical-Company-Ltd-Savient-Pharmaceuticals-AstraZeneca-plc-Merck-etc.html", "host": "openpr.com", "text": "Key Players: Some of the key players in the gout market are Takeda Pharmaceutical Company Ltd., Savient Pharmaceuticals, AstraZeneca plc, Merck& Co.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-02T08:16:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": -0.488905, "label": "negative"}, "text": "gout", "relevance": 0.94832, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gout", "dbpedia_resource": "http://dbpedia.org/resource/Gout"}}, {"count": 3, "sentiment": {"score": -0.0235047, "label": "negative"}, "text": "Europe", "relevance": 0.558693, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.454416, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": -0.312655, "label": "negative"}, "text": "Center for Disease Control and Prevention", "relevance": 0.422339, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "Centers for Disease Control and Prevention", "dbpedia_resource": "http://dbpedia.org/resource/Centers_for_Disease_Control_and_Prevention"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.375524, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.37131, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.290884, "label": "negative"}, "text": "pseudogout", "relevance": 0.361736, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Chondrocalcinosis", "dbpedia_resource": "http://dbpedia.org/resource/Chondrocalcinosis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas Pharma Inc.", "relevance": 0.352084, "type": "Company", "disambiguation": {"subtype": [], "name": "Astellas Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Astellas_Pharma"}}, {"count": 1, "sentiment": {"score": -0.517373, "label": "negative"}, "text": "U.S.", "relevance": 0.347805, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck& Co. Inc.", "relevance": 0.346391, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eurostat", "relevance": 0.345772, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd.", "relevance": 0.338003, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.33559, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": -0.43131, "label": "negative"}, "text": "Savient Pharmaceuticals", "relevance": 0.334376, "type": "Company", "disambiguation": {"subtype": [], "name": "Savient Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Savient_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.323959, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": -0.336374, "label": "negative"}, "text": "Allopurinol", "relevance": 0.304687, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.287264, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": -0.448984, "label": "negative"}, "text": "Ibuprofen", "relevance": 0.273864, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Probenecid", "relevance": 0.263553, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Diclofenac", "relevance": 0.263396, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "19.2%", "relevance": 0.263396, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "8.4%", "relevance": 0.263396, "type": "Quantity"}], "sentiment": {"document": {"score": -0.423988, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Reports", "keywords": [{"text": "Reports"}]}, "sentence": " Reports Provides the classifications and industry Structure with Top Industry Players, Recent Trends and Industry Dynamics up to 2023.", "object": {"text": "the classifications and industry Structure", "keywords": [{"text": "classifications"}, {"text": "industry Structure"}]}, "action": {"verb": {"text": "Provides", "tense": "present"}, "text": "Provides", "normalized": "Provides"}}, {"subject": {"text": "Gout Market - Overview Global gout market", "keywords": [{"text": "Overview Global gout"}, {"text": "gout market"}]}, "sentence": " Gout Market - Overview Global gout market is expected to register a healthy CAGR of 8.4% during the forecast.", "object": {"text": "a healthy CAGR of 8.4%", "keywords": [{"text": "healthy CAGR"}], "entities": [{"type": "Quantity", "text": "8.4"}]}, "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "Gout", "keywords": [{"text": "Gout"}]}, "sentence": " Gout is a common form of inflammatory arthritis.", "object": {"text": "a common form of inflammatory arthritis", "keywords": [{"text": "inflammatory arthritis"}, {"text": "common form"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "factors", "keywords": [{"text": "factors"}]}, "sentence": " Major risk factors that are likely to cause gout are certain health factors such as high cholesterol, high blood pressure, and certain medications that can cause high levels of uric acid.", "object": {"text": "gout", "keywords": [{"text": "gout"}]}, "action": {"verb": {"text": "cause", "tense": "future"}, "text": "to cause", "normalized": "to cause"}}, {"subject": {"text": "gout", "keywords": [{"text": "gout"}]}, "sentence": " Major risk factors that are likely to cause gout are certain health factors such as high cholesterol, high blood pressure, and certain medications that can cause high levels of uric acid.", "object": {"text": "certain health factors such as high cholesterol, high blood pressure, and certain medications that can cause high levels of uric acid", "keywords": [{"text": "certain health factors"}, {"text": "certain medications"}, {"text": "uric acid"}, {"text": "high blood pressure"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "certain medications", "keywords": [{"text": "certain medications"}]}, "sentence": " Major risk factors that are likely to cause gout are certain health factors such as high cholesterol, high blood pressure, and certain medications that can cause high levels of uric acid.", "object": {"text": "high levels of uric acid", "keywords": [{"text": "uric acid"}, {"text": "high levels"}]}, "action": {"verb": {"text": "cause", "tense": "future"}, "text": "can cause", "normalized": "can cause"}}, {"subject": {"text": "diet", "keywords": [{"text": "diet"}]}, "sentence": " Additionally, factors such as diet containing red meat, obesity, and high consumption of alcohol can cause gout.", "object": {"text": "red meat, obesity, and high consumption of alcohol", "keywords": [{"text": "red meat"}, {"text": "high consumption"}, {"text": "obesity"}, {"text": "alcohol"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "containing", "normalized": "contain"}}, {"subject": {"text": "factors such as diet containing red meat, obesity, and high consumption of alcohol", "keywords": [{"text": "high consumption"}, {"text": "red meat"}, {"text": "obesity"}, {"text": "factors"}]}, "sentence": " Additionally, factors such as diet containing red meat, obesity, and high consumption of alcohol can cause gout.", "object": {"text": "gout", "keywords": [{"text": "gout"}]}, "action": {"verb": {"text": "cause", "tense": "future"}, "text": "can cause", "normalized": "can cause"}}, {"subject": {"text": "The global gout market", "keywords": [{"text": "global gout market"}]}, "sentence": " The global gout market is expected to grow a healthy growth due to various factors such as increasing obesity rates, increasing aging mass, rising population indulging in smoking, and low fiber diet along with the increasing healthcare expenditure.", "object": {"text": "a healthy growth", "keywords": [{"text": "healthy growth"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "is expected to grow", "normalized": "be expect to grow"}}, {"subject": {"text": "increasing aging mass, rising population", "keywords": [{"text": "population"}, {"text": "mass"}]}, "sentence": " The global gout market is expected to grow a healthy growth due to various factors such as increasing obesity rates, increasing aging mass, rising population indulging in smoking, and low fiber diet along with the increasing healthcare expenditure.", "object": {"text": "in smoking, and low fiber diet along with the increasing healthcare expenditure", "keywords": [{"text": "healthcare expenditure"}, {"text": "low fiber diet"}, {"text": "smoking"}]}, "action": {"verb": {"text": "indulge", "tense": "present"}, "text": "indulging", "normalized": "indulge"}}, {"subject": {"text": "Some of the key players in the gout market", "keywords": [{"text": "gout market"}, {"text": "key players"}]}, "sentence": " Key Players: Some of the key players in the gout market are Takeda Pharmaceutical Company Ltd., Savient Pharmaceuticals, AstraZeneca plc, Merck& Co. Inc., Inc.Ardelyx, Inc., Astellas Pharma Inc., and Novartis AG.", "object": {"text": "Takeda Pharmaceutical Company Ltd., Savient Pharmaceuticals, AstraZeneca plc, Merck& Co. Inc.", "keywords": [{"text": "AstraZeneca plc"}, {"text": "Pharmaceutical Company Ltd."}, {"text": "Savient Pharmaceuticals"}, {"text": "Merck"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}, {"type": "Company", "text": "Savient Pharmaceuticals", "disambiguation": {"subtype": [], "name": "Savient Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Savient_Pharmaceuticals"}}, {"type": "Company", "text": "Merck& Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The Americas", "keywords": [{"text": "Americas"}]}, "sentence": " Request Sample copy at www.marketresearchfuture.com/sample_request/5909 Gout Market - Regional Analysis: The Americas dominates the global gout market owing to the increasingly obese population and increasing rate of cigarette smokers.", "object": {"text": "the global gout market owing to the increasingly obese population and increasing rate of cigarette smokers", "keywords": [{"text": "increasingly obese population"}, {"text": "global gout market"}, {"text": "cigarette smokers"}, {"text": "rate"}]}, "action": {"verb": {"text": "dominate", "tense": "present"}, "text": "dominates", "normalized": "dominate"}}, {"subject": {"text": "the growth of gout in the North American region", "keywords": [{"text": "North American region"}, {"text": "gout"}, {"text": "growth"}], "entities": []}, "sentence": " Additionally, increasing obesity rates along with the increasing healthcare expenditure are likely to enhance the growth of gout in the North American region.", "object": {"text": "the increasing healthcare expenditure", "keywords": [{"text": "healthcare expenditure"}]}, "action": {"verb": {"text": "enhance", "tense": "future"}, "text": "to enhance", "normalized": "to enhance"}}, {"subject": {"text": "high cholesterol levels", "keywords": [{"text": "high cholesterol levels"}]}, "sentence": " For instance, according to the Center for Disease Control and Prevention, in 2015, 1 in 8 American adults had high cholesterol levels.", "action": {"verb": {"text": "have", "tense": "past"}, "text": "had", "normalized": "have"}}, {"subject": {"text": "on healthcare expenditure", "keywords": [{"text": "healthcare expenditure"}]}, "sentence": " Additionally, around USD 3.2 trillion was spent on healthcare expenditure in the U.S. Europe accounts for the second largest market due to increasing aging mass and increasing obesity rates.", "action": {"verb": {"text": "spend", "tense": "past"}, "text": "was spent", "normalized": "be spend"}}, {"subject": {"text": "healthcare expenditure in the U.S. Europe", "keywords": [{"text": "healthcare expenditure"}, {"text": "U.S. Europe"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Additionally, around USD 3.2 trillion was spent on healthcare expenditure in the U.S. Europe accounts for the second largest market due to increasing aging mass and increasing obesity rates.", "object": {"text": "for the second largest market due to increasing aging mass and increasing obesity rates", "keywords": [{"text": "obesity rates"}, {"text": "largest market"}, {"text": "mass"}]}, "action": {"verb": {"text": "account", "tense": "present"}, "text": "accounts", "normalized": "account"}}, {"subject": {"text": "increasing healthcare spending along with the rising demand for technologically advanced treatments", "keywords": [{"text": "technologically advanced treatments"}, {"text": "healthcare spending"}, {"text": "demand"}]}, "sentence": " Additionally, increasing government initiatives and increasing healthcare spending along with the rising demand for technologically advanced treatments are driving the growth of the gout market in Europe.", "object": {"text": "driving the growth of the gout market in Europe", "keywords": [{"text": "gout market"}, {"text": "growth"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "increasing government initiatives and increasing healthcare spending along with the rising demand for technologically advanced treatments", "keywords": [{"text": "technologically advanced treatments"}, {"text": "healthcare spending"}, {"text": "government initiatives"}, {"text": "demand"}]}, "sentence": " Additionally, increasing government initiatives and increasing healthcare spending along with the rising demand for technologically advanced treatments are driving the growth of the gout market in Europe.", "object": {"text": "the growth of the gout market in Europe", "keywords": [{"text": "gout market"}, {"text": "growth"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "are driving", "normalized": "be drive"}}, {"subject": {"text": "Eurostat", "keywords": [{"text": "Eurostat"}], "entities": [{"type": "Company", "text": "Eurostat"}]}, "sentence": " For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above.", "object": {"text": "that over 19.2% of the population in Europe was aged 65 and above", "keywords": [{"text": "population"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Quantity", "text": "19.2"}]}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "Eurostat estimated that over 19.2% of the population in Europe", "keywords": [{"text": "Eurostat"}, {"text": "population"}, {"text": "Europe"}], "entities": [{"type": "Company", "text": "Eurostat"}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Quantity", "text": "19.2"}]}, "sentence": " For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above.", "object": {"text": "aged 65 and above"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "This"}, "sentence": " This increasing older population is likely to drive the growth of the gout market.", "object": {"text": "older population", "keywords": [{"text": "older population"}]}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "This increasing older population", "keywords": [{"text": "older population"}]}, "sentence": " This increasing older population is likely to drive the growth of the gout market.", "object": {"text": "likely to drive the growth of the gout market", "keywords": [{"text": "gout market"}, {"text": "growth"}], "entities": [{"type": "HealthCondition", "text": "gout", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gout", "dbpedia_resource": "http://dbpedia.org/resource/Gout"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This increasing older population", "keywords": [{"text": "older population"}]}, "sentence": " This increasing older population is likely to drive the growth of the gout market.", "object": {"text": "the growth of the gout market", "keywords": [{"text": "gout market"}, {"text": "growth"}], "entities": [{"type": "HealthCondition", "text": "gout", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gout", "dbpedia_resource": "http://dbpedia.org/resource/Gout"}}]}, "action": {"verb": {"text": "drive", "tense": "future"}, "text": "to drive", "normalized": "to drive"}}, {"subject": {"text": "gout whose growth", "keywords": [{"text": "growth"}]}, "sentence": " Asia Pacific is the fastest growing market for gout whose growth is attributed to the rising population which in turn increases the overall patient population, rising population indulging in smoking, and low fiber diet.", "object": {"text": "to the rising population which in turn increases the overall patient population, rising population indulging in smoking, and low fiber diet", "keywords": [{"text": "overall patient population"}, {"text": "low fiber diet"}, {"text": "turn"}, {"text": "smoking"}]}, "action": {"verb": {"text": "attribute", "tense": "past"}, "text": "is attributed", "normalized": "be attribute"}}, {"subject": {"text": "the rising population", "keywords": [{"text": "population"}]}, "sentence": " Asia Pacific is the fastest growing market for gout whose growth is attributed to the rising population which in turn increases the overall patient population, rising population indulging in smoking, and low fiber diet.", "object": {"text": "the overall patient population", "keywords": [{"text": "overall patient population"}]}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increases", "normalized": "increase"}}, {"subject": {"text": "the increasing healthcare expenditure and demand for new treatment options along with the rise in the standard of living", "keywords": [{"text": "new treatment options"}, {"text": "healthcare expenditure"}, {"text": "demand"}, {"text": "rise"}]}, "sentence": " Additionally, the increasing healthcare expenditure and demand for new treatment options along with the rise in the standard of living are likely to drive the growth of the market.", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "future"}, "text": "to drive", "normalized": "to drive"}}, {"subject": {"text": "the major contributors", "keywords": [{"text": "major contributors"}], "entities": [{"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}]}, "sentence": " India and China are the major contributors to the market growth due to the rapid development of healthcare infrastructure in these regions and increasing demand for diagnostic services.", "object": {"text": "demand", "keywords": [{"text": "demand"}]}, "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "the Middle East and Africa", "keywords": [{"text": "Middle East"}, {"text": "Africa"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}]}, "sentence": " On the other hand, the Middle East and Africa is expected to witness a slow growth due to limited access to healthcare services and affordability issues among individuals.", "object": {"text": "a slow growth due to limited access to healthcare services and affordability issues among individuals", "keywords": [{"text": "affordability issues"}, {"text": "slow growth"}, {"text": "limited access"}, {"text": "services"}], "entities": []}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "is expected to witness", "normalized": "be expect to witness"}}, {"subject": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "sentence": " In the Middle East, the growth of the market is driven by the increasing availability of new and advanced diagnostic and treatment methods for various chronic diseases.]", "object": {"text": "driven by the increasing availability of new and advanced diagnostic and treatment methods for various chronic diseases", "keywords": [{"text": "various chronic diseases"}, {"text": "treatment methods"}, {"text": "availability"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by the increasing availability of new and advanced diagnostic and treatment methods for various chronic diseases", "keywords": [{"text": "various chronic diseases"}, {"text": "treatment methods"}, {"text": "availability"}]}, "sentence": " In the Middle East, the growth of the market is driven by the increasing availability of new and advanced diagnostic and treatment methods for various chronic diseases.]", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "drive", "tense": "past"}, "text": "is driven", "normalized": "be drive"}}, {"subject": {"text": "The global gout market", "keywords": [{"text": "global gout market"}]}, "sentence": " Gout Market - Segmentation: The global gout market is segmented on the basis of treatment, type, end-user, and diagnosis.", "object": {"text": "segmented on the basis of treatment, type, end-user, and diagnosis", "keywords": [{"text": "end-user"}, {"text": "basis"}, {"text": "treatment"}, {"text": "type"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global gout market", "keywords": [{"text": "global gout market"}]}, "sentence": " Gout Market - Segmentation: The global gout market is segmented on the basis of treatment, type, end-user, and diagnosis.", "object": {"text": "on the basis of treatment, type, end-user, and diagnosis", "keywords": [{"text": "end-user"}, {"text": "basis"}, {"text": "treatment"}, {"text": "type"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " On the basis of type, the market is segmented into tophaceous gout and pseudogout.", "object": {"text": "segmented into tophaceous gout and pseudogout", "keywords": [{"text": "tophaceous gout"}, {"text": "pseudogout"}], "entities": [{"type": "HealthCondition", "text": "pseudogout", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Chondrocalcinosis", "dbpedia_resource": "http://dbpedia.org/resource/Chondrocalcinosis"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " On the basis of type, the market is segmented into tophaceous gout and pseudogout.", "object": {"text": "into tophaceous gout and pseudogout", "keywords": [{"text": "tophaceous gout"}, {"text": "pseudogout"}], "entities": [{"type": "HealthCondition", "text": "pseudogout", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Chondrocalcinosis", "dbpedia_resource": "http://dbpedia.org/resource/Chondrocalcinosis"}}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " On the basis of treatment, the market is segmented into medications and self-care.", "object": {"text": "segmented into medications", "keywords": [{"text": "medications"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " On the basis of treatment, the market is segmented into medications and self-care.", "object": {"text": "into medications", "keywords": [{"text": "medications"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "The medication segment", "keywords": [{"text": "medication segment"}]}, "sentence": " The medication segment is further sub-segmented into Allopurinol, Febuxostat, Probenecid, Indomethacin, Diclofenac, and Ibuprofen.", "object": {"text": "further sub-segmented into Allopurinol, Febuxostat, Probenecid, Indomethacin, Diclofenac, and Ibuprofen", "keywords": [{"text": "Allopurinol"}, {"text": "Probenecid"}, {"text": "Diclofenac"}, {"text": "Ibuprofen"}], "entities": [{"type": "Drug", "text": "Allopurinol"}, {"type": "Drug", "text": "Probenecid"}, {"type": "Drug", "text": "Diclofenac"}, {"type": "Drug", "text": "Ibuprofen"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " On the basis of end-user, the market is segmented into hospital specialty centers and homecare.", "object": {"text": "segmented into hospital specialty centers and homecare", "keywords": [{"text": "hospital specialty centers"}, {"text": "homecare"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}]}, "sentence": " On the basis of end-user, the market is segmented into hospital specialty centers and homecare.", "object": {"text": "into hospital specialty centers and homecare", "keywords": [{"text": "homecare"}, {"text": "hospital specialty centers"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}], "concepts": [{"text": "Gout", "relevance": 0.955342, "dbpedia_resource": "http://dbpedia.org/resource/Gout"}, {"text": "Obesity", "relevance": 0.795044, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}, {"text": "Metabolic syndrome", "relevance": 0.757545, "dbpedia_resource": "http://dbpedia.org/resource/Metabolic_syndrome"}, {"text": "Hypertension", "relevance": 0.634328, "dbpedia_resource": "http://dbpedia.org/resource/Hypertension"}, {"text": "Uric acid", "relevance": 0.624926, "dbpedia_resource": "http://dbpedia.org/resource/Uric_acid"}, {"text": "Hyperuricemia", "relevance": 0.620227, "dbpedia_resource": "http://dbpedia.org/resource/Hyperuricemia"}, {"text": "Arthritis", "relevance": 0.601181, "dbpedia_resource": "http://dbpedia.org/resource/Arthritis"}, {"text": "Kidney stone", "relevance": 0.513076, "dbpedia_resource": "http://dbpedia.org/resource/Kidney_stone"}, {"text": "Hypouricemia", "relevance": 0.492084, "dbpedia_resource": "http://dbpedia.org/resource/Hypouricemia"}, {"text": "Stroke", "relevance": 0.480411, "dbpedia_resource": "http://dbpedia.org/resource/Stroke"}, {"text": "Atherosclerosis", "relevance": 0.475079, "dbpedia_resource": "http://dbpedia.org/resource/Atherosclerosis"}, {"text": "Non-steroidal anti-inflammatory drug", "relevance": 0.467391, "dbpedia_resource": "http://dbpedia.org/resource/Non-steroidal_anti-inflammatory_drug"}, {"text": "Middle East", "relevance": 0.444354, "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}, {"text": "Fructose", "relevance": 0.411254, "dbpedia_resource": "http://dbpedia.org/resource/Fructose"}, {"text": "Purine metabolism", "relevance": 0.410481, "dbpedia_resource": "http://dbpedia.org/resource/Purine_metabolism"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.405457, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Chondrocalcinosis", "relevance": 0.393708, "dbpedia_resource": "http://dbpedia.org/resource/Chondrocalcinosis"}, {"text": "Allopurinol", "relevance": 0.388263, "dbpedia_resource": "http://dbpedia.org/resource/Allopurinol"}, {"text": "Myocardial infarction", "relevance": 0.385317, "dbpedia_resource": "http://dbpedia.org/resource/Myocardial_infarction"}, {"text": "Economics", "relevance": 0.376252, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}, {"text": "Medicine", "relevance": 0.369942, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Urine", "relevance": 0.354778, "dbpedia_resource": "http://dbpedia.org/resource/Urine"}, {"text": "Nutrition", "relevance": 0.353699, "dbpedia_resource": "http://dbpedia.org/resource/Nutrition"}, {"text": "Probenecid", "relevance": 0.347717, "dbpedia_resource": "http://dbpedia.org/resource/Probenecid"}, {"text": "Rheumatology", "relevance": 0.344103, "dbpedia_resource": "http://dbpedia.org/resource/Rheumatology"}, {"text": "Uricosuric", "relevance": 0.343585, "dbpedia_resource": "http://dbpedia.org/resource/Uricosuric"}, {"text": "Diuretic", "relevance": 0.342122, "dbpedia_resource": "http://dbpedia.org/resource/Diuretic"}, {"text": "Diabetes mellitus", "relevance": 0.338921, "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}, {"text": "Atorvastatin", "relevance": 0.331623, "dbpedia_resource": "http://dbpedia.org/resource/Atorvastatin"}, {"text": "Febuxostat", "relevance": 0.324482, "dbpedia_resource": "http://dbpedia.org/resource/Febuxostat"}, {"text": "Novartis", "relevance": 0.324269, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Astellas Pharma", "relevance": 0.318123, "dbpedia_resource": "http://dbpedia.org/resource/Astellas_Pharma"}, {"text": "Blood", "relevance": 0.310591, "dbpedia_resource": "http://dbpedia.org/resource/Blood"}, {"text": "Pharmaceutical drug", "relevance": 0.309682, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Hydrochlorothiazide", "relevance": 0.305888, "dbpedia_resource": "http://dbpedia.org/resource/Hydrochlorothiazide"}, {"text": "Xanthine oxidase", "relevance": 0.305855, "dbpedia_resource": "http://dbpedia.org/resource/Xanthine_oxidase"}, {"text": "The Rising", "relevance": 0.305724, "dbpedia_resource": "http://dbpedia.org/resource/The_Rising"}, {"text": "Childhood obesity", "relevance": 0.301549, "dbpedia_resource": "http://dbpedia.org/resource/Childhood_obesity"}, {"text": "Blood pressure", "relevance": 0.292151, "dbpedia_resource": "http://dbpedia.org/resource/Blood_pressure"}, {"text": "Economic growth", "relevance": 0.29049, "dbpedia_resource": "http://dbpedia.org/resource/Economic_growth"}, {"text": "Health care in the United States", "relevance": 0.290205, "dbpedia_resource": "http://dbpedia.org/resource/Health_care_in_the_United_States"}, {"text": "Supply and demand", "relevance": 0.281735, "dbpedia_resource": "http://dbpedia.org/resource/Supply_and_demand"}, {"text": "Colchicine", "relevance": 0.27945, "dbpedia_resource": "http://dbpedia.org/resource/Colchicine"}], "categories": [{"score": 0.669138, "label": "/health and fitness"}, {"score": 0.468918, "label": "/health and fitness/disease/heart disease"}, {"score": 0.358979, "label": "/health and fitness/disease/cholesterol"}], "relations": [{"type": "partOf", "sentence": "Press release from: Market Research Future Market Research Future Market Research Future Introduces the \"Global Gout Market\" Research Report.", "score": 0.399026, "arguments": [{"text": "Market Research Future Market Research Future Market Research Future Introduces", "location": [20, 99], "entities": [{"type": "Organization", "text": "Market Research Future Market Research Future Market Research Future Introduces"}]}, {"text": "Global Gout Market", "location": [105, 123], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "residesIn", "sentence": "For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above.", "score": 0.412127, "arguments": [{"text": "population", "location": [2244, 2254], "entities": [{"type": "Person", "text": "contributors"}]}, {"text": "Europe", "location": [2258, 2264], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Asia Pacific is the fastest growing market for gout whose growth is attributed to the rising population which in turn increases the overall patient population, rising population indulging in smoking, and low fiber diet.", "score": 0.403134, "arguments": [{"text": "Asia", "location": [2371, 2375], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [2376, 2383], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "The medication segment is further sub-segmented into Allopurinol, Febuxostat, Probenecid, Indomethacin, Diclofenac, and Ibuprofen.", "score": 0.68216, "arguments": [{"text": "Allopurinol", "location": [3641, 3652], "entities": [{"type": "GeopoliticalEntity", "text": "Allopurinol"}]}, {"text": "Febuxostat", "location": [3654, 3664], "entities": [{"type": "GeopoliticalEntity", "text": "Febuxostat"}]}]}, {"type": "locatedAt", "sentence": "The medication segment is further sub-segmented into Allopurinol, Febuxostat, Probenecid, Indomethacin, Diclofenac, and Ibuprofen.", "score": 0.643263, "arguments": [{"text": "Probenecid", "location": [3666, 3676], "entities": [{"type": "GeopoliticalEntity", "text": "Probenecid"}]}, {"text": "Indomethacin", "location": [3678, 3690], "entities": [{"type": "GeopoliticalEntity", "text": "Indomethacin"}]}]}, {"type": "employedBy", "sentence": "The medication segment is further sub-segmented into Allopurinol, Febuxostat, Probenecid, Indomethacin, Diclofenac, and Ibuprofen.", "score": 0.510381, "arguments": [{"text": "Diclofenac", "location": [3692, 3702], "entities": [{"type": "Person", "text": "Diclofenac"}]}, {"text": "Ibuprofen", "location": [3708, 3717], "entities": [{"type": "Organization", "text": "Ibuprofen", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Press release from: Market Research Future Market Research Future Market Research Future Introduces the \"Global Gout Market\" Research Report.", "score": 0.75872, "arguments": [{"text": "Global Gout Market", "location": [105, 123], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Report", "location": [134, 140], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "locatedAt", "sentence": "Reports Provides the classifications and industry Structure with Top Industry Players, Recent Trends and Industry Dynamics up to 2023.", "score": 0.256303, "arguments": [{"text": "Players", "location": [220, 227], "entities": [{"type": "Person", "text": "Players"}]}, {"text": "Structure", "location": [192, 201], "entities": [{"type": "Facility", "text": "Structure"}]}]}, {"type": "timeOf", "sentence": "Request Sample copy at www.marketresearchfuture.com/sample_request/5909 Gout Market - Regional Analysis: The Americas dominates the global gout market owing to the increasingly obese population and increasing rate of cigarette smokers.", "score": 0.681096, "arguments": [{"text": "www.marketresearchfuture.com/sample_request/5909 Gout", "location": [1285, 1338], "entities": [{"type": "Time", "text": "www.marketresearchfuture.com/sample_request/5909 Gout"}]}, {"text": "dominates", "location": [1380, 1389], "entities": [{"type": "EventCommunication", "text": "dominates"}]}]}, {"type": "partOf", "sentence": "Request Sample copy at www.marketresearchfuture.com/sample_request/5909 Gout Market - Regional Analysis: The Americas dominates the global gout market owing to the increasingly obese population and increasing rate of cigarette smokers.", "score": 0.417075, "arguments": [{"text": "Regional Analysis", "location": [1348, 1365], "entities": [{"type": "Organization", "text": "Regional Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Market", "location": [1339, 1345], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Request Sample copy at www.marketresearchfuture.com/sample_request/5909 Gout Market - Regional Analysis: The Americas dominates the global gout market owing to the increasingly obese population and increasing rate of cigarette smokers.", "score": 0.531652, "arguments": [{"text": "Regional Analysis", "location": [1348, 1365], "entities": [{"type": "Organization", "text": "Regional Analysis", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "The Americas", "location": [1367, 1379], "entities": [{"type": "Organization", "text": "The Americas", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Request Sample copy at www.marketresearchfuture.com/sample_request/5909 Gout Market - Regional Analysis: The Americas dominates the global gout market owing to the increasingly obese population and increasing rate of cigarette smokers.", "score": 0.972961, "arguments": [{"text": "The Americas", "location": [1367, 1379], "entities": [{"type": "Organization", "text": "The Americas", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "dominates", "location": [1380, 1389], "entities": [{"type": "EventCommunication", "text": "dominates"}]}]}, {"type": "partOfMany", "sentence": "For instance, according to the Center for Disease Control and Prevention, in 2015, 1 in 8 American adults had high cholesterol levels.", "score": 0.924615, "arguments": [{"text": "adults", "location": [1756, 1762], "entities": [{"type": "Person", "text": "adults"}]}, {"text": "American", "location": [1747, 1755], "entities": [{"type": "GeopoliticalEntity", "text": "American", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Additionally, around USD 3.2 trillion was spent on healthcare expenditure in the U.S. Europe accounts for the second largest market due to increasing aging mass and increasing obesity rates.", "score": 0.508251, "arguments": [{"text": "Europe", "location": [1878, 1884], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "U.S.", "location": [1873, 1877], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "gout market", "sentiment": {"score": 0.119286, "label": "positive"}, "relevance": 0.976549}, {"text": "global gout market", "sentiment": {"score": -0.304517, "label": "negative"}, "relevance": 0.863474}, {"text": "Overview Global gout", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541546}, {"text": "Gout Market Research", "sentiment": {"score": -0.507532, "label": "negative"}, "relevance": 0.514031}, {"text": "Market Research Future", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506931}, {"text": "healthcare expenditure", "sentiment": {"score": -0.444539, "label": "negative"}, "relevance": 0.470847}, {"text": "Research Future Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.438907}, {"text": "Future Market Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43887}, {"text": "tophaceous gout", "sentiment": {"score": -0.290884, "label": "negative"}, "relevance": 0.424743}, {"text": "low fiber diet", "sentiment": {"score": -0.448122, "label": "negative"}, "relevance": 0.419863}, {"text": "obesity rates", "sentiment": {"score": -0.48578, "label": "negative"}, "relevance": 0.394532}, {"text": "fastest growing market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.343367}, {"text": "increasingly obese population", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.336003}, {"text": "high cholesterol", "sentiment": {"score": -0.427057, "label": "negative"}, "relevance": 0.325162}, {"text": "high blood pressure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.324877}, {"text": "overall patient population", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.324517}, {"text": "uric acid", "sentiment": {"score": -0.577792, "label": "negative"}, "relevance": 0.324385}, {"text": "Major risk factors", "sentiment": {"score": -0.427057, "label": "negative"}, "relevance": 0.322157}, {"text": "Research Report", "sentiment": {"score": -0.507532, "label": "negative"}, "relevance": 0.321363}, {"text": "high cholesterol levels", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.320598}, {"text": "certain health factors", "sentiment": {"score": -0.427057, "label": "negative"}, "relevance": 0.320163}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.31848}, {"text": "Astellas Pharma Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.317164}, {"text": "North American region", "sentiment": {"score": -0.454188, "label": "negative"}, "relevance": 0.313562}, {"text": "Request Sample copy", "sentiment": {"score": -0.268075, "label": "negative"}, "relevance": 0.312027}, {"text": "technologically advanced treatments", "sentiment": {"score": 0.470364, "label": "positive"}, "relevance": 0.311445}, {"text": "new treatment options", "sentiment": {"score": -0.346761, "label": "negative"}, "relevance": 0.310139}, {"text": "key players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.307829}, {"text": "hospital specialty centers", "sentiment": {"score": -0.302694, "label": "negative"}, "relevance": 0.305723}, {"text": "market growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.30392}, {"text": "Middle East", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.302168}, {"text": "various chronic diseases", "sentiment": {"score": -0.353765, "label": "negative"}, "relevance": 0.301862}, {"text": "largest market", "sentiment": {"score": -0.517373, "label": "negative"}, "relevance": 0.296706}, {"text": "older population", "sentiment": {"score": -0.488905, "label": "negative"}, "relevance": 0.275592}, {"text": "healthy growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.273471}, {"text": "Industry Players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.272115}, {"text": "industry Structure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.271128}, {"text": "Press release", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.270646}, {"text": "high levels", "sentiment": {"score": -0.471138, "label": "negative"}, "relevance": 0.270468}, {"text": "healthcare spending", "sentiment": {"score": 0.470364, "label": "positive"}, "relevance": 0.269033}, {"text": "slow growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.267824}, {"text": "high consumption", "sentiment": {"score": -0.353988, "label": "negative"}, "relevance": 0.267282}, {"text": "Industry Dynamics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.267261}, {"text": "various factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.266508}, {"text": "healthy CAGR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.265965}, {"text": "common form", "sentiment": {"score": -0.90053, "label": "negative"}, "relevance": 0.265716}, {"text": "Co. Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.264047}, {"text": "inflammatory arthritis", "sentiment": {"score": -0.90053, "label": "negative"}, "relevance": 0.263679}, {"text": "higher levels", "sentiment": {"score": -0.684446, "label": "negative"}, "relevance": 0.263268}, {"text": "healthcare infrastructure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.263174}]}, "extracted_metadata": {"sha1": "2c5a0ce9342ce7fb73404eefd77746c777d4f587", "filename": "1541147136969.zip-948cb2682d5d08aad80e2f08a91fd8fb.xml", "file_type": "json"}, "external_links": ["https://www.marketresearchfuture.com/sample_request/5909"], "title": "Gout Market Detail Analysis | Focusing on major Vendors as Takeda Pharmaceutical Company Ltd., Savient Pharmaceuticals, AstraZeneca plc, Merck, etc", "forum_title": "openPR.com - New Public Relations: Business, Economy, Finances, Banking & Insurance"}, {"id": "i4H-xPHdd92r75wqMqta6NGPMTQ6dHrRMW1IaWeLesQsxNhpWMzMmqUW6UmWP5XC", "result_metadata": {"score": 36.55999}, "author": "Future Market Insights", "enriched_title": {"entities": [], "sentiment": {"document": {"score": -0.425315, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Fabry Disease Market", "keywords": [{"text": "Fabry Disease Market"}]}, "sentence": "Fabry Disease Market Prophesied to Grow at a Faster Pace by 2026", "object": {"text": "at a Faster Pace", "keywords": [{"text": "Faster Pace"}]}, "action": {"verb": {"text": "Grow", "tense": "future"}, "text": "Prophesied to Grow", "normalized": "Prophesied to Grow"}}], "concepts": [{"text": "Diseases and disorders", "relevance": 0.856964, "dbpedia_resource": "http://dbpedia.org/resource/Diseases_and_disorders"}], "categories": [{"score": 0.961119, "label": "/health and fitness/disease"}], "relations": [], "keywords": [{"text": "Fabry Disease Market", "sentiment": {"score": -0.425315, "label": "negative"}, "relevance": 0.919509}, {"text": "Faster Pace", "sentiment": {"score": -0.425315, "label": "negative"}, "relevance": 0.733004}]}, "crawl_date": "2018-11-01T15:02:25Z", "url": "https://www.openpr.com/news/1346575/Fabry-Disease-Market-Prophesied-to-Grow-at-a-Faster-Pace-by-2026.html", "host": "openpr.com", "text": "Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co.", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-01T14:51:00Z", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": -0.72272, "label": "negative"}, "text": "fabry disease", "relevance": 0.980933, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}, {"count": 2, "sentiment": {"score": -0.786549, "label": "negative"}, "text": "APAC", "relevance": 0.360409, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.297804, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eastern Europe", "relevance": 0.291668, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": -0.581545, "label": "negative"}, "text": "Novartis Pharmaceuticals", "relevance": 0.254327, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.25389, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "FMI", "relevance": 0.239715, "type": "Organization", "disambiguation": {"subtype": [], "name": "Investment company", "dbpedia_resource": "http://dbpedia.org/resource/Investment_company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva pharmaceutical Industries Ltd.", "relevance": 0.235069, "type": "Company", "disambiguation": {"subtype": [], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"count": 1, "sentiment": {"score": 0.435777, "label": "positive"}, "text": "Valley Cottage", "relevance": 0.234557, "type": "Facility", "disambiguation": {"subtype": [], "name": "Valley Cottage (Georgetown, Maryland)", "dbpedia_resource": "http://dbpedia.org/resource/Valley_Cottage_(Georgetown,_Maryland)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd", "relevance": 0.222938, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NY", "relevance": 0.222262, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.221646, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.221183, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0.258488, "label": "positive"}, "text": "Western Europe", "relevance": 0.218383, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi-Aventis LLC", "relevance": 0.217879, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "America", "relevance": 0.21574, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.214626, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": -0.428578, "label": "negative"}, "text": "Neuraltus Pharmaceuticals", "relevance": 0.213279, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.209215, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "TouristAttraction", "City"], "name": "City of London", "dbpedia_resource": "http://dbpedia.org/resource/City_of_London"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.209173, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Genzyme Corporation", "relevance": 0.206841, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genzyme", "dbpedia_resource": "http://dbpedia.org/resource/Genzyme"}}, {"count": 1, "sentiment": {"score": 0.26394, "label": "positive"}, "text": "Amgen Inc.", "relevance": 0.199135, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.198693, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.195371, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.186469, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merc & Co., Inc.", "relevance": 0.18276, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "iBio, Inc.", "relevance": 0.176196, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.173485, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.173485, "type": "TwitterHandle"}], "sentiment": {"document": {"score": 0.00516637, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "the global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": "Based on end user type, the global fabry disease market is divided into following: Hospitals Clinics Fabry Disease Market: Overview The enzyme replacement therapy is designed to provide enzyme to the patients suffering from enzyme deficiency.", "object": {"text": "divided into following"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": "Based on end user type, the global fabry disease market is divided into following: Hospitals Clinics Fabry Disease Market: Overview The enzyme replacement therapy is designed to provide enzyme to the patients suffering from enzyme deficiency.", "object": {"text": "into following: Hospitals Clinics Fabry Disease Market: Overview The enzyme replacement therapy is designed to provide enzyme to the patients suffering from enzyme deficiency", "keywords": [{"text": "enzyme replacement therapy"}, {"text": "enzyme deficiency"}, {"text": "Hospitals Clinics Fabry"}, {"text": "Disease Market"}]}, "action": {"verb": {"text": "divide", "tense": "past"}, "text": "is divided", "normalized": "be divide"}}, {"subject": {"text": "Enzyme replacement therapy", "keywords": [{"text": "Enzyme replacement therapy"}]}, "sentence": " Enzyme replacement therapy is the most expensive and unaffordable treatment among the treatments for fabry disease, hence the market for enzyme replacement therapy is expected to register moderate growth in overall fabry disease market.", "object": {"text": "the most expensive and unaffordable treatment among the treatments for fabry disease", "keywords": [{"text": "fabry disease"}, {"text": "unaffordable treatment"}, {"text": "treatments"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "enzyme replacement therapy", "keywords": [{"text": "enzyme replacement therapy"}]}, "sentence": " Enzyme replacement therapy is the most expensive and unaffordable treatment among the treatments for fabry disease, hence the market for enzyme replacement therapy is expected to register moderate growth in overall fabry disease market.", "object": {"text": "moderate growth", "keywords": [{"text": "moderate growth"}]}, "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "The analgesics, anticonvulsants and NSAIDs", "keywords": [{"text": "analgesics"}, {"text": "NSAIDs"}, {"text": "anticonvulsants"}]}, "sentence": " The analgesics, anticonvulsants and NSAIDs are generally known for the treatment of pain and other symptoms associated with fabry disease hence, contributing majorly to the market.", "object": {"text": "for the treatment of pain and other symptoms associated with fabry disease hence, contributing majorly to the market", "keywords": [{"text": "fabry disease"}, {"text": "pain"}, {"text": "treatment"}, {"text": "symptoms"}], "entities": [{"type": "HealthCondition", "text": "fabry disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition"], "name": "Fabry disease", "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "are generally known", "normalized": "be generally know"}}, {"subject": {"text": "Regional Overview Geographically, the global fabry disease market", "keywords": [{"text": "Regional Overview Geographically"}, {"text": "global fabry disease"}, {"text": "market"}]}, "sentence": " Fabry Disease Market: Regional Overview Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America", "keywords": [{"text": "Middle East"}, {"text": "Western Europe"}, {"text": "Eastern Europe"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Company", "text": "APAC"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global fabry disease market", "keywords": [{"text": "global fabry disease"}]}, "sentence": " Fabry Disease Market: Regional Overview Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe", "keywords": [{"text": "lucrative region"}, {"text": "Middle East"}, {"text": "North America"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Company", "text": "APAC"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "action": {"verb": {"text": "classify", "tense": "past"}, "text": "is classified", "normalized": "be classify"}}, {"subject": {"text": "Middle East and Africa.North America", "keywords": [{"text": "Middle East"}, {"text": "Africa.North America"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Fabry Disease Market: Regional Overview Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "to be the most lucrative region", "keywords": [{"text": "lucrative region"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "by Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Fabry Disease Market: Regional Overview Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "object": {"text": "the affordability of the treatment", "keywords": [{"text": "affordability"}, {"text": "treatment"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "The rare incidences in APAC and MEA countries", "keywords": [{"text": "rare incidences"}, {"text": "MEA countries"}, {"text": "APAC"}], "entities": []}, "sentence": " The rare incidences in APAC and MEA countries are expected to limit the growth of fabry disease market in these regions.", "object": {"text": "the growth of fabry disease market in these regions", "keywords": [{"text": "fabry disease market"}, {"text": "regions"}]}, "action": {"verb": {"text": "limit", "tense": "future"}, "text": "are expected to limit", "normalized": "be expect to limit"}}, {"subject": {"text": "Key Players The major players", "keywords": [{"text": "Key Players"}, {"text": "major players"}]}, "sentence": " Request Report for TOC @ www.futuremarketinsights.com/toc/rep-gb-1365 Fabry Disease Market: Key Players The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc.", "object": {"text": "in development of new medications", "keywords": [{"text": "new medications"}, {"text": "development"}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "involved", "normalized": "involve"}}, {"subject": {"text": "Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc", "keywords": [{"text": "GlaxoSmithKline plc"}, {"text": "Sanofi-Aventis LLC"}, {"text": "Genzyme Corporation"}, {"text": "Neuraltus Pharmaceuticals"}], "entities": [{"type": "Company", "text": "Sanofi-Aventis LLC"}, {"type": "Company", "text": "iBio, Inc."}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Genzyme Corporation", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Genzyme", "dbpedia_resource": "http://dbpedia.org/resource/Genzyme"}}, {"type": "Company", "text": "Neuraltus Pharmaceuticals"}]}, "sentence": " Request Report for TOC @ www.futuremarketinsights.com/toc/rep-gb-1365 Fabry Disease Market: Key Players The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc.", "object": {"text": "new medications", "keywords": [{"text": "new medications"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Some of the existing key players in the global fabry disease market", "keywords": [{"text": "global fabry disease"}, {"text": "key players"}]}, "sentence": " Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd.", "object": {"text": "Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd", "keywords": [{"text": "Bristol-Myers Squibb Company"}, {"text": "Teva pharmaceutical Industries"}, {"text": "Novartis Pharmaceuticals"}, {"text": "Pfizer Inc."}], "entities": [{"type": "Company", "text": "Novartis Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Merc & Co., Inc."}, {"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "AbbVie Inc."}, {"type": "Company", "text": "Amgen Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"type": "Company", "text": "Teva pharmaceutical Industries Ltd.", "disambiguation": {"subtype": ["Company"], "name": "Teva Pharmaceutical Industries", "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co. Ltd"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Us"}, "sentence": " About Us Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries.", "object": {"text": "Market Insights", "keywords": [{"text": "Market Insights"}]}, "action": {"verb": {"text": "Future", "tense": "present"}, "text": "Future", "normalized": "Future"}}, {"subject": {"text": "About Us Future Market Insights", "keywords": [{"text": "Future Market Insights"}]}, "sentence": " About Us Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries.", "object": {"text": "the premier provider of market intelligence", "keywords": [{"text": "premier provider"}, {"text": "market intelligence"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "FMI", "keywords": [{"text": "FMI"}], "entities": [{"type": "Organization", "text": "FMI", "disambiguation": {"subtype": [], "name": "Investment company", "dbpedia_resource": "http://dbpedia.org/resource/Investment_company"}}]}, "sentence": " FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.", "action": {"verb": {"text": "headquarter", "tense": "past"}, "text": "is headquartered", "normalized": "be headquarter"}}, {"subject": {"text": "FMI", "keywords": [{"text": "FMI"}], "entities": [{"type": "Organization", "text": "FMI", "disambiguation": {"subtype": [], "name": "Investment company", "dbpedia_resource": "http://dbpedia.org/resource/Investment_company"}}]}, "sentence": " FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.", "object": {"text": "delivery centres", "keywords": [{"text": "delivery centres"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "FMI\u00e2s research", "keywords": [{"text": "FMI\u00e2s research"}]}, "sentence": " FMI\u00e2s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity.", "object": {"text": "services", "keywords": [{"text": "services"}]}, "action": {"verb": {"text": "consult", "tense": "present"}, "text": "consulting", "normalized": "consult"}}, {"subject": {"text": "FMI\u00e2s research and consulting services", "keywords": [{"text": "FMI\u00e2s research"}, {"text": "services"}]}, "sentence": " FMI\u00e2s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity.", "object": {"text": "businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity", "keywords": [{"text": "rapidly evolving marketplace"}, {"text": "clarity"}, {"text": "confidence"}, {"text": "globe"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "help", "normalized": "help"}}, {"subject": {"text": "FMI\u00e2s research and consulting services help businesses around the globe", "keywords": [{"text": "FMI\u00e2s research"}, {"text": "globe"}, {"text": "services"}, {"text": "businesses"}]}, "sentence": " FMI\u00e2s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity.", "object": {"text": "the challenges", "keywords": [{"text": "challenges"}]}, "action": {"verb": {"text": "navigate", "tense": "present"}, "text": "navigate", "normalized": "navigate"}}, {"subject": {"text": "Our customised and syndicated market research", "keywords": [{"text": "market research"}]}, "sentence": " Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth.", "object": {"text": "deliver actionable insights that drive sustainable growth", "keywords": [{"text": "actionable insights"}, {"text": "sustainable growth"}]}, "action": {"verb": {"text": "report", "tense": "present"}, "text": "reports", "normalized": "report"}}, {"subject": {"text": "We"}, "sentence": " We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.", "object": {"text": "emerging trends and events in a broad range of end industries", "keywords": [{"text": "broad range"}, {"text": "end industries"}, {"text": "trends"}, {"text": "events"}]}, "action": {"verb": {"text": "track", "tense": "present"}, "text": "track", "normalized": "track"}}, {"subject": {"text": "We"}, "sentence": " We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.", "object": {"text": "our clients prepare for the evolving needs of their consumers", "keywords": [{"text": "consumers"}, {"text": "clients"}, {"text": "needs"}]}, "action": {"verb": {"text": "ensure", "tense": "future"}, "text": "to ensure", "normalized": "to ensure"}}], "concepts": [{"text": "Bristol-Myers Squibb", "relevance": 0.963448, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.763713, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.760075, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Clopidogrel", "relevance": 0.743128, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "United States", "relevance": 0.700969, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Medicine", "relevance": 0.664859, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Therapy", "relevance": 0.579922, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "New York City", "relevance": 0.571074, "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}, {"text": "Enzyme replacement therapy", "relevance": 0.5698, "dbpedia_resource": "http://dbpedia.org/resource/Enzyme_replacement_therapy"}, {"text": "Europe", "relevance": 0.557583, "dbpedia_resource": "http://dbpedia.org/resource/Europe"}, {"text": "Fabry disease", "relevance": 0.54164, "dbpedia_resource": "http://dbpedia.org/resource/Fabry_disease"}, {"text": "Irbesartan", "relevance": 0.540486, "dbpedia_resource": "http://dbpedia.org/resource/Irbesartan"}, {"text": "Paclitaxel", "relevance": 0.538196, "dbpedia_resource": "http://dbpedia.org/resource/Paclitaxel"}, {"text": "Eastern Europe", "relevance": 0.533056, "dbpedia_resource": "http://dbpedia.org/resource/Eastern_Europe"}, {"text": "GlaxoSmithKline", "relevance": 0.529106, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Pharmaceutical drug", "relevance": 0.510925, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Pharmacology", "relevance": 0.510015, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical industry", "relevance": 0.495623, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Biotechnology companies", "relevance": 0.481453, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "Pfizer", "relevance": 0.481452, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}], "categories": [{"score": 0.848083, "label": "/health and fitness/disease"}], "relations": [{"type": "partOf", "sentence": "Fabry Disease Market: Regional Overview Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "score": 0.535899, "arguments": [{"text": "Regional Overview Geographically", "location": [775, 807], "entities": [{"type": "Organization", "text": "Regional Overview Geographically"}]}, {"text": "Fabry Disease Market", "location": [753, 773], "entities": [{"type": "Organization", "text": "Hospitals Clinics Fabry Disease Market"}]}]}, {"type": "locatedAt", "sentence": "U.S. Office 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989,", "score": 0.474417, "arguments": [{"text": "Office 616 Corporate Way", "location": [2469, 2493], "entities": [{"type": "Organization", "text": "Hospitals Clinics Fabry Disease Market"}]}, {"text": "Suite", "location": [2495, 2500], "entities": [{"type": "GeopoliticalEntity", "text": "Suite"}]}]}, {"type": "populationOf", "sentence": "U.S. Office 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989,", "score": 0.542845, "arguments": [{"text": "2-9018", "location": [2501, 2507], "entities": [{"type": "Cardinal", "text": "2-9018"}]}, {"text": "Suite", "location": [2495, 2500], "entities": [{"type": "GeopoliticalEntity", "text": "Suite"}]}]}, {"type": "locatedAt", "sentence": "U.S. Office 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989,", "score": 0.846513, "arguments": [{"text": "Valley Cottage", "location": [2509, 2523], "entities": [{"type": "GeopoliticalEntity", "text": "Valley Cottage"}]}, {"text": "NY", "location": [2525, 2527], "entities": [{"type": "GeopoliticalEntity", "text": "NY"}]}]}, {"type": "locatedAt", "sentence": "Fabry Disease Market: Regional Overview Geographically, the global fabry disease market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa.North America is estimated to be the most lucrative region owing to the affordability of the treatment followed by Europe.", "score": 0.829838, "arguments": [{"text": "APAC", "location": [938, 942], "entities": [{"type": "GeopoliticalEntity", "text": "APAC"}]}, {"text": "Japan", "location": [944, 949], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The rare incidences in APAC and MEA countries are expected to limit the growth of fabry disease market in these regions.", "score": 0.80263, "arguments": [{"text": "countries", "location": [1133, 1142], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "APAC", "location": [1120, 1124], "entities": [{"type": "GeopoliticalEntity", "text": "APAC"}]}]}, {"type": "partOf", "sentence": "The rare incidences in APAC and MEA countries are expected to limit the growth of fabry disease market in these regions.", "score": 0.651857, "arguments": [{"text": "MEA", "location": [1129, 1132], "entities": [{"type": "Organization", "text": "MEA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "countries", "location": [1133, 1142], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "timeOf", "sentence": "Request Report for TOC @ www.futuremarketinsights.com/toc/rep-gb-1365 Fabry Disease Market: Key Players The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc. Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd. About Us Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries.", "score": 0.70273, "arguments": [{"text": "www.futuremarketinsights.com/toc/rep-gb-1365", "location": [1243, 1287], "entities": [{"type": "Date", "text": "www.futuremarketinsights.com/toc/rep-gb-1365"}]}, {"text": "Report", "location": [1226, 1232], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "agentOf", "sentence": "Request Report for TOC @ www.futuremarketinsights.com/toc/rep-gb-1365 Fabry Disease Market: Key Players The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc. Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd. About Us Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries.", "score": 0.562624, "arguments": [{"text": "Fabry Disease Market", "location": [1288, 1308], "entities": [{"type": "Organization", "text": "Hospitals Clinics Fabry Disease Market"}]}, {"text": "Report", "location": [1226, 1232], "entities": [{"type": "EventCommunication", "text": "Report"}]}]}, {"type": "partOf", "sentence": "Request Report for TOC @ www.futuremarketinsights.com/toc/rep-gb-1365 Fabry Disease Market: Key Players The major players operating in this market and involved in development of new medications include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus Pharmaceuticals, Inc. Some of the existing key players in the global fabry disease market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd. About Us Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries.", "score": 0.491522, "arguments": [{"text": "Fabry Disease Market", "location": [1288, 1308], "entities": [{"type": "Organization", "text": "Hospitals Clinics Fabry Disease Market"}]}, {"text": "TOC @", "location": [1237, 1242], "entities": [{"type": "Organization", "text": "TOC @"}]}]}, {"type": "basedIn", "sentence": "FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.", "score": 0.57014, "arguments": [{"text": "FMI", "location": [1925, 1928], "entities": [{"type": "Organization", "text": "FMI"}]}, {"text": "London", "location": [1949, 1955], "entities": [{"type": "GeopoliticalEntity", "text": "London"}]}]}, {"type": "employedBy", "sentence": "We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.", "score": 0.611328, "arguments": [{"text": "clients", "location": [2405, 2412], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "our", "location": [2401, 2404], "entities": [{"type": "Organization", "text": "FMI"}]}]}], "keywords": [{"text": "fabry disease market", "sentiment": {"score": -0.578884, "label": "negative"}, "relevance": 0.940377}, {"text": "global fabry disease", "sentiment": {"score": -0.525444, "label": "negative"}, "relevance": 0.584106}, {"text": "enzyme replacement therapy", "sentiment": {"score": -0.691522, "label": "negative"}, "relevance": 0.493764}, {"text": "Clinics Fabry Disease", "sentiment": {"score": -0.699051, "label": "negative"}, "relevance": 0.433717}, {"text": "overall fabry disease", "sentiment": {"score": -0.538371, "label": "negative"}, "relevance": 0.41277}, {"text": "www.futuremarketinsights.com/toc/rep-gb-1365 Fabry Disease", "sentiment": {"score": -0.446361, "label": "negative"}, "relevance": 0.401814}, {"text": "end user type", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.308993}, {"text": "Regional Overview Geographically", "sentiment": {"score": -0.213782, "label": "negative"}, "relevance": 0.298704}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.298314}, {"text": "key players", "sentiment": {"score": -0.581545, "label": "negative"}, "relevance": 0.29658}, {"text": "Teva pharmaceutical Industries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.295715}, {"text": "Takeda Pharmaceutical Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.294178}, {"text": "global financial capital", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.291263}, {"text": "rapidly evolving marketplace", "sentiment": {"score": 0.775868, "label": "positive"}, "relevance": 0.288924}, {"text": "enzyme deficiency", "sentiment": {"score": -0.806439, "label": "negative"}, "relevance": 0.288588}, {"text": "deliver actionable insights", "sentiment": {"score": 0.896484, "label": "positive"}, "relevance": 0.287963}, {"text": "Market Insights", "sentiment": {"score": 0.575072, "label": "positive"}, "relevance": 0.266145}, {"text": "market intelligence", "sentiment": {"score": 0.575072, "label": "positive"}, "relevance": 0.265992}, {"text": "market research", "sentiment": {"score": 0.896484, "label": "positive"}, "relevance": 0.263285}, {"text": "Amgen Inc.", "sentiment": {"score": 0.26394, "label": "positive"}, "relevance": 0.257859}, {"text": "unaffordable treatment", "sentiment": {"score": -0.729756, "label": "negative"}, "relevance": 0.257443}, {"text": "complete cure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.257195}, {"text": "lucrative region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.2569}, {"text": "rare incidences", "sentiment": {"score": -0.786549, "label": "negative"}, "relevance": 0.256626}, {"text": "moderate growth", "sentiment": {"score": -0.538371, "label": "negative"}, "relevance": 0.256237}, {"text": "Pfizer Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.256002}, {"text": "Sanofi-Aventis LLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.255463}, {"text": "MEA countries", "sentiment": {"score": -0.786549, "label": "negative"}, "relevance": 0.254823}, {"text": "Novartis Pharmaceuticals", "sentiment": {"score": -0.581545, "label": "negative"}, "relevance": 0.25434}, {"text": "Genzyme Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.254268}, {"text": "AbbVie Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253871}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.25387}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253826}, {"text": "Western Europe", "sentiment": {"score": 0.258488, "label": "positive"}, "relevance": 0.253782}, {"text": "Eastern Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253738}, {"text": "Africa.North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.253591}, {"text": "Neuraltus Pharmaceuticals", "sentiment": {"score": -0.428578, "label": "negative"}, "relevance": 0.252795}, {"text": "Middle East", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.252521}, {"text": "major players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.251993}, {"text": "GlaxoSmithKline plc", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.251274}, {"text": "Request Report", "sentiment": {"score": -0.446361, "label": "negative"}, "relevance": 0.251097}, {"text": "new medications", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.249698}, {"text": "premier provider", "sentiment": {"score": 0.575072, "label": "positive"}, "relevance": 0.248966}, {"text": "broad range", "sentiment": {"score": 0.718135, "label": "positive"}, "relevance": 0.248785}, {"text": "end industries", "sentiment": {"score": 0.718135, "label": "positive"}, "relevance": 0.248565}, {"text": "Corporate Way", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.248107}, {"text": "U.S. Office", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.248062}, {"text": "sustainable growth", "sentiment": {"score": 0.896484, "label": "positive"}, "relevance": 0.247866}, {"text": "FMI\u00e2s research", "sentiment": {"score": 0.775868, "label": "positive"}, "relevance": 0.247629}, {"text": "Valley Cottage", "sentiment": {"score": 0.435777, "label": "positive"}, "relevance": 0.247193}]}, "extracted_metadata": {"sha1": "13d43ddbab86ba59e9a991e29895bcc03f0decba", "filename": "1541084545464.zip-14029c61cdc383fed56e71d1ce6eb05a.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/toc/rep-gb-1365"], "title": "Fabry Disease Market Prophesied to Grow at a Faster Pace by 2026", "forum_title": "openPR.com - New Public Relations: Health & Medicine"}, {"id": "oWzmszV8mnZREygvclLOBJr60dRiIOrhI8gVZ8_yFBdkXLazzPmuRVBY6aTP6xj_", "result_metadata": {"score": 36.4541}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Prurigo", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3.4%", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Prurigo nodularis", "relevance": 0.932431, "dbpedia_resource": "http://dbpedia.org/resource/Prurigo_nodularis"}], "categories": [{"score": 0.547876, "label": "/health and fitness/disorders/mental disorder/depression"}, {"score": 0.513768, "label": "/health and fitness/therapy"}, {"score": 0.438519, "label": "/science/weather"}], "relations": [], "keywords": [{"text": "Global Prurigo Nodularis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.910553}, {"text": "Forecast Period", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.400238}, {"text": "Treatment Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315627}]}, "crawl_date": "2018-11-01T21:27:58Z", "url": "http://www.sbwire.com/press-releases/global-prurigo-nodularis-treatment-market-is-poised-to-expand-at-34-cagr-over-the-forecast-period-of-2018-2028-1077735.htm", "host": "sbwire.com", "text": "., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co.", "main_image_url": "http://media.releasewire.com/photos/show/?id=79336", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-01T21:27:00Z", "enriched_text": {"entities": [{"count": 15, "sentiment": {"score": 0.423668, "label": "positive"}, "text": "Global Prurigo Nodularis Treatment Market", "relevance": 0.91043, "type": "Company"}, {"count": 12, "sentiment": {"score": 0.0621648, "label": "positive"}, "text": "Prurigo", "relevance": 0.355197, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}, {"count": 3, "sentiment": {"score": 0.270347, "label": "positive"}, "text": "Mn", "relevance": 0.0526793, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Orphan Products Development", "relevance": 0.0507143, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.0414819, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.0413356, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Media Relations Contact", "relevance": 0.0411888, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0.702921, "label": "positive"}, "text": "China", "relevance": 0.0405941, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.0404254, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": -0.358157, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.0402205, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0.702921, "label": "positive"}, "text": "Asia Pacific", "relevance": 0.040042, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.0398617, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Western Europe", "relevance": 0.0369384, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer AG", "relevance": 0.035987, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.A", "relevance": 0.0357782, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.0350326, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.0350217, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd", "relevance": 0.0347335, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co. Inc.", "relevance": 0.0344748, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.0344581, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson Services Inc.", "relevance": 0.0338013, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.0329622, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": -0.449951, "label": "negative"}, "text": "Sanofi SA", "relevance": 0.03268, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "3.4%", "relevance": 0.03268, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.03268, "type": "TwitterHandle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2028", "relevance": 0.03268, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "4.8%", "relevance": 0.03268, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "40%", "relevance": 0.03268, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "45%", "relevance": 0.03268, "type": "Quantity"}], "sentiment": {"document": {"score": 0.701469, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "by Future Market Insights titled ' Prurigo Nodularis Treatment Market", "keywords": [{"text": "Prurigo Nodularis Treatment"}, {"text": "Future Market Insights"}], "entities": [{"type": "Company", "text": "Global Prurigo Nodularis Treatment Market", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " According to the latest report published by Future Market Insights titled ' Prurigo Nodularis Treatment Market : Global Industry Analysis 2013 \u2013 2017 and Opportunity Assessment 2018 \u2013 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018\u20132028.", "object": {"text": "the latest report", "keywords": [{"text": "latest report"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "Insights", "keywords": [{"text": "Insights"}]}, "sentence": " According to the latest report published by Future Market Insights titled ' Prurigo Nodularis Treatment Market : Global Industry Analysis 2013 \u2013 2017 and Opportunity Assessment 2018 \u2013 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018\u20132028.", "object": {"text": "Prurigo Nodularis Treatment Market", "keywords": [{"text": "Treatment Market"}], "entities": [{"type": "Company", "text": "Global Prurigo Nodularis Treatment Market", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "action": {"verb": {"text": "title", "tense": "past"}, "text": "titled", "normalized": "title"}}, {"subject": {"text": "The global market for prurigo nodularis treatment", "keywords": [{"text": "prurigo nodularis"}, {"text": "global market"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018\u20132028.", "object": {"text": "a valuation of US$ 697.9 Mn", "keywords": [{"text": "valuation"}, {"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is expected to reach", "normalized": "be expect to reach"}}, {"subject": {"text": "Factors", "keywords": [{"text": "Factors"}]}, "sentence": " Global Prurigo Nodularis Treatment Market: Factors Influencing Growth Favourable regulations and initiatives for orphan drug development in various regions is expected to fuel the market for prurigo nodularis treatment in the near future.", "object": {"text": "Growth Favourable regulations", "keywords": [{"text": "Growth Favourable regulations"}]}, "action": {"verb": {"text": "Influencing", "tense": "present"}, "text": "Influencing", "normalized": "Influencing"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Global Prurigo Nodularis Treatment Market"}]}, "sentence": " Global Prurigo Nodularis Treatment Market: Factors Influencing Growth Favourable regulations and initiatives for orphan drug development in various regions is expected to fuel the market for prurigo nodularis treatment in the near future.", "object": {"text": "Factors Influencing Growth Favourable regulations and initiatives for orphan drug development in various regions", "keywords": [{"text": "Growth Favourable regulations"}, {"text": "orphan drug development"}, {"text": "various regions"}, {"text": "initiatives"}]}, "action": {"verb": {"text": "fuel", "tense": "future"}, "text": "is expected to fuel", "normalized": "be expect to fuel"}}, {"subject": {"text": "awareness programmes", "keywords": [{"text": "awareness programmes"}]}, "sentence": " The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China", "keywords": [{"text": "highly populated regions"}, {"text": "rapidly developing healthcare"}, {"text": "awareness programmes"}, {"text": "Asia Pacific"}], "entities": [{"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "sentence": " The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "object": {"text": "an important role", "keywords": [{"text": "important role"}]}, "action": {"verb": {"text": "play", "tense": "future"}, "text": "is expected to play", "normalized": "be expect to play"}}, {"subject": {"text": "Segmental Insights The global prurigo nodularis treatment market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "Segmental Insights"}, {"text": "treatment market"}], "entities": [{"type": "Company", "text": "Global Prurigo Nodularis Treatment Market"}]}, "sentence": " To know key findings Request Sample Report @: 3339 Global Prurigo Nodularis Treatment Market: Segmental Insights The global prurigo nodularis treatment market has been segmented on the basis of product type, distribution channel and region.", "object": {"text": "been segmented on the basis of product type, distribution channel and region", "keywords": [{"text": "product type"}, {"text": "distribution channel"}, {"text": "basis"}, {"text": "region"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Segmental Insights The global prurigo nodularis treatment market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "Segmental Insights"}, {"text": "treatment market"}], "entities": [{"type": "Company", "text": "Global Prurigo Nodularis Treatment Market"}]}, "sentence": " To know key findings Request Sample Report @: 3339 Global Prurigo Nodularis Treatment Market: Segmental Insights The global prurigo nodularis treatment market has been segmented on the basis of product type, distribution channel and region.", "object": {"text": "on the basis of product type, distribution channel and region", "keywords": [{"text": "product type"}, {"text": "distribution channel"}, {"text": "basis"}, {"text": "region"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "Prurigo", "keywords": [{"text": "Prurigo"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " Prurigo nodularis treatment product types include corticosteroids, emollients, capsacin cream, antihistamines and others.", "object": {"text": "treatment product types include corticosteroids, emollients, capsacin cream, antihistamines and others", "keywords": [{"text": "treatment product types"}, {"text": "capsacin cream"}, {"text": "corticosteroids"}, {"text": "antihistamines"}]}, "action": {"verb": {"text": "nodularis", "tense": "present"}, "text": "nodularis", "normalized": "nodularis"}}, {"subject": {"text": "corticosteroids, emollients, capsacin cream, antihistamines and others", "keywords": [{"text": "capsacin cream"}, {"text": "corticosteroids"}, {"text": "antihistamines"}, {"text": "emollients"}]}, "sentence": " Prurigo nodularis treatment product types include corticosteroids, emollients, capsacin cream, antihistamines and others.", "object": {"text": "Prurigo nodularis treatment product types", "keywords": [{"text": "Prurigo"}, {"text": "treatment product types"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "capsacin cream under the product type segment", "keywords": [{"text": "product type segment"}, {"text": "capsacin cream"}]}, "sentence": " Globally, capsacin cream under the product type segment stands the most attractive product form amongst the different product types.", "object": {"text": "the most attractive product form amongst the different product types", "keywords": [{"text": "attractive product form"}, {"text": "different product types"}]}, "action": {"verb": {"text": "stand", "tense": "present"}, "text": "stands", "normalized": "stand"}}, {"subject": {"text": "retail pharmacies", "keywords": [{"text": "retail pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "object": {"text": "anticipated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "retail pharmacies", "keywords": [{"text": "retail pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "action": {"verb": {"text": "anticipate", "tense": "past"}, "text": "are anticipated to be", "normalized": "be anticipate to be"}}, {"subject": {"text": "retail pharmacies", "keywords": [{"text": "retail pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "object": {"text": "the most lucrative distribution channel", "keywords": [{"text": "lucrative distribution channel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are anticipated to be", "normalized": "be anticipate to be"}}, {"subject": {"text": "by hospital pharmacies", "keywords": [{"text": "hospital pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "object": {"text": "the most lucrative distribution channel", "keywords": [{"text": "lucrative distribution channel"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "Regional Highlights With nearly 40% - 45% market share, Western Europe", "keywords": [{"text": "Regional Highlights"}, {"text": "market share"}, {"text": "Western Europe"}], "entities": [{"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Quantity", "text": "40"}, {"type": "Quantity", "text": "45"}]}, "sentence": " Global Prurigo Nodularis Treatment Market: Regional Highlights With nearly 40% - 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "object": {"text": "the global prurigo nodularis treatment Market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "treatment Market"}], "entities": [{"type": "Company", "text": "Global Prurigo Nodularis Treatment Market"}]}, "action": {"verb": {"text": "dominate", "tense": "past"}, "text": "dominated", "normalized": "dominate"}}, {"subject": {"text": "by governments", "keywords": [{"text": "governments"}]}, "sentence": " Global Prurigo Nodularis Treatment Market: Regional Highlights With nearly 40% - 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "object": {"text": "key research and development initiatives", "keywords": [{"text": "development initiatives"}, {"text": "key research"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "taken", "normalized": "take"}}, {"subject": {"text": "advanced medical facilities", "keywords": [{"text": "advanced medical facilities"}]}, "sentence": " Moreover, in developing regions such as Latin America, advanced medical facilities are helping the region cope with the current healthcare crisis.", "object": {"text": "the region cope with the current healthcare crisis", "keywords": [{"text": "current healthcare crisis"}, {"text": "region cope"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "are helping", "normalized": "be help"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America is the second largest regional market for prurigo nodularis treatment and is expected to be valued at US$ 75.6 Mn by 2028, with the markets in U.S.A and Canada growing at a faster rate.", "object": {"text": "the second largest regional market for prurigo nodularis treatment", "keywords": [{"text": "prurigo nodularis"}, {"text": "largest regional market"}, {"text": "treatment"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}, {"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the markets in U.S.A and Canada", "keywords": [{"text": "U.S.A"}, {"text": "markets"}, {"text": "Canada"}], "entities": [{"type": "Location", "text": "U.S.A", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}]}, "sentence": " North America is the second largest regional market for prurigo nodularis treatment and is expected to be valued at US$ 75.6 Mn by 2028, with the markets in U.S.A and Canada growing at a faster rate.", "object": {"text": "at a faster rate", "keywords": [{"text": "faster rate"}]}, "action": {"verb": {"text": "grow", "tense": "present"}, "text": "growing", "normalized": "grow"}}, {"subject": {"text": "Eastern Europe", "keywords": [{"text": "Eastern Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Eastern Europe is projected to be the third largest market for prurigo nodularis treatment.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Key Research Findings The global prurigo nodularis treatment market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "Key Research Findings"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " Key Research Findings The global prurigo nodularis treatment market is expected to create incremental opportunity of US$ 197.9 Mn between 2018 and 2028 The prurigo nodularis treatment market is expected to witness fast and steady growth, partly due to the rising government support across various regions and increasing demand for prurigo nodularis treatment across the world.", "object": {"text": "incremental opportunity of US$ 197.9 Mn between 2018 and 2028 The prurigo nodularis treatment market", "keywords": [{"text": "incremental opportunity"}, {"text": "treatment market"}, {"text": "prurigo"}, {"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "is expected to create", "normalized": "be expect to create"}}, {"subject": {"text": "US$ 197.9 Mn between 2018 and 2028 The prurigo nodularis treatment market", "keywords": [{"text": "treatment market"}, {"text": "prurigo"}, {"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " Key Research Findings The global prurigo nodularis treatment market is expected to create incremental opportunity of US$ 197.9 Mn between 2018 and 2028 The prurigo nodularis treatment market is expected to witness fast and steady growth, partly due to the rising government support across various regions and increasing demand for prurigo nodularis treatment across the world.", "object": {"text": "steady growth", "keywords": [{"text": "steady growth"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "is expected to witness", "normalized": "be expect to witness"}}, {"subject": {"text": "Vendor Insights The global market for prurigo nodularis treatment", "keywords": [{"text": "prurigo nodularis"}, {"text": "Vendor Insights"}, {"text": "global market"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " Request for Report Methodology @: https://www.futuremarketinsights.com/askus/rep-gb-3339 Global Prurigo Nodularis Treatment Market: Vendor Insights The global market for prurigo nodularis treatment is highly competitive with many players operating in the global market.", "object": {"text": "highly competitive"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "many players", "keywords": [{"text": "players"}]}, "sentence": " Request for Report Methodology @: https://www.futuremarketinsights.com/askus/rep-gb-3339 Global Prurigo Nodularis Treatment Market: Vendor Insights The global market for prurigo nodularis treatment is highly competitive with many players operating in the global market.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "Some of the companies", "keywords": [{"text": "companies"}]}, "sentence": " Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "action": {"verb": {"text": "identify", "tense": "past"}, "text": "identified", "normalized": "identify"}}, {"subject": {"text": "Some of the companies identified in global prurigo nodularis treatment market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "treatment market"}], "entities": [{"type": "Company", "text": "Global Prurigo Nodularis Treatment Market"}]}, "sentence": " Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "object": {"text": "Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others", "keywords": [{"text": "Teva Pharmaceutical Industries"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "GlaxoSmithKline plc"}, {"text": "Sanofi SA"}], "entities": [{"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd"}, {"type": "Company", "text": "Johnson & Johnson Services Inc."}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Sanofi SA"}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "companies", "keywords": [{"text": "companies"}]}, "sentence": " In order to increase market coverage, companies are focussing on building close collaborations with local distributers as these partnerships allow firms to grow and expand in the global market.", "object": {"text": "close collaborations", "keywords": [{"text": "close collaborations"}]}, "action": {"verb": {"text": "build", "tense": "future"}, "text": "building", "normalized": "build"}}, {"subject": {"text": "these partnerships", "keywords": [{"text": "partnerships"}]}, "sentence": " In order to increase market coverage, companies are focussing on building close collaborations with local distributers as these partnerships allow firms to grow and expand in the global market.", "object": {"text": "firms to grow and expand in the global market", "keywords": [{"text": "global market"}, {"text": "firms"}], "entities": []}, "action": {"verb": {"text": "allow", "tense": "present"}, "text": "allow", "normalized": "allow"}}, {"subject": {"text": "firms", "keywords": [{"text": "firms"}]}, "sentence": " In order to increase market coverage, companies are focussing on building close collaborations with local distributers as these partnerships allow firms to grow and expand in the global market.", "action": {"verb": {"text": "expand", "tense": "present"}, "text": "expand", "normalized": "expand"}}], "concepts": [{"text": "Marketing", "relevance": 0.965583, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.872196, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Prurigo nodularis", "relevance": 0.718918, "dbpedia_resource": "http://dbpedia.org/resource/Prurigo_nodularis"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.656026, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Distribution", "relevance": 0.643905, "dbpedia_resource": "http://dbpedia.org/resource/Distribution_(business)"}, {"text": "Pharmacy", "relevance": 0.61367, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Pharmaceutical industry", "relevance": 0.581748, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Drug discovery", "relevance": 0.554808, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Region", "relevance": 0.542829, "dbpedia_resource": "http://dbpedia.org/resource/Region"}, {"text": "Pfizer", "relevance": 0.517745, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "GlaxoSmithKline", "relevance": 0.50602, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Economics", "relevance": 0.488067, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}], "categories": [{"score": 0.518943, "label": "/finance/financial news"}, {"score": 0.490525, "label": "/finance/investing"}, {"score": 0.490525, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "partOf", "sentence": "RSS Global Prurigo Nodularis Treatment Market Is Poised to Expand at 3.4% CAGR over the Forecast Period of 2018-2028 Global Prurigo Nodularis Treatment Market to Gain Traction in the Coming Years Owing to Favourable Regulations for Orphan Products Development  According to the latest report published by Future Market Insights titled ' Prurigo Nodularis Treatment Market : Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.701633, "arguments": [{"text": "Global Prurigo Nodularis Treatment Market", "location": [117, 158], "entities": [{"type": "Organization", "text": "RSS Global Prurigo Nodularis Treatment Market"}]}, {"text": "Gain Traction", "location": [162, 175], "entities": [{"type": "Organization", "text": "Gain Traction"}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.891549, "arguments": [{"text": "regions", "location": [1146, 1153], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Asia", "location": [1157, 1161], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.848801, "arguments": [{"text": "regions", "location": [1146, 1153], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Pacific", "location": [1162, 1169], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.647654, "arguments": [{"text": "regions", "location": [1146, 1153], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "China", "location": [1174, 1179], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.614891, "arguments": [{"text": "Asia", "location": [1157, 1161], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [1162, 1169], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "Global Prurigo Nodularis Treatment Market: Regional Highlights With nearly 40% - 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "score": 0.875969, "arguments": [{"text": "Western", "location": [2066, 2073], "entities": [{"type": "Location", "text": "Western"}]}, {"text": "Europe", "location": [2074, 2080], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Global Prurigo Nodularis Treatment Market: Regional Highlights With nearly 40% - 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "score": 0.457813, "arguments": [{"text": "governments", "location": [2253, 2264], "entities": [{"type": "GeopoliticalEntity", "text": "hospital pharmacies"}]}, {"text": "region", "location": [2272, 2278], "entities": [{"type": "GeopoliticalEntity", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "Moreover, in developing regions such as Latin America, advanced medical facilities are helping the region cope with the current healthcare crisis.", "score": 0.82137, "arguments": [{"text": "regions", "location": [2304, 2311], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Latin America", "location": [2320, 2333], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Moreover, in developing regions such as Latin America, advanced medical facilities are helping the region cope with the current healthcare crisis.", "score": 0.667622, "arguments": [{"text": "facilities", "location": [2352, 2362], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "region", "location": [2379, 2385], "entities": [{"type": "GeopoliticalEntity", "text": "regions"}]}]}, {"type": "agentOf", "sentence": "Request for Report Methodology @: https://www.futuremarketinsights.com/askus/rep-gb-3339 Global Prurigo Nodularis Treatment Market: Vendor Insights The global market for prurigo nodularis treatment is highly competitive with many players operating in the global market.", "score": 0.72331, "arguments": [{"text": "Methodology @", "location": [3115, 3128], "entities": [{"type": "Organization", "text": "Methodology @", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Report", "location": [3108, 3114], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.473218, "arguments": [{"text": "Bayer AG", "location": [3448, 3456], "entities": [{"type": "Organization", "text": "Bayer AG", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3378, 3387], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "RSS Global Prurigo Nodularis Treatment Market Is Poised to Expand at 3.4% CAGR over the Forecast Period of 2018-2028 Global Prurigo Nodularis Treatment Market to Gain Traction in the Coming Years Owing to Favourable Regulations for Orphan Products Development  According to the latest report published by Future Market Insights titled ' Prurigo Nodularis Treatment Market : Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.811509, "arguments": [{"text": "Favourable Regulations", "location": [205, 227], "entities": [{"type": "Organization", "text": "Favourable Regulations"}]}, {"text": "Orphan Products Development", "location": [232, 259], "entities": [{"type": "Organization", "text": "Orphan Products Development"}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.671821, "arguments": [{"text": "Pfizer Inc.", "location": [3458, 3469], "entities": [{"type": "Organization", "text": "Pfizer Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3378, 3387], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.607119, "arguments": [{"text": "GlaxoSmithKline plc", "location": [3471, 3490], "entities": [{"type": "Organization", "text": "GlaxoSmithKline plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3378, 3387], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.598112, "arguments": [{"text": "Johnson & Johnson Services Inc.", "location": [3528, 3559], "entities": [{"type": "Organization", "text": "Johnson & Johnson Services Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3378, 3387], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.507685, "arguments": [{"text": "Merck & Co. Inc.", "location": [3561, 3577], "entities": [{"type": "Organization", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3378, 3387], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.577551, "arguments": [{"text": "Sanofi SA", "location": [3579, 3588], "entities": [{"type": "Organization", "text": "Sanofi SA", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3378, 3387], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "RSS Global Prurigo Nodularis Treatment Market Is Poised to Expand at 3.4% CAGR over the Forecast Period of 2018-2028 Global Prurigo Nodularis Treatment Market to Gain Traction in the Coming Years Owing to Favourable Regulations for Orphan Products Development  According to the latest report published by Future Market Insights titled ' Prurigo Nodularis Treatment Market : Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.362004, "arguments": [{"text": "published", "location": [292, 301], "entities": [{"type": "EventCommunication", "text": "published"}]}, {"text": "report", "location": [285, 291], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "RSS Global Prurigo Nodularis Treatment Market Is Poised to Expand at 3.4% CAGR over the Forecast Period of 2018-2028 Global Prurigo Nodularis Treatment Market to Gain Traction in the Coming Years Owing to Favourable Regulations for Orphan Products Development  According to the latest report published by Future Market Insights titled ' Prurigo Nodularis Treatment Market : Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.544855, "arguments": [{"text": "Future Market Insights", "location": [305, 327], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "report", "location": [285, 291], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "agentOf", "sentence": "RSS Global Prurigo Nodularis Treatment Market Is Poised to Expand at 3.4% CAGR over the Forecast Period of 2018-2028 Global Prurigo Nodularis Treatment Market to Gain Traction in the Coming Years Owing to Favourable Regulations for Orphan Products Development  According to the latest report published by Future Market Insights titled ' Prurigo Nodularis Treatment Market : Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028', the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.889228, "arguments": [{"text": "Future Market Insights", "location": [305, 327], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "published", "location": [292, 301], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "populationOf", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.577512, "arguments": [{"text": "697.9", "location": [660, 665], "entities": [{"type": "Cardinal", "text": "697.9"}]}, {"text": "US$", "location": [656, 659], "entities": [{"type": "GeopoliticalEntity", "text": "US$"}]}]}, {"type": "agentOf", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.516048, "arguments": [{"text": "Mn", "location": [666, 668], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "attesting", "location": [682, 691], "entities": [{"type": "EventCommunication", "text": "attesting"}]}]}, {"type": "agentOf", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.42228, "arguments": [{"text": "& Africa", "location": [731, 739], "entities": [{"type": "Organization", "text": "& Africa"}]}, {"text": "attesting", "location": [682, 691], "entities": [{"type": "EventCommunication", "text": "attesting"}]}]}, {"type": "basedIn", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.611012, "arguments": [{"text": "& Africa", "location": [731, 739], "entities": [{"type": "Organization", "text": "& Africa"}]}, {"text": "Middle East", "location": [719, 730], "entities": [{"type": "GeopoliticalEntity", "text": "Middle East", "disambiguation": {"subtype": ["Area"]}}]}]}], "keywords": [{"text": "prurigo nodularis treatment", "sentiment": {"score": 0.149607, "label": "positive"}, "relevance": 0.948306}, {"text": "global prurigo nodularis", "sentiment": {"score": 0.217138, "label": "positive"}, "relevance": 0.748745}, {"text": "nodularis treatment market", "sentiment": {"score": 0.217138, "label": "positive"}, "relevance": 0.633392}, {"text": "RSS Global Prurigo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.263237}, {"text": "https://www.futuremarketinsights.com/askus/rep-gb-3339 Global Prurigo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.231484}]}, "extracted_metadata": {"sha1": "2032e44df43cc94e49fb268711d668fec859bff0", "filename": "1541107678680.zip-a4df40f6461964608512fc4aa14a3dcd.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/askus/rep-gb-3339", "https://www.futuremarketinsights.com/reports/prurigo-nodularis-treatment-and-management-market", "http://www.releasewire.com/rss/", "https://www.futuremarketinsights.com/reports/sample/rep-gb-3339"], "title": "Global Prurigo Nodularis Treatment Market Is Poised to Expand at 3.4% CAGR over the Forecast Period of 2018-2028", "forum_title": "ReleaseWire - Latest Press Releases"}, {"id": "n4DJHio7z2VcFsaiokN_7Hn3rKAxpk9qgG79AFQQIvdxF6BiFGHte4s5nD8Bfv8u", "result_metadata": {"score": 33.72984}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}], "sentiment": {"document": {"score": -0.349763, "label": "negative"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.655089, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.444627, "label": "/science/weather"}, {"score": 0.396737, "label": "/science/weather/meteorological disaster/hurricane"}], "relations": [], "keywords": [{"text": "Consolidated Financials", "sentiment": {"score": -0.429702, "label": "negative"}, "relevance": 0.952538}, {"text": "Revised Forecast", "sentiment": {"score": -0.429702, "label": "negative"}, "relevance": 0.910168}, {"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.827586}, {"text": "Notice", "sentiment": {"score": -0.429702, "label": "negative"}, "relevance": 0.567506}]}, "crawl_date": "2018-11-01T15:24:15Z", "url": "http://www.4-traders.com/TAKEDA-PHARMACEUTICAL-CO-6491073/news/Takeda-Pharmaceutical-Notice-of-the-Revised-Forecast-of-Consolidated-Financials-for-FY2018-27527901/", "host": "4-traders.com", "text": "Ltd. and negative foreign currency effect.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-01T00:00:00+01:00", "enriched_text": {"entities": [{"count": 16, "sentiment": {"score": -0.315646, "label": "negative"}, "text": "Takeda", "relevance": 0.925638, "type": "Company"}, {"count": 9, "sentiment": {"score": -0.365544, "label": "negative"}, "text": "Takeda", "relevance": 0.757164, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.428917, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 3, "sentiment": {"score": 0.470485, "label": "positive"}, "text": "Shire plc", "relevance": 0.307408, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 3, "sentiment": {"score": -0.507423, "label": "negative"}, "text": "Shire", "relevance": 0.263859, "type": "Organization"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "solicitation", "relevance": 0.226259, "type": "Crime"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Osaka", "relevance": 0.203384, "type": "Location", "disambiguation": {"subtype": ["JapaneseDesignatedCity", "OlympicBiddingCity", "City"], "name": "Osaka", "dbpedia_resource": "http://dbpedia.org/resource/Osaka"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire", "relevance": 0.189755, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "multiple myeloma", "relevance": 0.184071, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Multiple myeloma", "dbpedia_resource": "http://dbpedia.org/resource/Multiple_myeloma"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.183142, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0.74301, "label": "positive"}, "text": "Takashi Okubo", "relevance": 0.169946, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Guangdong Techpool Bio-Pharma Co.", "relevance": 0.166301, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Growth Driver", "relevance": 0.161452, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Electronic News Publishing", "relevance": 0.149888, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "product development", "relevance": 0.14089, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ENP Newswire", "relevance": 0.139939, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.126115, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "takeda.ir.contact@takeda.com", "relevance": 0.126115, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "39.3%", "relevance": 0.126115, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "47.7%", "relevance": 0.126115, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "48.2%", "relevance": 0.126115, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "0.7%", "relevance": 0.126115, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6.6%", "relevance": 0.126115, "type": "Quantity"}], "sentiment": {"document": {"score": -0.130118, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Osaka - Takeda Pharmaceutical Company Limited (' Takeda ')", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Osaka"}, {"text": "Company Limited"}], "entities": [{"type": "Location", "text": "Osaka", "disambiguation": {"subtype": ["JapaneseDesignatedCity", "OlympicBiddingCity", "CityTown", "City"], "name": "Osaka", "dbpedia_resource": "http://dbpedia.org/resource/Osaka"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "sentence": "Osaka - Takeda Pharmaceutical Company Limited (' Takeda ') announced today, based on the latest business circumstances, the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2019 , as below.", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "Osaka - Takeda Pharmaceutical Company Limited (' Takeda '", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Osaka"}, {"text": "Company Limited"}], "entities": [{"type": "Location", "text": "Osaka", "disambiguation": {"subtype": ["JapaneseDesignatedCity", "OlympicBiddingCity", "CityTown", "City"], "name": "Osaka", "dbpedia_resource": "http://dbpedia.org/resource/Osaka"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "sentence": "Osaka - Takeda Pharmaceutical Company Limited (' Takeda ') announced today, based on the latest business circumstances, the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2019 , as below.", "object": {"text": "on the latest business circumstances", "keywords": [{"text": "latest business circumstances"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "based", "normalized": "base"}}, {"subject": {"text": "the fiscal year", "entities": []}, "sentence": "Osaka - Takeda Pharmaceutical Company Limited (' Takeda ') announced today, based on the latest business circumstances, the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2019 , as below.", "action": {"verb": {"text": "end", "tense": "present"}, "text": "ending", "normalized": "end"}}, {"subject": {"text": "This"}, "sentence": " This revised forecast includes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen ); however, it does not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year.", "object": {"text": "forecast", "keywords": [{"text": "forecast"}]}, "action": {"verb": {"text": "revise", "tense": "past"}, "text": "revised", "normalized": "revise"}}, {"subject": {"text": "the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen ); however, it does not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year", "keywords": [{"text": "Shire plc"}, {"text": "Net profit"}, {"text": "Shire-related costs"}, {"text": "tax impact"}], "entities": [{"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"type": "Company", "text": "Takeda"}]}, "sentence": " This revised forecast includes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen ); however, it does not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year.", "object": {"text": "This revised forecast", "keywords": [{"text": "forecast"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "the costs", "keywords": [{"text": "costs"}]}, "sentence": " This revised forecast includes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen ); however, it does not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year.", "object": {"text": "in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen )", "keywords": [{"text": "Shire plc"}, {"text": "Net profit"}, {"text": "tax impact"}, {"text": "yen"}], "entities": [{"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "incur", "tense": "past"}, "text": "incurred", "normalized": "incur"}}, {"subject": {"text": "it"}, "sentence": " This revised forecast includes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen ); however, it does not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year.", "object": {"text": "not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year", "keywords": [{"text": "Shire-related costs"}, {"text": "half"}], "entities": []}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "does", "normalized": "do"}}, {"subject": {"text": "it"}, "sentence": " This revised forecast includes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen ); however, it does not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year.", "object": {"text": "any Shire-related costs anticipated to be incurred in the second half of the fiscal year", "keywords": [{"text": "Shire-related costs"}, {"text": "half"}], "entities": []}, "action": {"verb": {"text": "include", "tense": "present", "negated": true}, "text": "include", "normalized": "include"}}, {"subject": {"text": "any Shire-related costs", "keywords": [{"text": "Shire-related costs"}]}, "sentence": " This revised forecast includes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen ); however, it does not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year.", "object": {"text": "incurred"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "any Shire-related costs", "keywords": [{"text": "Shire-related costs"}]}, "sentence": " This revised forecast includes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen ); however, it does not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year.", "action": {"verb": {"text": "incur", "tense": "past"}, "text": "anticipated to be incurred", "normalized": "anticipate to be incur"}}, {"subject": {"text": "any projected earnings", "keywords": [{"text": "earnings"}]}, "sentence": " Furthermore, the forecast does not include any projected earnings from Shire should the closing of the acquisition occur within fiscal 2018.", "object": {"text": "the forecast", "keywords": [{"text": "forecast"}]}, "action": {"verb": {"text": "include", "tense": "present", "negated": true}, "text": "include", "normalized": "include"}}, {"subject": {"text": "the closing of the acquisition", "keywords": [{"text": "closing"}, {"text": "acquisition"}]}, "sentence": " Furthermore, the forecast does not include any projected earnings from Shire should the closing of the acquisition occur within fiscal 2018.", "action": {"verb": {"text": "occur", "tense": "present"}, "text": "occur", "normalized": "occur"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda estimates a portion of the Shire-related costs to be incurred in fiscal 2018 to be between 40.0 billion yen and 60.0 billion yen .", "object": {"text": "a portion of the Shire-related costs to be incurred in fiscal 2018 to be between 40.0 billion yen and 60.0 billion yen", "keywords": [{"text": "Shire-related costs"}, {"text": "yen"}, {"text": "portion"}]}, "action": {"verb": {"text": "estimate", "tense": "present"}, "text": "estimates", "normalized": "estimate"}}, {"subject": {"text": "a portion of the Shire-related costs", "keywords": [{"text": "portion"}, {"text": "Shire-related"}]}, "sentence": " Takeda estimates a portion of the Shire-related costs to be incurred in fiscal 2018 to be between 40.0 billion yen and 60.0 billion yen .", "object": {"text": "between 40.0 billion yen and 60.0 billion yen", "keywords": [{"text": "yen"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "to be", "normalized": "to be"}}, {"subject": {"text": "This"}, "sentence": " This does not include integration costs, debt interest and other financial expenses, as the amount of these expenses will change depending on the timing of deal closing.", "object": {"text": "not include integration costs, debt interest and other financial expenses", "keywords": [{"text": "financial expenses"}, {"text": "integration costs"}, {"text": "debt"}]}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "does", "normalized": "do"}}, {"subject": {"text": "integration costs, debt interest and other financial expenses, as the amount of these expenses will change depending on the timing of deal closing", "keywords": [{"text": "financial expenses"}, {"text": "deal closing"}, {"text": "integration costs"}, {"text": "timing"}]}, "sentence": " This does not include integration costs, debt interest and other financial expenses, as the amount of these expenses will change depending on the timing of deal closing.", "object": {"text": "This"}, "action": {"verb": {"text": "include", "tense": "present", "negated": true}, "text": "include", "normalized": "include"}}, {"subject": {"text": "This revised forecast", "keywords": [{"text": "forecast"}]}, "sentence": " This revised forecast excludes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda .", "object": {"text": "the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda", "keywords": [{"text": "Shire plc"}, {"text": "Takeda"}, {"text": "costs"}, {"text": "acquisition"}], "entities": [{"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "exclude", "tense": "present"}, "text": "excludes", "normalized": "exclude"}}, {"subject": {"text": "The previous forecast of May 14, 2018", "keywords": [{"text": "previous forecast"}]}, "sentence": " The previous forecast of May 14, 2018 also does not include any Shire-related expenses.", "object": {"text": "not include any Shire-related expenses", "keywords": [{"text": "Shire-related expenses"}]}, "action": {"verb": {"text": "do", "tense": "future"}, "text": "does", "normalized": "do"}}, {"subject": {"text": "any Shire-related expenses", "keywords": [{"text": "Shire-related expenses"}]}, "sentence": " The previous forecast of May 14, 2018 also does not include any Shire-related expenses.", "object": {"text": "The previous forecast of May 14, 2018", "keywords": [{"text": "previous forecast"}]}, "action": {"verb": {"text": "include", "tense": "present", "negated": true}, "text": "include", "normalized": "include"}}, {"subject": {"text": "any Shire-related costs", "keywords": [{"text": "Shire-related costs"}]}, "sentence": " As both forecasts do not include any Shire-related costs throughout the year, like-for-like comparison is as below.", "object": {"text": "both forecasts", "keywords": [{"text": "forecasts"}]}, "action": {"verb": {"text": "include", "tense": "present", "negated": true}, "text": "include", "normalized": "include"}}, {"subject": {"text": "like-for-like comparison", "keywords": [{"text": "like-for-like comparison"}]}, "sentence": " As both forecasts do not include any Shire-related costs throughout the year, like-for-like comparison is as below.", "object": {"text": "as below"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Revenue projection", "keywords": [{"text": "Revenue projection"}]}, "sentence": " Revenue projection has been increased by 13.0 billion yen (+0.7%) to 1,750.0 billion yen .", "object": {"text": "increased by 13.0 billion yen (+0.7%)", "keywords": [{"text": "yen"}], "entities": [{"type": "Quantity", "text": "0.7"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Revenue projection", "keywords": [{"text": "Revenue projection"}]}, "sentence": " Revenue projection has been increased by 13.0 billion yen (+0.7%) to 1,750.0 billion yen .", "object": {"text": "by 13.0 billion yen (+0.7%)", "keywords": [{"text": "yen"}], "entities": [{"type": "Quantity", "text": "0.7"}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "has been increased", "normalized": "have be increase"}}, {"subject": {"text": "factors", "keywords": [{"text": "factors"}]}, "sentence": " The positive revenue impact from a revised outlook on launch timing of additional competitors to multiple myeloma product VELCADE in the U.S. combined with Growth Driver momentum is expected to offset factors including no longer booking revenue from divested former subsidiary Guangdong Techpool Bio-Pharma Co. .", "object": {"text": "myeloma product VELCADE in the U.S. combined with Growth Driver momentum", "keywords": [{"text": "myeloma product VELCADE"}, {"text": "Growth Driver momentum"}, {"text": "U.S."}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "offset", "tense": "future"}, "text": "is expected to offset", "normalized": "be expect to offset"}}, {"subject": {"text": "no longer booking revenue from divested former subsidiary Guangdong Techpool Bio-Pharma Co.", "keywords": [{"text": "Guangdong Techpool Bio-Pharma"}, {"text": "revenue"}, {"text": "subsidiary"}], "entities": [{"type": "Company", "text": "Guangdong Techpool Bio-Pharma Co."}]}, "sentence": " The positive revenue impact from a revised outlook on launch timing of additional competitors to multiple myeloma product VELCADE in the U.S. combined with Growth Driver momentum is expected to offset factors including no longer booking revenue from divested former subsidiary Guangdong Techpool Bio-Pharma Co. .", "object": {"text": "factors", "keywords": [{"text": "factors"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "The Operating Profit forecast", "keywords": [{"text": "Operating Profit forecast"}]}, "sentence": " The Operating Profit forecast has been increased by 79.0 billion yen (+39.3%) to 280.0 billion yen .", "object": {"text": "increased by 79.0 billion yen (+39.3%)", "keywords": [{"text": "yen"}], "entities": [{"type": "Quantity", "text": "39.3"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The Operating Profit forecast", "keywords": [{"text": "Operating Profit forecast"}]}, "sentence": " The Operating Profit forecast has been increased by 79.0 billion yen (+39.3%) to 280.0 billion yen .", "object": {"text": "by 79.0 billion yen (+39.3%)", "keywords": [{"text": "yen"}], "entities": [{"type": "Quantity", "text": "39.3"}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "has been increased", "normalized": "have be increase"}}, {"subject": {"text": "we"}, "sentence": " Although we expect R&D expenses to increase, the Operating Profit margin is expected to improve for reasons such as Takeda's global cost reduction initiatives and Growth Driver momentum.", "object": {"text": "R&D expenses to increase", "keywords": [{"text": "R&D expenses"}]}, "action": {"verb": {"text": "expect", "tense": "present"}, "text": "expect", "normalized": "expect"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Considering the strong business performance in the first half of the fiscal year, Takeda is also raising its Core Earnings forecast by 20.5 billion yen (+6.6%) to 330.0 billion yen .", "object": {"text": "the strong business performance in the first half of the fiscal year", "keywords": [{"text": "strong business performance"}, {"text": "half"}], "entities": []}, "action": {"verb": {"text": "Considering", "tense": "present"}, "text": "Considering", "normalized": "Considering"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Considering the strong business performance in the first half of the fiscal year, Takeda is also raising its Core Earnings forecast by 20.5 billion yen (+6.6%) to 330.0 billion yen .", "object": {"text": "its Core Earnings forecast", "keywords": [{"text": "Core Earnings forecast"}]}, "action": {"verb": {"text": "raise", "tense": "present"}, "text": "is also raising", "normalized": "be also raise"}}, {"subject": {"text": "Net profit for the year (attributable to owners of the Company) and EPS forecasts", "keywords": [{"text": "EPS forecasts"}, {"text": "Net profit"}, {"text": "owners"}, {"text": "Company"}], "entities": []}, "sentence": " Net profit for the year (attributable to owners of the Company) and EPS forecasts are being increased by 48.2% and 47.7%, respectively.", "object": {"text": "being increased by 48.2% and 47.7%, respectively", "entities": [{"type": "Quantity", "text": "47.7"}, {"type": "Quantity", "text": "48.2"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Net profit for the year (attributable to owners of the Company) and EPS forecasts", "keywords": [{"text": "EPS forecasts"}, {"text": "Net profit"}, {"text": "owners"}, {"text": "Company"}], "entities": []}, "sentence": " Net profit for the year (attributable to owners of the Company) and EPS forecasts are being increased by 48.2% and 47.7%, respectively.", "object": {"text": "increased by 48.2% and 47.7%, respectively", "entities": [{"type": "Quantity", "text": "47.7"}, {"type": "Quantity", "text": "48.2"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "being", "normalized": "be"}}, {"subject": {"text": "Net profit for the year (attributable to owners of the Company) and EPS forecasts", "keywords": [{"text": "EPS forecasts"}, {"text": "Net profit"}, {"text": "owners"}, {"text": "Company"}], "entities": []}, "sentence": " Net profit for the year (attributable to owners of the Company) and EPS forecasts are being increased by 48.2% and 47.7%, respectively.", "object": {"text": "by 48.2%", "entities": [{"type": "Quantity", "text": "48.2"}]}, "action": {"verb": {"text": "increase", "tense": "past"}, "text": "are being increased", "normalized": "be be increase"}}, {"subject": {"text": "the estimated financial impact of the proposed acquisition of Shire", "keywords": [{"text": "proposed acquisition"}, {"text": "financial impact"}, {"text": "Shire"}], "entities": [{"type": "Company", "text": "Shire"}]}, "sentence": " A forecast that does include the estimated financial impact of the proposed acquisition of Shire will be announced by Takeda once a reasonable assumption has been confirmed.", "object": {"text": "A forecast", "keywords": [{"text": "forecast"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "does include", "normalized": "do include"}}, {"subject": {"text": "financial impact of the proposed acquisition of Shire", "keywords": [{"text": "proposed acquisition"}, {"text": "financial impact"}, {"text": "Shire"}], "entities": [{"type": "Company", "text": "Shire"}]}, "sentence": " A forecast that does include the estimated financial impact of the proposed acquisition of Shire will be announced by Takeda once a reasonable assumption has been confirmed.", "object": {"text": "announced by Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "by Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " A forecast that does include the estimated financial impact of the proposed acquisition of Shire will be announced by Takeda once a reasonable assumption has been confirmed.", "object": {"text": "the estimated financial impact of the proposed acquisition of Shire", "keywords": [{"text": "proposed acquisition"}, {"text": "financial impact"}, {"text": "Shire"}], "entities": [{"type": "Company", "text": "Shire"}]}, "action": {"verb": {"text": "announce", "tense": "future"}, "text": "will be announced", "normalized": "will be announce"}}, {"subject": {"text": "any oral briefing and any question-and-answer in connection with it", "keywords": [{"text": "oral briefing"}, {"text": "question-and-answer"}, {"text": "connection"}]}, "sentence": " This release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction.", "object": {"text": "This release", "keywords": [{"text": "release"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "No shares", "keywords": [{"text": "shares"}]}, "sentence": " No shares are being offered to the public by means of this release.", "object": {"text": "to the public", "keywords": [{"text": "public"}]}, "action": {"verb": {"text": "offer", "tense": "past"}, "text": "are being offered", "normalized": "be be offer"}}, {"subject": {"text": "This release", "keywords": [{"text": "release"}]}, "sentence": " This release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction).", "object": {"text": "with any further information which may be provided to the recipient)", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "give", "tense": "past"}, "text": "is being given", "normalized": "be be give"}}, {"subject": {"text": "any further information", "keywords": [{"text": "information"}]}, "sentence": " This release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction).", "object": {"text": "provided to the recipient"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "any further information", "keywords": [{"text": "information"}]}, "sentence": " This release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction).", "object": {"text": "to the recipient"}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "may be provided", "normalized": "may be provide"}}, {"subject": {"text": "it"}, "sentence": " This release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction).", "object": {"text": "for the evaluation of any investment, acquisition, disposal or any other transaction)", "keywords": [{"text": "disposal"}, {"text": "transaction"}, {"text": "acquisition"}, {"text": "evaluation"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Any failure to comply with these restrictions", "keywords": [{"text": "restrictions"}, {"text": "failure"}]}, "sentence": " Any failure to comply with these restrictions may constitute a violation of applicable securities laws.", "object": {"text": "a violation of applicable securities laws", "keywords": [{"text": "applicable securities"}, {"text": "violation"}, {"text": "laws"}]}, "action": {"verb": {"text": "constitute", "tense": "future"}, "text": "may constitute", "normalized": "may constitute"}}, {"subject": {"text": "this release", "keywords": [{"text": "release"}]}, "sentence": " Unless specified otherwise, no statement in this release (including any statement of estimated synergies) is intended as a profit forecast or estimate for any period and no statement in this release should be interpreted to mean that earnings or earnings per share for Takeda for the current or future financial years would necessarily match or exceed the historical published earnings per share for Takeda .", "object": {"text": "interpreted to mean that earnings or earnings per share for Takeda", "keywords": [{"text": "earnings"}, {"text": "Takeda"}, {"text": "share"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "no statement in this release", "keywords": [{"text": "statement"}, {"text": "release"}]}, "sentence": " Unless specified otherwise, no statement in this release (including any statement of estimated synergies) is intended as a profit forecast or estimate for any period and no statement in this release should be interpreted to mean that earnings or earnings per share for Takeda for the current or future financial years would necessarily match or exceed the historical published earnings per share for Takeda .", "object": {"text": "to mean that earnings or earnings per share for Takeda for the current or future financial years would necessarily match or exceed the historical published earnings per share for Takeda", "keywords": [{"text": "historical published earnings"}, {"text": "Takeda"}, {"text": "share"}], "entities": [{"type": "Person", "text": "Takeda"}, {"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "interpret", "tense": "future"}, "text": "interpreted", "normalized": "interpret"}}, {"subject": {"text": "separate entities", "keywords": [{"text": "separate entities"}]}, "sentence": " The companies in which Takeda directly and indirectly owns investments are separate entities.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "references", "keywords": [{"text": "references"}]}, "sentence": " In this release, ' Takeda ' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general.", "object": {"text": "to Takeda and its subsidiaries in general", "keywords": [{"text": "Takeda"}, {"text": "subsidiaries"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "are made", "normalized": "be make"}}, {"subject": {"text": "These expressions", "keywords": [{"text": "expressions"}]}, "sentence": " These expressions are also used where no useful purpose is served by identifying the particular company or companies.", "action": {"verb": {"text": "use", "tense": "past"}, "text": "are also used", "normalized": "be also use"}}, {"subject": {"text": "no useful purpose", "keywords": [{"text": "useful purpose"}]}, "sentence": " These expressions are also used where no useful purpose is served by identifying the particular company or companies.", "object": {"text": "served by identifying the particular company or companies", "keywords": [{"text": "particular company"}, {"text": "companies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This release and any materials distributed in connection with this release", "keywords": [{"text": "release"}, {"text": "materials"}, {"text": "connection"}]}, "sentence": " This release and any materials distributed in connection with this release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda .", "object": {"text": "forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations", "keywords": [{"text": "forward-looking statements"}, {"text": "future position"}, {"text": "future business"}, {"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "contain", "tense": "future"}, "text": "may contain", "normalized": "may contain"}}], "concepts": [{"text": "Generally Accepted Accounting Principles", "relevance": 0.96136, "dbpedia_resource": "http://dbpedia.org/resource/Generally_Accepted_Accounting_Principles"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.6141, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Revenue", "relevance": 0.608502, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Profit", "relevance": 0.574014, "dbpedia_resource": "http://dbpedia.org/resource/Profit"}, {"text": "Future", "relevance": 0.5239, "dbpedia_resource": "http://dbpedia.org/resource/Future"}], "categories": [{"score": 0.624106, "label": "/finance/financial news"}, {"score": 0.51497, "label": "/business and industrial/company/earnings"}, {"score": 0.36195, "label": "/finance/investing"}], "relations": [{"type": "basedIn", "sentence": "Osaka - Takeda Pharmaceutical Company Limited (' Takeda ') announced today, based on the latest business circumstances, the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2019 , as below.", "score": 0.534167, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [8, 45], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Osaka", "location": [0, 5], "entities": [{"type": "GeopoliticalEntity", "text": "Osaka"}]}]}, {"type": "agentOf", "sentence": "Furthermore, the forecast does not include any projected earnings from Shire should the closing of the acquisition occur within fiscal 2018.", "score": 0.557343, "arguments": [{"text": "Shire", "location": [760, 765], "entities": [{"type": "Person", "text": "Shire plc"}]}, {"text": "occur", "location": [804, 809], "entities": [{"type": "EventCommunication", "text": "occur"}]}]}, {"type": "timeOf", "sentence": "Furthermore, the forecast does not include any projected earnings from Shire should the closing of the acquisition occur within fiscal 2018.", "score": 0.528782, "arguments": [{"text": "2018", "location": [824, 828], "entities": [{"type": "Date", "text": "2018"}]}, {"text": "acquisition", "location": [792, 803], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "Furthermore, the forecast does not include any projected earnings from Shire should the closing of the acquisition occur within fiscal 2018.", "score": 0.611949, "arguments": [{"text": "2018", "location": [824, 828], "entities": [{"type": "Date", "text": "2018"}]}, {"text": "occur", "location": [804, 809], "entities": [{"type": "EventCommunication", "text": "occur"}]}]}, {"type": "hasAttribute", "sentence": "Takeda estimates a portion of the Shire-related costs to be incurred in fiscal 2018 to be between 40.0 billion yen and 60.0 billion yen .", "score": 0.666629, "arguments": [{"text": "Shire", "location": [864, 869], "entities": [{"type": "Organization", "text": "Shire plc"}]}, {"text": "40.0 billion yen", "location": [928, 944], "entities": [{"type": "Money", "text": "40.0 billion yen", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Takeda estimates a portion of the Shire-related costs to be incurred in fiscal 2018 to be between 40.0 billion yen and 60.0 billion yen .", "score": 0.763098, "arguments": [{"text": "Shire", "location": [864, 869], "entities": [{"type": "Organization", "text": "Shire plc"}]}, {"text": "60.0 billion yen", "location": [949, 965], "entities": [{"type": "Money", "text": "60.0 billion yen", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Considering the strong business performance in the first half of the fiscal year, Takeda is also raising its Core Earnings forecast by 20.5 billion yen (+6.6%) to 330.0 billion yen .", "score": 0.797964, "arguments": [{"text": "Takeda", "location": [2376, 2382], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "20.5 billion yen", "location": [2429, 2445], "entities": [{"type": "Money", "text": "20.5 billion yen", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "partOf", "sentence": "Considering the strong business performance in the first half of the fiscal year, Takeda is also raising its Core Earnings forecast by 20.5 billion yen (+6.6%) to 330.0 billion yen .", "score": 0.867544, "arguments": [{"text": "Core Earnings", "location": [2403, 2416], "entities": [{"type": "Organization", "text": "Underlying Core Earnings and Underlying Core EPS"}]}, {"text": "its", "location": [2399, 2402], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "hasAttribute", "sentence": "Considering the strong business performance in the first half of the fiscal year, Takeda is also raising its Core Earnings forecast by 20.5 billion yen (+6.6%) to 330.0 billion yen .", "score": 0.760985, "arguments": [{"text": "Core Earnings", "location": [2403, 2416], "entities": [{"type": "Organization", "text": "Underlying Core Earnings and Underlying Core EPS"}]}, {"text": "20.5 billion yen", "location": [2429, 2445], "entities": [{"type": "Money", "text": "20.5 billion yen", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Considering the strong business performance in the first half of the fiscal year, Takeda is also raising its Core Earnings forecast by 20.5 billion yen (+6.6%) to 330.0 billion yen .", "score": 0.6144, "arguments": [{"text": "Core Earnings", "location": [2403, 2416], "entities": [{"type": "Organization", "text": "Underlying Core Earnings and Underlying Core EPS"}]}, {"text": "330.0 billion yen", "location": [2457, 2474], "entities": [{"type": "Money", "text": "330.0 billion yen", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "employedBy", "sentence": "Net profit for the year (attributable to owners of the Company) and EPS forecasts are being increased by 48.2% and 47.7%, respectively.", "score": 0.406606, "arguments": [{"text": "owners", "location": [2518, 2524], "entities": [{"type": "Person", "text": "owners"}]}, {"text": "Company", "location": [2532, 2539], "entities": [{"type": "Organization", "text": "Shire plc"}]}]}, {"type": "agentOf", "sentence": "Osaka - Takeda Pharmaceutical Company Limited (' Takeda ') announced today, based on the latest business circumstances, the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2019 , as below.", "score": 0.746711, "arguments": [{"text": "Takeda Pharmaceutical Company Limited", "location": [8, 45], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [59, 68], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "A forecast that does include the estimated financial impact of the proposed acquisition of Shire will be announced by Takeda once a reasonable assumption has been confirmed.", "score": 0.923126, "arguments": [{"text": "Takeda", "location": [2731, 2737], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "announced", "location": [2718, 2727], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "agentOf", "sentence": "A forecast that does include the estimated financial impact of the proposed acquisition of Shire will be announced by Takeda once a reasonable assumption has been confirmed.", "score": 0.615799, "arguments": [{"text": "Shire", "location": [2704, 2709], "entities": [{"type": "Organization", "text": "Shire plc"}]}, {"text": "announced", "location": [2718, 2727], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "partOf", "sentence": "The companies in which Takeda directly and indirectly owns investments are separate entities.", "score": 0.440143, "arguments": [{"text": "companies", "location": [4140, 4149], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Takeda", "location": [4159, 4165], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "In this release, ' Takeda ' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general.", "score": 0.846359, "arguments": [{"text": "subsidiaries", "location": [4336, 4348], "entities": [{"type": "Organization", "text": "subsidiaries"}]}, {"text": "its", "location": [4332, 4335], "entities": [{"type": "Organization", "text": "its"}]}]}, {"type": "partOf", "sentence": "These expressions are also used where no useful purpose is served by identifying the particular company or companies.", "score": 0.91617, "arguments": [{"text": "companies", "location": [4590, 4599], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "company", "location": [4579, 4586], "entities": [{"type": "Organization", "text": "subsidiaries"}]}]}, {"type": "employedBy", "sentence": "In particular, this release contains forecasts and management estimates related to the financial and operational performance of Takeda , including statements regarding forecasts for FY2018 revenue, Core Earnings, Operating profit, Profit before income taxes, Net profit attributable to owners of the company, Basic earnings per share, R&D expenses, Amortisation and impairment and other income/expense, Underlying Revenue, Underlying Core Earnings and Underlying Core EPS.", "score": 0.38187, "arguments": [{"text": "owners", "location": [5191, 5197], "entities": [{"type": "Person", "text": "owners"}]}, {"text": "company", "location": [5205, 5212], "entities": [{"type": "Organization", "text": "subsidiaries"}]}]}, {"type": "employedBy", "sentence": "Pursuant to Rule 28 of the Code, statements made regarding Takeda's guidance for FY2018 (including statements regarding forecasts for FY2018 revenue, Core Earnings, Operating profit, Profit before income taxes, Net profit attributable to owners of the company, Basic earnings per share, R&D expenses, Amortisation and impairment and other income/expense, Underlying Revenue, Underlying Core Earnings and Underlying Core EPS) constitute a profit forecast for the year ending March 31, 2019 (the 'Takeda Profit Forecast').", "score": 0.515595, "arguments": [{"text": "Takeda", "location": [7922, 7928], "entities": [{"type": "Person", "text": "Takeda Profit Forecast"}]}, {"text": "FY2018", "location": [7944, 7950], "entities": [{"type": "Organization", "text": "FY2018"}]}]}, {"type": "employedBy", "sentence": "Pursuant to Rule 28 of the Code, statements made regarding Takeda's guidance for FY2018 (including statements regarding forecasts for FY2018 revenue, Core Earnings, Operating profit, Profit before income taxes, Net profit attributable to owners of the company, Basic earnings per share, R&D expenses, Amortisation and impairment and other income/expense, Underlying Revenue, Underlying Core Earnings and Underlying Core EPS) constitute a profit forecast for the year ending March 31, 2019 (the 'Takeda Profit Forecast').", "score": 0.428926, "arguments": [{"text": "owners", "location": [8101, 8107], "entities": [{"type": "Person", "text": "owners"}]}, {"text": "company", "location": [8115, 8122], "entities": [{"type": "Organization", "text": "subsidiaries"}]}]}, {"type": "managerOf", "sentence": "(C) 2018 Electronic News Publishing, source ENP Newswire", "score": 0.438665, "arguments": [{"text": "source", "location": [8421, 8427], "entities": [{"type": "Person", "text": "source"}]}, {"text": "ENP Newswire", "location": [8428, 8440], "entities": [{"type": "Organization", "text": "ENP Newswire", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "timeOf", "sentence": "Osaka - Takeda Pharmaceutical Company Limited (' Takeda ') announced today, based on the latest business circumstances, the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2019 , as below.", "score": 0.986978, "arguments": [{"text": "today", "location": [69, 74], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [59, 68], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "affectedBy", "sentence": "Reasons for Revision Revised Forecast1 (including fiscal 2018 first half Shire related costs) This revised forecast includes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen ); however, it does not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year.", "score": 0.812705, "arguments": [{"text": "Shire plc", "location": [452, 461], "entities": [{"type": "Organization", "text": "Shire plc"}]}, {"text": "acquisition", "location": [437, 448], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "Revised Forecast2 (excluding fiscal 2018 first half Shire related costs) This revised forecast excludes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda .", "score": 0.68255, "arguments": [{"text": "Shire plc", "location": [1333, 1342], "entities": [{"type": "Organization", "text": "Shire plc"}]}, {"text": "acquisition", "location": [1318, 1329], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "affectedBy", "sentence": "A forecast that does include the estimated financial impact of the proposed acquisition of Shire will be announced by Takeda once a reasonable assumption has been confirmed.", "score": 0.80902, "arguments": [{"text": "Shire", "location": [2704, 2709], "entities": [{"type": "Organization", "text": "Shire plc"}]}, {"text": "acquisition", "location": [2689, 2700], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "Reasons for Revision Revised Forecast1 (including fiscal 2018 first half Shire related costs) This revised forecast includes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen ); however, it does not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year.", "score": 0.484931, "arguments": [{"text": "Takeda", "location": [465, 471], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [437, 448], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "Revised Forecast2 (excluding fiscal 2018 first half Shire related costs) This revised forecast excludes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda .", "score": 0.702971, "arguments": [{"text": "Takeda", "location": [1346, 1352], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [1318, 1329], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "agentOf", "sentence": "A forecast that does include the estimated financial impact of the proposed acquisition of Shire will be announced by Takeda once a reasonable assumption has been confirmed.", "score": 0.683641, "arguments": [{"text": "Takeda", "location": [2731, 2737], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [2689, 2700], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "timeOf", "sentence": "Reasons for Revision Revised Forecast1 (including fiscal 2018 first half Shire related costs) This revised forecast includes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen ); however, it does not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year.", "score": 0.551513, "arguments": [{"text": "the year", "location": [533, 541], "entities": [{"type": "Date", "text": "the year"}]}, {"text": "acquisition", "location": [437, 448], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOf", "sentence": "Reasons for Revision Revised Forecast1 (including fiscal 2018 first half Shire related costs) This revised forecast includes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen ); however, it does not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year.", "score": 0.558649, "arguments": [{"text": "Shire plc", "location": [452, 461], "entities": [{"type": "Organization", "text": "Shire plc"}]}, {"text": "Takeda", "location": [465, 471], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Revised Forecast2 (excluding fiscal 2018 first half Shire related costs) This revised forecast excludes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda .", "score": 0.69393, "arguments": [{"text": "Shire plc", "location": [1333, 1342], "entities": [{"type": "Organization", "text": "Shire plc"}]}, {"text": "Takeda", "location": [1346, 1352], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Reasons for Revision Revised Forecast1 (including fiscal 2018 first half Shire related costs) This revised forecast includes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen ); however, it does not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year.", "score": 0.896897, "arguments": [{"text": "Takeda", "location": [465, 471], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "19.8 billion yen", "location": [499, 515], "entities": [{"type": "Money", "text": "19.8 billion yen", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "hasAttribute", "sentence": "Reasons for Revision Revised Forecast1 (including fiscal 2018 first half Shire related costs) This revised forecast includes the costs incurred in the first half of fiscal 2018 related to the proposed acquisition of Shire plc by Takeda (Profit before tax impact: 19.8 billion yen , Net profit for the year impact: 16.5 billion yen ); however, it does not include any Shire-related costs anticipated to be incurred in the second half of the fiscal year.", "score": 0.736432, "arguments": [{"text": "Takeda", "location": [465, 471], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "16.5 billion yen", "location": [550, 566], "entities": [{"type": "Money", "text": "16.5 billion yen", "disambiguation": {"subtype": ["Gainloss"]}}]}]}], "keywords": [{"text": "Takeda", "sentiment": {"score": -0.340595, "label": "negative"}, "relevance": 0.916024}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.782519}, {"text": "forward-looking statements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.776352}, {"text": "profit forecast", "sentiment": {"score": -0.300168, "label": "negative"}, "relevance": 0.740115}, {"text": "Core Earnings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.732884}, {"text": "Net profit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.7261}, {"text": "operating profit", "sentiment": {"score": 0.267946, "label": "positive"}, "relevance": 0.702531}, {"text": "Shire related costs", "sentiment": {"score": -0.494572, "label": "negative"}, "relevance": 0.700051}, {"text": "Growth Driver momentum", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.670912}, {"text": "Underlying Core EPS", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.669921}, {"text": "Core Earnings forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.665443}, {"text": "Shire-related costs", "sentiment": {"score": -0.441994, "label": "negative"}, "relevance": 0.659659}, {"text": "Operating Profit forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.658833}, {"text": "Shire plc", "sentiment": {"score": 0.470485, "label": "positive"}, "relevance": 0.65833}, {"text": "R&D expenses", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.652435}, {"text": "yen", "sentiment": {"score": -0.365544, "label": "negative"}, "relevance": 0.648762}, {"text": "Operating Profit margin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.624448}, {"text": "historical published earnings", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.622585}, {"text": "Basic earnings", "sentiment": {"score": 0.2795, "label": "positive"}, "relevance": 0.620444}, {"text": "release", "sentiment": {"score": -0.367442, "label": "negative"}, "relevance": 0.613514}, {"text": "half Shire", "sentiment": {"score": -0.494572, "label": "negative"}, "relevance": 0.609569}, {"text": "positive revenue impact", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.605292}, {"text": "future results", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.604961}, {"text": "latest business circumstances", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.604388}, {"text": "Techpool Bio-Pharma Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.599527}, {"text": "Underlying Revenue", "sentiment": {"score": 0.248918, "label": "positive"}, "relevance": 0.598574}, {"text": "myeloma product VELCADE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.59639}, {"text": "strong business performance", "sentiment": {"score": 0.319864, "label": "positive"}, "relevance": 0.594628}, {"text": "global cost reduction", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.592338}, {"text": "foreign currency effect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.59079}, {"text": "income taxes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.590503}, {"text": "forward looking statements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.589489}, {"text": "previous forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.587754}, {"text": "Electronic News Publishing", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.58494}, {"text": "source ENP Newswire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.584351}, {"text": "general economic conditions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.583826}, {"text": "applicable securities laws", "sentiment": {"score": -0.707214, "label": "negative"}, "relevance": 0.583337}, {"text": "product development programs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.583285}, {"text": "financial position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.574228}, {"text": "financial expenses", "sentiment": {"score": -0.384343, "label": "negative"}, "relevance": 0.565371}, {"text": "Shire-related expenses", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.562981}, {"text": "booking revenue", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561309}, {"text": "Revenue projection", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559319}, {"text": "integration costs", "sentiment": {"score": -0.494965, "label": "negative"}, "relevance": 0.55893}, {"text": "forecasts", "sentiment": {"score": -0.446402, "label": "negative"}, "relevance": 0.558558}, {"text": "Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558344}, {"text": "tax impact", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.557523}, {"text": "consolidated financials", "sentiment": {"score": -0.451808, "label": "negative"}, "relevance": 0.555377}, {"text": "EPS forecasts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555249}, {"text": "acquisition", "sentiment": {"score": -0.520273, "label": "negative"}, "relevance": 0.554527}]}, "extracted_metadata": {"sha1": "7f07a6a95da48ce8b277835cc83b1fc34752a646", "filename": "1541085855977.zip-de6c622018954a7c2a85ac03c9f521fb.xml", "file_type": "json"}, "title": "Takeda Pharmaceutical : Notice of the Revised Forecast of Consolidated Financials for FY2018", "forum_title": "Markets : News, Latest News - Marketscreener.com"}, {"id": "Na6_UyjHIe51oiS0sbtZV9j9B2FnCYu1fW2xBv9O_lSylJKs1h_zD0ISPz3VctGT", "result_metadata": {"score": 33.54856}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "medical cannabis", "relevance": 0.33, "type": "Drug"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Creso", "keywords": [{"text": "Creso"}]}, "sentence": "Creso to launch its first medical cannabis product in Brazil", "object": {"text": "its first medical cannabis product in Brazil", "keywords": [{"text": "medical cannabis product"}, {"text": "Brazil"}], "entities": [{"type": "Drug", "text": "medical cannabis"}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "launch", "tense": "future"}, "text": "to launch", "normalized": "to launch"}}], "concepts": [{"text": "Cannabis", "relevance": 0.9044, "dbpedia_resource": "http://dbpedia.org/resource/Cannabis"}, {"text": "Medical cannabis", "relevance": 0.889404, "dbpedia_resource": "http://dbpedia.org/resource/Medical_cannabis"}], "categories": [{"score": 0.508579, "label": "/business and industrial/metals"}, {"score": 0.504629, "label": "/health and fitness/addiction/smoking addiction"}, {"score": 0.486794, "label": "/business and industrial/advertising and marketing"}], "relations": [], "keywords": [{"text": "medical cannabis product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.981421}, {"text": "Brazil", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52898}, {"text": "Creso", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331517}]}, "crawl_date": "2018-11-01T18:36:59Z", "url": "https://www.businesspress24.com/pressrelease1543451/creso-to-launch-its-first-medical-cannabis-product-in-brazil-br.html", "host": "businesspress24.com", "text": "SIN Solution has an extensive commercial network, working with a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries including global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brasil and Danone.Forward Looking statements", "main_image_url": "https://www.businesspress24.com/images/logo.jpg", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-01T12:11:00Z", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": 0.605143, "label": "positive"}, "text": "SIN Solution", "relevance": 0.836982, "type": "Company"}, {"count": 12, "sentiment": {"score": 0.250734, "label": "positive"}, "text": "Brazil", "relevance": 0.807241, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}, {"count": 8, "sentiment": {"score": 0.335129, "label": "positive"}, "text": "cannabis", "relevance": 0.601263, "type": "Drug"}, {"count": 6, "sentiment": {"score": 0.121297, "label": "positive"}, "text": "Brasil", "relevance": 0.565866, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 6, "sentiment": {"score": 0.605471, "label": "positive"}, "text": "Cresos", "relevance": 0.455273, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": -0.383908, "label": "negative"}, "text": "MedDepot Brasil", "relevance": 0.446016, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MedDepot Brazil", "relevance": 0.41695, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil- Creso", "relevance": 0.398795, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 3, "sentiment": {"score": 0.386625, "label": "positive"}, "text": "Creso", "relevance": 0.376141, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.298346, "label": "positive"}, "text": "San Paulo", "relevance": 0.371973, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "S\u00e3o Paulo", "dbpedia_resource": "http://dbpedia.org/resource/S\u00e3o_Paulo"}}, {"count": 2, "sentiment": {"score": 0.373237, "label": "positive"}, "text": "Med Depot Brasil", "relevance": 0.348966, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "medical cannabis", "relevance": 0.34062, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Med Depot Brazil", "relevance": 0.340263, "type": "Company"}, {"count": 3, "sentiment": {"score": -0.383908, "label": "negative"}, "text": "partner", "relevance": 0.319595, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.316859, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 2, "sentiment": {"score": 0.823546, "label": "positive"}, "text": "Switzerland", "relevance": 0.291167, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.288214, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": -0.451505, "label": "negative"}, "text": "painCreso Pharma Limited", "relevance": 0.287667, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "SR Group", "relevance": 0.286174, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0.454725, "label": "positive"}, "text": "Latin America", "relevance": 0.286077, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Galderma", "relevance": 0.28416, "type": "Company", "disambiguation": {"subtype": [], "name": "Galderma", "dbpedia_resource": "http://dbpedia.org/resource/Galderma"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "marketing and sales", "relevance": 0.284061, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.280073, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.383908, "label": "negative"}, "text": "Creso", "relevance": 0.276235, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Miami", "relevance": 0.272675, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Creso Pharma Ltd", "relevance": 0.266678, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "neurologic diseases", "relevance": 0.265484, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Neurological disorder", "dbpedia_resource": "http://dbpedia.org/resource/Neurological_disorder"}}, {"count": 2, "sentiment": {"score": 0.792635, "label": "positive"}, "text": "Partner", "relevance": 0.26531, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.258228, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.792635, "label": "positive"}, "text": "Director", "relevance": 0.256726, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.675935, "label": "positive"}, "text": "Marketing and Sales services", "relevance": 0.256543, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "CBD", "relevance": 0.250247, "type": "Company", "disambiguation": {"subtype": [], "name": "Grupo P\u00e3o de A\u00e7\u00facar", "dbpedia_resource": "http://dbpedia.org/resource/Grupo_P\u00e3o_de_A\u00e7\u00facar"}}, {"count": 1, "sentiment": {"score": 0.347459, "label": "positive"}, "text": "Creso Pharma", "relevance": 0.23852, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.909335, "label": "positive"}, "text": "Sergio Rigueto", "relevance": 0.231461, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.383908, "label": "negative"}, "text": "representative", "relevance": 0.23099, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.675935, "label": "positive"}, "text": "Dr. Miri Halperin Wernli", "relevance": 0.230326, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Parana", "relevance": 0.227846, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr. med Aufdermaur AG", "relevance": 0.224302, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.675935, "label": "positive"}, "text": "Alessandra Cesar", "relevance": 0.219495, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Call Center Service", "relevance": 0.217918, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Curitiba", "relevance": 0.216486, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Curitiba", "dbpedia_resource": "http://dbpedia.org/resource/Curitiba"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "niacin", "relevance": 0.20715, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0.386625, "label": "positive"}, "text": "cannabidiol", "relevance": 0.206137, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Domaco", "relevance": 0.204455, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Domaco", "relevance": 0.204325, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland.", "relevance": 0.198535, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0.675935, "label": "positive"}, "text": "Co-founder and CEO", "relevance": 0.194672, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.384477, "label": "positive"}, "text": "Janeiro", "relevance": 0.183278, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3 years", "relevance": 0.183278, "type": "Quantity"}], "sentiment": {"document": {"score": 0.796524, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "MedDepot Brazil", "keywords": [{"text": "Brazil"}, {"text": "MedDepot"}], "entities": [{"type": "Company", "text": "MedDepot Brazil"}]}, "sentence": " MedDepot Brazil specializes in the importation of medicines that are not commercialized in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient.", "object": {"text": "in the importation of medicines that are not commercialized in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient", "keywords": [{"text": "initial request"}, {"text": "ultimate delivery"}, {"text": "medicines"}, {"text": "patient access"}], "entities": [{"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}]}, "action": {"verb": {"text": "specialize", "tense": "present"}, "text": "specializes", "normalized": "specialize"}}, {"subject": {"text": "the importation of medicines", "keywords": [{"text": "importation"}, {"text": "medicines"}]}, "sentence": " MedDepot Brazil specializes in the importation of medicines that are not commercialized in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient.", "object": {"text": "not commercialized in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient", "keywords": [{"text": "initial request"}, {"text": "ultimate delivery"}, {"text": "patient access"}, {"text": "medicines"}], "entities": [{"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "medicines", "keywords": [{"text": "medicines"}]}, "sentence": " MedDepot Brazil specializes in the importation of medicines that are not commercialized in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient.", "action": {"verb": {"text": "commercialize", "tense": "past", "negated": true}, "text": "commercialized", "normalized": "commercialize"}}, {"subject": {"text": "the initial request", "keywords": [{"text": "initial request"}]}, "sentence": " MedDepot Brazil specializes in the importation of medicines that are not commercialized in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient.", "object": {"text": "to the ultimate delivery in the hands of the patient", "keywords": [{"text": "hands"}, {"text": "ultimate delivery"}, {"text": "patient"}]}, "action": {"verb": {"text": "monitor", "tense": "present"}, "text": "monitoring", "normalized": "monitor"}}, {"subject": {"text": "by Cresos established partnership with SIN Solution, who will engage in the sales and marketing of Cresos products through its well established Call Center Service", "keywords": [{"text": "SIN Solution"}, {"text": "Cresos products"}, {"text": "partnership"}, {"text": "sales"}], "entities": [{"type": "Company", "text": "Cresos"}, {"type": "Company", "text": "SIN Solution"}, {"type": "Company", "text": "Creso"}, {"type": "Organization", "text": "Call Center Service"}]}, "sentence": " Sales and marketing efforts in Brazil will be supported by Cresos established partnership with SIN Solution, who will engage in the sales and marketing of Cresos products through its well established Call Center Service.", "object": {"text": "Sales and marketing efforts in Brazil", "keywords": [{"text": "marketing efforts"}, {"text": "Brazil"}, {"text": "Sales"}], "entities": [{"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}]}, "action": {"verb": {"text": "support", "tense": "future"}, "text": "will be supported", "normalized": "will be support"}}, {"subject": {"text": "Cresos", "keywords": [{"text": "Cresos"}], "entities": [{"type": "Company", "text": "Cresos"}]}, "sentence": " Sales and marketing efforts in Brazil will be supported by Cresos established partnership with SIN Solution, who will engage in the sales and marketing of Cresos products through its well established Call Center Service.", "object": {"text": "partnership", "keywords": [{"text": "partnership"}]}, "action": {"verb": {"text": "establish", "tense": "future"}, "text": "established", "normalized": "establish"}}, {"subject": {"text": "SIN Solution", "keywords": [{"text": "SIN Solution"}], "entities": [{"type": "Company", "text": "SIN Solution"}]}, "sentence": " SIN Solution is a Brazil based company that specialised in the market-access sales, doctors and patients support for health care products in Brazil and across Latin America.", "object": {"text": "a Brazil based company that specialised in the market-access sales, doctors and patients support for health care products in Brazil and across Latin America", "keywords": [{"text": "Brazil based company"}, {"text": "health care products"}, {"text": "market-access sales"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}, {"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a Brazil based company", "keywords": [{"text": "Brazil based company"}], "entities": [{"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}]}, "sentence": " SIN Solution is a Brazil based company that specialised in the market-access sales, doctors and patients support for health care products in Brazil and across Latin America.", "action": {"verb": {"text": "specialise", "tense": "past"}, "text": "specialised", "normalized": "specialise"}}, {"subject": {"text": "It"}, "sentence": " It has direct access to more than 350,000 health professionals and over 200,000 patients.In addition SIN Solution works with a number of high-profile commercial partners in Brazil and beyond, including Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brazil and Danone.The first focus of its marketing, sales and patient support activities will be in the big agglomerations of Sao Paulo, Rio de Janeiro, Curitiba (Parana) with a total population of over 22 million people.", "object": {"text": "direct access to more than 350,000 health professionals and over 200,000 patients.In", "keywords": [{"text": "direct access"}, {"text": "health professionals"}, {"text": "patients.In"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache", "keywords": [{"text": "Galderma"}, {"text": "GSK"}, {"text": "Takeda"}, {"text": "Ache"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "GSK"}, {"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Novartis", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Galderma", "disambiguation": {"subtype": [], "name": "Galderma", "dbpedia_resource": "http://dbpedia.org/resource/Galderma"}}]}, "sentence": " It has direct access to more than 350,000 health professionals and over 200,000 patients.In addition SIN Solution works with a number of high-profile commercial partners in Brazil and beyond, including Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brazil and Danone.The first focus of its marketing, sales and patient support activities will be in the big agglomerations of Sao Paulo, Rio de Janeiro, Curitiba (Parana) with a total population of over 22 million people.", "object": {"text": "Brazil", "keywords": [{"text": "Brazil"}], "entities": [{"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}]}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "do", "normalized": "do"}}, {"subject": {"text": "sales and patient support activities", "keywords": [{"text": "patient support activities"}, {"text": "sales"}]}, "sentence": " It has direct access to more than 350,000 health professionals and over 200,000 patients.In addition SIN Solution works with a number of high-profile commercial partners in Brazil and beyond, including Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brazil and Danone.The first focus of its marketing, sales and patient support activities will be in the big agglomerations of Sao Paulo, Rio de Janeiro, Curitiba (Parana) with a total population of over 22 million people.", "object": {"text": "in the big agglomerations of Sao Paulo, Rio de Janeiro, Curitiba (Parana)", "keywords": [{"text": "Sao Paulo"}, {"text": "big agglomerations"}, {"text": "Parana"}, {"text": "Curitiba"}], "entities": [{"type": "Location", "text": "San Paulo", "disambiguation": {"subtype": ["City"], "name": "S\u00e3o Paulo", "dbpedia_resource": "http://dbpedia.org/resource/S\u00e3o_Paulo"}}, {"type": "Location", "text": "Janeiro", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "Curitiba", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Curitiba", "dbpedia_resource": "http://dbpedia.org/resource/Curitiba"}}, {"type": "Location", "text": "Parana", "disambiguation": {"subtype": ["Region"]}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "Main addressees", "keywords": [{"text": "Main addressees"}]}, "sentence": " Main addressees are doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution is in a good position to provide the marketing / sales services combined with the needed doctors and patients support in this new evolving area says Sergio Rigueto Director Partner of SIN Solution.", "object": {"text": "doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution", "keywords": [{"text": "50000.SIN Solution"}, {"text": "neurology"}, {"text": "oncology"}, {"text": "doctors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "an expected number of patients over 50000.SIN Solution", "keywords": [{"text": "expected number"}, {"text": "50000.SIN Solution"}, {"text": "patients"}]}, "sentence": " Main addressees are doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution is in a good position to provide the marketing / sales services combined with the needed doctors and patients support in this new evolving area says Sergio Rigueto Director Partner of SIN Solution.", "object": {"text": "in a good position", "keywords": [{"text": "good position"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution", "keywords": [{"text": "50000.SIN Solution"}, {"text": "neurology"}, {"text": "oncology"}, {"text": "doctors"}]}, "sentence": " Main addressees are doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution is in a good position to provide the marketing / sales services combined with the needed doctors and patients support in this new evolving area says Sergio Rigueto Director Partner of SIN Solution.", "object": {"text": "the marketing / sales services combined with the needed doctors and patients support in this new evolving area", "keywords": [{"text": "new evolving area"}, {"text": "marketing / sales"}, {"text": "patients support"}, {"text": "doctors"}], "entities": [{"type": "JobTitle", "text": "Marketing and Sales services"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "Sergio Rigueto Director Partner of SIN Solution", "keywords": [{"text": "Sergio Rigueto Director"}, {"text": "SIN"}, {"text": "Partner"}], "entities": [{"type": "Person", "text": "Sergio Rigueto"}, {"type": "JobTitle", "text": "Director"}, {"type": "JobTitle", "text": "Partner"}, {"type": "Company", "text": "SIN Solution"}]}, "sentence": " Main addressees are doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution is in a good position to provide the marketing / sales services combined with the needed doctors and patients support in this new evolving area says Sergio Rigueto Director Partner of SIN Solution.", "object": {"text": "Main addressees are doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution is in a good position to provide the marketing / sales services combined with the needed doctors and patients support in this new evolving area", "keywords": [{"text": "new evolving area"}, {"text": "good position"}, {"text": "Main addressees"}, {"text": "50000.SIN Solution"}], "entities": [{"type": "JobTitle", "text": "Marketing and Sales services"}]}, "action": {"verb": {"text": "say", "tense": "present"}, "text": "says", "normalized": "say"}}, {"subject": {"text": "SIN Solution", "keywords": [{"text": "SIN Solution"}], "entities": [{"type": "Company", "text": "SIN Solution"}]}, "sentence": " The Marketing and Sales services combined with doctors and patients support which SIN Solution can provide are very innovative and provide an added value to all stakeholders involved says Alessandra Cesar Director Partner of SIN Solution.Cresos Co-founder and CEO Dr. Miri Halperin Wernli, said: We are very excited about the launch of our first medicinal cannabis product in Brazil through our partnerships with MedDepot Brasil and SIN Solution.", "object": {"text": "very innovative"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Alessandra Cesar Director Partner of SIN Solution.Cresos Co-founder and CEO Dr. Miri Halperin Wernli", "keywords": [{"text": "Dr. Miri Halperin"}, {"text": "Alessandra Cesar Director"}, {"text": "SIN Solution.Cresos Co-founder"}, {"text": "CEO"}], "entities": [{"type": "Person", "text": "Alessandra Cesar"}, {"type": "JobTitle", "text": "Director"}, {"type": "JobTitle", "text": "Partner"}, {"type": "JobTitle", "text": "Co-founder and CEO"}, {"type": "Person", "text": "Dr. Miri Halperin Wernli"}]}, "sentence": " The Marketing and Sales services combined with doctors and patients support which SIN Solution can provide are very innovative and provide an added value to all stakeholders involved says Alessandra Cesar Director Partner of SIN Solution.Cresos Co-founder and CEO Dr. Miri Halperin Wernli, said: We are very excited about the launch of our first medicinal cannabis product in Brazil through our partnerships with MedDepot Brasil and SIN Solution.", "object": {"text": "The Marketing and Sales services combined with doctors and patients support which SIN Solution can provide are very innovative and provide an added value to all stakeholders involved", "keywords": [{"text": "SIN Solution"}, {"text": "Sales services"}, {"text": "stakeholders"}, {"text": "doctors"}], "entities": [{"type": "JobTitle", "text": "Marketing and Sales services"}, {"type": "Company", "text": "SIN Solution"}]}, "action": {"verb": {"text": "say", "tense": "present"}, "text": "says", "normalized": "say"}}, {"subject": {"text": "We"}, "sentence": " The Marketing and Sales services combined with doctors and patients support which SIN Solution can provide are very innovative and provide an added value to all stakeholders involved says Alessandra Cesar Director Partner of SIN Solution.Cresos Co-founder and CEO Dr. Miri Halperin Wernli, said: We are very excited about the launch of our first medicinal cannabis product in Brazil through our partnerships with MedDepot Brasil and SIN Solution.", "object": {"text": "very excited about the launch of our first medicinal cannabis product in Brazil", "keywords": [{"text": "medicinal cannabis product"}, {"text": "launch"}, {"text": "Brazil"}], "entities": [{"type": "Drug", "text": "cannabis"}, {"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "We"}, "sentence": " We see that there is a great unmet need in the areas of neuropathic pain and pains related to cancer and other neurologic diseases in Brazil and we believe both MedDepot Brasil and SIN Solution are well placed to ensure our successful launch in the region.", "object": {"text": "that there is a great unmet need in the areas of neuropathic pain and pains related to cancer and other neurologic diseases in Brazil and we believe both MedDepot Brasil and SIN Solution are well placed to ensure our successful launch in the region", "keywords": [{"text": "great unmet need"}, {"text": "neuropathic pain"}, {"text": "neurologic diseases"}, {"text": "MedDepot Brasil"}], "entities": [{"type": "HealthCondition", "text": "neurologic diseases", "disambiguation": {"subtype": [], "name": "Neurological disorder", "dbpedia_resource": "http://dbpedia.org/resource/Neurological_disorder"}}, {"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}, {"type": "Company", "text": "SIN Solution"}]}, "action": {"verb": {"text": "see", "tense": "present"}, "text": "see", "normalized": "see"}}, {"subject": {"text": "both MedDepot Brasil and SIN Solution", "keywords": [{"text": "MedDepot Brasil"}, {"text": "SIN Solution"}], "entities": [{"type": "Company", "text": "SIN Solution"}]}, "sentence": " We see that there is a great unmet need in the areas of neuropathic pain and pains related to cancer and other neurologic diseases in Brazil and we believe both MedDepot Brasil and SIN Solution are well placed to ensure our successful launch in the region.", "object": {"text": "our successful launch in the region", "keywords": [{"text": "successful launch"}, {"text": "region"}]}, "action": {"verb": {"text": "ensure", "tense": "future"}, "text": "to ensure", "normalized": "to ensure"}}, {"subject": {"text": "the active ingredients", "keywords": [{"text": "active ingredients"}]}, "sentence": " By being dissolved in the mouth, the active ingredients enter the blood stream directly, avoiding this first pass through the liver.The standardized, user-friendly strength and formulation allows precise dosage control, ensuring a reliable and stable effect.", "object": {"text": "the blood stream", "keywords": [{"text": "blood stream"}]}, "action": {"verb": {"text": "enter", "tense": "present"}, "text": "enter", "normalized": "enter"}}, {"subject": {"text": "user-friendly strength and formulation", "keywords": [{"text": "user-friendly strength"}, {"text": "formulation"}]}, "sentence": " By being dissolved in the mouth, the active ingredients enter the blood stream directly, avoiding this first pass through the liver.The standardized, user-friendly strength and formulation allows precise dosage control, ensuring a reliable and stable effect.", "object": {"text": "precise dosage control, ensuring a reliable and stable effect", "keywords": [{"text": "precise dosage control"}, {"text": "stable effect"}]}, "action": {"verb": {"text": "allow", "tense": "present"}, "text": "allows", "normalized": "allow"}}, {"subject": {"text": "The cannaQIX\u00ae range", "keywords": [{"text": "cannaQIX\u00ae range"}]}, "sentence": " The cannaQIX\u00ae range has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Cresos partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality with a Swiss Made label.", "object": {"text": "to Good Manufacturing Practice standards", "keywords": [{"text": "Good Manufacturing Practice"}, {"text": "standards"}]}, "action": {"verb": {"text": "develop", "tense": "past"}, "text": "has been developed", "normalized": "have be develop"}}, {"subject": {"text": "by Cresos partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco)", "keywords": [{"text": "pharma development company"}, {"text": "Swiss-based food"}, {"text": "Cresos partner"}, {"text": "Aufdermaur AG"}], "entities": [{"type": "JobTitle", "text": "partner"}, {"type": "Location", "text": "Domaco", "disambiguation": {"subtype": ["City"]}}, {"type": "Person", "text": "Dr. med Aufdermaur AG"}, {"type": "Company", "text": "Domaco"}]}, "sentence": " The cannaQIX\u00ae range has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Cresos partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality with a Swiss Made label.", "object": {"text": "The cannaQIX\u00ae range", "keywords": [{"text": "cannaQIX\u00ae range"}]}, "action": {"verb": {"text": "produce", "tense": "past"}, "text": "is produced", "normalized": "be produce"}}, {"subject": {"text": "END -About Creso Pharma Ltd (www.cresopharma.com)Creso Pharma", "keywords": [{"text": ")Creso Pharma"}], "entities": [{"type": "Company", "text": "Creso Pharma Ltd"}, {"type": "Company", "text": "Creso Pharma"}]}, "sentence": " - END -About Creso Pharma Ltd (www.cresopharma.com)Creso Pharma brings the best of cannabis to better the lives of people and animals.", "object": {"text": "the best of cannabis", "keywords": [{"text": "cannabis"}], "entities": [{"type": "Drug", "text": "cannabis"}]}, "action": {"verb": {"text": "bring", "tense": "present"}, "text": "brings", "normalized": "bring"}}, {"subject": {"text": "It"}, "sentence": " It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products.", "object": {"text": "pharmaceutical expertise and methodological rigor to the cannabis world", "keywords": [{"text": "methodological rigor"}, {"text": "cannabis world"}, {"text": "pharmaceutical expertise"}], "entities": [{"type": "Drug", "text": "cannabis"}]}, "action": {"verb": {"text": "bring", "tense": "present"}, "text": "brings", "normalized": "bring"}}, {"subject": {"text": "for the highest quality", "keywords": [{"text": "highest quality"}]}, "sentence": " It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products.", "action": {"verb": {"text": "strive", "tense": "present"}, "text": "strives", "normalized": "strive"}}, {"subject": {"text": "It"}, "sentence": " It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.", "object": {"text": "cannabis and hemp derived therapeutic, nutraceutical,", "keywords": [{"text": "cannabis"}, {"text": "hemp"}], "entities": [{"type": "Drug", "text": "cannabis"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develops", "normalized": "develop"}}, {"subject": {"text": "Creso", "keywords": [{"text": "Creso"}], "entities": [{"type": "Location", "text": "Cresos", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland.", "object": {"text": "GMP development and manufacturing standards", "keywords": [{"text": "GMP development"}, {"text": "manufacturing standards"}]}, "action": {"verb": {"text": "use", "tense": "present"}, "text": "uses", "normalized": "use"}}, {"subject": {"text": "It"}, "sentence": " It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines.", "object": {"text": "worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.About Med Depot Brasil", "keywords": [{"text": "Med Depot Brasil"}, {"text": "proprietary innovative delivery"}, {"text": "worldwide rights"}, {"text": "bioavailability"}], "entities": [{"type": "Company", "text": "Med Depot Brasil"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the bioavailability and absorption of cannabinoids.About Med Depot Brasil", "keywords": [{"text": "Med Depot Brasil"}, {"text": "bioavailability"}, {"text": "absorption"}], "entities": [{"type": "Company", "text": "Med Depot Brasil"}]}, "sentence": " It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines.", "object": {"text": "proprietary innovative delivery technologies", "keywords": [{"text": "delivery technologies"}]}, "action": {"verb": {"text": "enhance", "tense": "present"}, "text": "enhance", "normalized": "enhance"}}, {"subject": {"text": "technologies which enhance the bioavailability and absorption of cannabinoids.About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil", "keywords": [{"text": "Med Depot Brasil"}, {"text": "bioavailability"}, {"text": "absorption"}, {"text": "technologies"}], "entities": [{"type": "Company", "text": "Med Depot Brasil"}, {"type": "Company", "text": "Med Depot Brasil"}]}, "sentence": " It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines.", "object": {"text": "a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines", "keywords": [{"text": "Brasil based company"}, {"text": "North American group"}, {"text": "SR Group"}, {"text": "strong performance"}], "entities": [{"type": "Location", "text": "MedDepot Brasil", "disambiguation": {"subtype": ["City"]}}, {"type": "Organization", "text": "SR Group"}, {"type": "Location", "text": "Miami", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It is based in Sao Paulo, Brasil.", "action": {"verb": {"text": "base", "tense": "past"}, "text": "is based", "normalized": "be base"}}, {"subject": {"text": "It"}, "sentence": " It has a potent structure with global access and expertise to take care of all steps involving the purchase of imported medicines, monitoring from the request to the delivery in the hands of the patient.About SIN Solution (www.sinsolution.com)SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America.", "object": {"text": "a potent structure with global access and expertise to take care of all steps involving the purchase of imported medicines, monitoring from the request to the delivery in the hands of the patient.About SIN Solution (www.sinsolution.com)SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America", "keywords": [{"text": "Brasil based company"}, {"text": "health care products"}, {"text": "potent structure"}, {"text": "global access"}], "entities": [{"type": "Company", "text": "SIN Solution"}, {"type": "Location", "text": "Brasil", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "MedDepot Brasil", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "care", "keywords": [{"text": "care"}]}, "sentence": " It has a potent structure with global access and expertise to take care of all steps involving the purchase of imported medicines, monitoring from the request to the delivery in the hands of the patient.About SIN Solution (www.sinsolution.com)SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America.", "object": {"text": "of all steps involving the purchase of imported medicines", "keywords": [{"text": "medicines"}, {"text": "steps"}, {"text": "purchase"}]}, "action": {"verb": {"text": "take", "tense": "future"}, "text": "to take", "normalized": "to take"}}, {"subject": {"text": "the purchase of imported medicines", "keywords": [{"text": "medicines"}, {"text": "purchase"}]}, "sentence": " It has a potent structure with global access and expertise to take care of all steps involving the purchase of imported medicines, monitoring from the request to the delivery in the hands of the patient.About SIN Solution (www.sinsolution.com)SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America.", "object": {"text": "all steps", "keywords": [{"text": "steps"}]}, "action": {"verb": {"text": "involve", "tense": "present"}, "text": "involving", "normalized": "involve"}}, {"subject": {"text": "a Brasil based company", "keywords": [{"text": "Brasil based company"}], "entities": [{"type": "Location", "text": "Brasil", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " It has a potent structure with global access and expertise to take care of all steps involving the purchase of imported medicines, monitoring from the request to the delivery in the hands of the patient.About SIN Solution (www.sinsolution.com)SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America.", "object": {"text": "in the market-access, sale and distribution services of health care products in Brasil and across Latin America", "keywords": [{"text": "health care products"}, {"text": "distribution services"}, {"text": "Latin America"}, {"text": "Brasil"}], "entities": [{"type": "Location", "text": "MedDepot Brasil", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "specialise", "tense": "past"}, "text": "specialised", "normalized": "specialise"}}, {"subject": {"text": "It"}, "sentence": " It has access to more than 350,000 health professionals and over 200,000 direct patient contacts in the region.", "object": {"text": "access to more than 350,000 health professionals and over 200,000 direct patient contacts in the region", "keywords": [{"text": "direct patient contacts"}, {"text": "health professionals"}, {"text": "access"}, {"text": "region"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "SIN Solution", "keywords": [{"text": "SIN Solution"}], "entities": [{"type": "Company", "text": "SIN Solution"}]}, "sentence": " SIN Solution has an extensive commercial network, working with a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries including global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brasil and Danone.Forward Looking statements", "object": {"text": "an extensive commercial network, working with a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries including global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma", "keywords": [{"text": "high-profile commercial partners"}, {"text": "global medical device"}, {"text": "extensive commercial network"}, {"text": "various consumer goods"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "GSK"}, {"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Novartis", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Galderma", "disambiguation": {"subtype": [], "name": "Galderma", "dbpedia_resource": "http://dbpedia.org/resource/Galderma"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache", "keywords": [{"text": "global medical device"}, {"text": "various consumer goods"}, {"text": "Galderma"}, {"text": "GSK"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "GSK"}, {"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Novartis", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Galderma", "disambiguation": {"subtype": [], "name": "Galderma", "dbpedia_resource": "http://dbpedia.org/resource/Galderma"}}]}, "sentence": " SIN Solution has an extensive commercial network, working with a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries including global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brasil and Danone.Forward Looking statements", "object": {"text": "a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries", "keywords": [{"text": "high-profile commercial partners"}, {"text": "food manufacturing"}, {"text": "pharmaceutical industries"}, {"text": "number"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache", "keywords": [{"text": "Galderma"}, {"text": "GSK"}, {"text": "Takeda"}, {"text": "Ache"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "GSK"}, {"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Novartis", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Galderma", "disambiguation": {"subtype": [], "name": "Galderma", "dbpedia_resource": "http://dbpedia.org/resource/Galderma"}}]}, "sentence": " SIN Solution has an extensive commercial network, working with a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries including global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brasil and Danone.Forward Looking statements", "object": {"text": "Brasil", "keywords": [{"text": "Brasil"}], "entities": [{"type": "Company", "text": "MedDepot Brasil"}]}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "do", "normalized": "do"}}], "concepts": [{"text": "S\u00e3o Paulo", "relevance": 0.946602, "dbpedia_resource": "http://dbpedia.org/resource/S\u00e3o_Paulo"}, {"text": "Medical cannabis", "relevance": 0.739598, "dbpedia_resource": "http://dbpedia.org/resource/Medical_cannabis"}, {"text": "Latin America", "relevance": 0.684671, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}, {"text": "Brazil", "relevance": 0.667838, "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}, {"text": "Neuropathic pain", "relevance": 0.667159, "dbpedia_resource": "http://dbpedia.org/resource/Neuropathic_pain"}, {"text": "Medicine", "relevance": 0.610244, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Cannabis", "relevance": 0.600528, "dbpedia_resource": "http://dbpedia.org/resource/Cannabis"}, {"text": "Rio de Janeiro", "relevance": 0.5635, "dbpedia_resource": "http://dbpedia.org/resource/Rio_de_Janeiro"}, {"text": "Pain", "relevance": 0.51128, "dbpedia_resource": "http://dbpedia.org/resource/Pain"}, {"text": "Tetrahydrocannabinol", "relevance": 0.496054, "dbpedia_resource": "http://dbpedia.org/resource/Tetrahydrocannabinol"}, {"text": "Pharmacology", "relevance": 0.490264, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Chemotherapy", "relevance": 0.465487, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "Cannabis sativa", "relevance": 0.462331, "dbpedia_resource": "http://dbpedia.org/resource/Cannabis_sativa"}, {"text": "Legality of cannabis by country", "relevance": 0.460997, "dbpedia_resource": "http://dbpedia.org/resource/Legality_of_cannabis_by_country"}, {"text": "Belo Horizonte", "relevance": 0.422823, "dbpedia_resource": "http://dbpedia.org/resource/Belo_Horizonte"}, {"text": "Pharmaceutical drug", "relevance": 0.411574, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Patient", "relevance": 0.410765, "dbpedia_resource": "http://dbpedia.org/resource/Patient"}, {"text": "Multiple sclerosis", "relevance": 0.400991, "dbpedia_resource": "http://dbpedia.org/resource/Multiple_sclerosis"}, {"text": "Antiemetic", "relevance": 0.391266, "dbpedia_resource": "http://dbpedia.org/resource/Antiemetic"}, {"text": "Futsal", "relevance": 0.383426, "dbpedia_resource": "http://dbpedia.org/resource/Futsal"}, {"text": "Americas", "relevance": 0.383287, "dbpedia_resource": "http://dbpedia.org/resource/Americas"}, {"text": "Italian Brazilian", "relevance": 0.38326, "dbpedia_resource": "http://dbpedia.org/resource/Italian_Brazilian"}, {"text": "South America", "relevance": 0.373309, "dbpedia_resource": "http://dbpedia.org/resource/South_America"}], "categories": [{"score": 0.912202, "label": "/health and fitness/disease/chronic pain"}], "relations": [{"type": "employedBy", "sentence": "(businesspress24) - Creso to launch its first medical cannabis product in Brazil1 November 2018Highlights:- Creso signs an import agreement with MedDepot Brasil for the import and delivery of its first medicinal cannabis product in Brazil- Creso initiates its marketing and sales activities with its Brazilian partner SIN Solution with prescribing physicians- cannaQIX\u00ae50 is Cresos first medicinal cannabis product being made available in Brazil, for the treatment of patients with neuropathic and cancer related painCreso Pharma Limited (ASX:CPH, the Company or Creso) is pleased to announce that it is commenced the importation and sale of its medicinal cannabis product, cannaQIX\u00ae50 to patients in Brazil through its importation representative partner MedDepot Brasil.", "score": 0.762517, "arguments": [{"text": "partner", "location": [310, 317], "entities": [{"type": "Person", "text": "SIN Solution.Cresos Co-founder"}]}, {"text": "Brazilian", "location": [300, 309], "entities": [{"type": "GeopoliticalEntity", "text": "Brazilian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.879785, "arguments": [{"text": "San Paulo", "location": [1197, 1206], "entities": [{"type": "GeopoliticalEntity", "text": "San Paulo"}]}, {"text": "Brazil", "location": [1208, 1214], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil.For"}]}]}, {"type": "basedIn", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.908333, "arguments": [{"text": "group", "location": [1269, 1274], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}, {"text": "North American", "location": [1254, 1268], "entities": [{"type": "GeopoliticalEntity", "text": "North American"}]}]}, {"type": "basedIn", "sentence": "About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines.", "score": 0.953007, "arguments": [{"text": "group", "location": [5990, 5995], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}, {"text": "North American", "location": [5975, 5989], "entities": [{"type": "GeopoliticalEntity", "text": "North American"}]}]}, {"type": "basedIn", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.452349, "arguments": [{"text": "group", "location": [1269, 1274], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}, {"text": "headquarters", "location": [1280, 1292], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "basedIn", "sentence": "About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines.", "score": 0.367274, "arguments": [{"text": "group", "location": [5990, 5995], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}, {"text": "headquarters", "location": [6001, 6013], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "locatedAt", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.970479, "arguments": [{"text": "headquarters", "location": [1280, 1292], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "Miami", "location": [1296, 1301], "entities": [{"type": "GeopoliticalEntity", "text": "Miami"}]}]}, {"type": "locatedAt", "sentence": "About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines.", "score": 0.959579, "arguments": [{"text": "headquarters", "location": [6001, 6013], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "Miami", "location": [6017, 6022], "entities": [{"type": "GeopoliticalEntity", "text": "Miami"}]}]}, {"type": "managerOf", "sentence": "MedDepot Brazil specializes in the importation of medicines that are not commercialized in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient.", "score": 0.719954, "arguments": [{"text": "MedDepot", "location": [1367, 1375], "entities": [{"type": "Person", "text": "years.MedDepot Brasil"}]}, {"text": "Brazil", "location": [1376, 1382], "entities": [{"type": "GeopoliticalEntity", "text": "Brazilian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Sales and marketing efforts in Brazil will be supported by Cresos established partnership with SIN Solution, who will engage in the sales and marketing of Cresos products through its well established Call Center Service.", "score": 0.721117, "arguments": [{"text": "Call Center Service", "location": [1836, 1855], "entities": [{"type": "Organization", "text": "Call Center Service"}]}, {"text": "its", "location": [1815, 1818], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}]}, {"type": "basedIn", "sentence": "SIN Solution is a Brazil based company that specialised in the market-access sales, doctors and patients support for health care products in Brazil and across Latin America.", "score": 0.953456, "arguments": [{"text": "company", "location": [1888, 1895], "entities": [{"type": "Organization", "text": "Cresos", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Brazil", "location": [1875, 1881], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil.For"}]}]}, {"type": "partOfMany", "sentence": "In addition SIN Solution works with a number of high-profile commercial partners in Brazil and beyond, including Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brazil and Danone.The first focus of its marketing, sales and patient support activities will be in the big agglomerations of Sao Paulo, Rio de Janeiro, Curitiba (Parana) with a total population of over 22 million people.", "score": 0.374847, "arguments": [{"text": "SIN Solution", "location": [2132, 2144], "entities": [{"type": "Person", "text": "SIN Solution.Cresos Co-founder"}]}, {"text": "partners", "location": [2192, 2200], "entities": [{"type": "Person", "text": "partners"}]}]}, {"type": "locatedAt", "sentence": "In addition SIN Solution works with a number of high-profile commercial partners in Brazil and beyond, including Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brazil and Danone.The first focus of its marketing, sales and patient support activities will be in the big agglomerations of Sao Paulo, Rio de Janeiro, Curitiba (Parana) with a total population of over 22 million people.", "score": 0.960441, "arguments": [{"text": "Sao Paulo", "location": [2429, 2438], "entities": [{"type": "GeopoliticalEntity", "text": "Sao Paulo"}]}, {"text": "Rio de Janeiro", "location": [2440, 2454], "entities": [{"type": "GeopoliticalEntity", "text": "Rio de Janeiro"}]}]}, {"type": "locatedAt", "sentence": "In addition SIN Solution works with a number of high-profile commercial partners in Brazil and beyond, including Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brazil and Danone.The first focus of its marketing, sales and patient support activities will be in the big agglomerations of Sao Paulo, Rio de Janeiro, Curitiba (Parana) with a total population of over 22 million people.", "score": 0.518204, "arguments": [{"text": "Curitiba", "location": [2456, 2464], "entities": [{"type": "GeopoliticalEntity", "text": "Curitiba"}]}, {"text": "Parana", "location": [2466, 2472], "entities": [{"type": "GeopoliticalEntity", "text": "Parana"}]}]}, {"type": "hasAttribute", "sentence": "(businesspress24) - Creso to launch its first medical cannabis product in Brazil1 November 2018Highlights:- Creso signs an import agreement with MedDepot Brasil for the import and delivery of its first medicinal cannabis product in Brazil- Creso initiates its marketing and sales activities with its Brazilian partner SIN Solution with prescribing physicians- cannaQIX\u00ae50 is Cresos first medicinal cannabis product being made available in Brazil, for the treatment of patients with neuropathic and cancer related painCreso Pharma Limited (ASX:CPH, the Company or Creso) is pleased to announce that it is commenced the importation and sale of its medicinal cannabis product, cannaQIX\u00ae50 to patients in Brazil through its importation representative partner MedDepot Brasil.", "score": 0.913587, "arguments": [{"text": "patients", "location": [468, 476], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "neuropathic", "location": [482, 493], "entities": [{"type": "HealthCondition", "text": "neuropathic pain"}]}]}, {"type": "agentOf", "sentence": "Main addressees are doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution is in a good position to provide the marketing / sales services combined with the needed doctors and patients support in this new evolving area says Sergio Rigueto Director Partner of SIN Solution.", "score": 0.677898, "arguments": [{"text": "Sergio Rigueto", "location": [2787, 2801], "entities": [{"type": "Person", "text": "Sergio Rigueto"}]}, {"text": "says", "location": [2782, 2786], "entities": [{"type": "EventCommunication", "text": "says"}]}]}, {"type": "colleague", "sentence": "Main addressees are doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution is in a good position to provide the marketing / sales services combined with the needed doctors and patients support in this new evolving area says Sergio Rigueto Director Partner of SIN Solution.", "score": 0.239357, "arguments": [{"text": "Director Partner", "location": [2802, 2818], "entities": [{"type": "Person", "text": "Sergio Rigueto"}]}, {"text": "SIN Solution", "location": [2822, 2834], "entities": [{"type": "Person", "text": "SIN Solution.Cresos Co-founder"}]}]}, {"type": "agentOf", "sentence": "The Marketing and Sales services combined with doctors and patients support which SIN Solution can provide are very innovative and provide an added value to all stakeholders involved says Alessandra Cesar Director Partner of SIN Solution.Cresos Co-founder and CEO Dr. Miri Halperin Wernli, said: We are very excited about the launch of our first medicinal cannabis product in Brazil through our partnerships with MedDepot Brasil and SIN Solution.", "score": 0.481614, "arguments": [{"text": "stakeholders", "location": [2997, 3009], "entities": [{"type": "Person", "text": "stakeholders"}]}, {"text": "says", "location": [3019, 3023], "entities": [{"type": "EventCommunication", "text": "says"}]}]}, {"type": "agentOf", "sentence": "The Marketing and Sales services combined with doctors and patients support which SIN Solution can provide are very innovative and provide an added value to all stakeholders involved says Alessandra Cesar Director Partner of SIN Solution.Cresos Co-founder and CEO Dr. Miri Halperin Wernli, said: We are very excited about the launch of our first medicinal cannabis product in Brazil through our partnerships with MedDepot Brasil and SIN Solution.", "score": 0.902434, "arguments": [{"text": "Miri Halperin Wernli", "location": [3104, 3124], "entities": [{"type": "Person", "text": "Miri Halperin Wernli"}]}, {"text": "said", "location": [3126, 3130], "entities": [{"type": "EventCommunication", "text": "says"}]}]}, {"type": "locatedAt", "sentence": "The LatAm market is key for Creso, and a successful launch of its products in Brazil will put the Company in a prime position to expand its products to surrounding LatAm countries.", "score": 0.465472, "arguments": [{"text": "its", "location": [3602, 3605], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}, {"text": "Brazil", "location": [3618, 3624], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil.For"}]}]}, {"type": "hasAttribute", "sentence": "About cannaQIX\u00ae 50cannaQIX\u00ae50 is Cresos proprietary buccally formulated cannabidiol (CBD) lozenge which is designed to support the management of chronic pain.", "score": 0.902182, "arguments": [{"text": "Cresos", "location": [3753, 3759], "entities": [{"type": "Person", "text": "Cresos"}]}, {"text": "chronic pain", "location": [3865, 3877], "entities": [{"type": "HealthCondition", "text": "chronic pain"}]}]}, {"type": "managerOf", "sentence": "The cannaQIX\u00ae range has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Cresos partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality with a Swiss Made label.", "score": 0.337429, "arguments": [{"text": "Aufdermaur AG", "location": [5029, 5042], "entities": [{"type": "Person", "text": "Aufdermaur AG"}]}, {"text": "Domaco", "location": [5044, 5050], "entities": [{"type": "Organization", "text": "Domaco"}]}]}, {"type": "employedBy", "sentence": "About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines.", "score": 0.332158, "arguments": [{"text": "Brasil", "location": [5922, 5928], "entities": [{"type": "Person", "text": "years.MedDepot Brasil"}]}, {"text": "company", "location": [5935, 5942], "entities": [{"type": "Organization", "text": "Cresos", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "About SIN Solution (www.sinsolution.com)SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America.", "score": 0.600491, "arguments": [{"text": "Brasil", "location": [6382, 6388], "entities": [{"type": "Person", "text": "years.MedDepot Brasil"}]}, {"text": "company", "location": [6395, 6402], "entities": [{"type": "Organization", "text": "Cresos", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "It is based in Sao Paulo, Brasil.", "score": 0.395328, "arguments": [{"text": "Brasil", "location": [6113, 6119], "entities": [{"type": "Person", "text": "years.MedDepot Brasil"}]}, {"text": "Sao Paulo", "location": [6102, 6111], "entities": [{"type": "GeopoliticalEntity", "text": "Sao Paulo"}]}]}, {"type": "employedBy", "sentence": "About SIN Solution (www.sinsolution.com)SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America.", "score": 0.291738, "arguments": [{"text": "SIN Solution", "location": [6364, 6376], "entities": [{"type": "Person", "text": "SIN Solution.Cresos Co-founder"}]}, {"text": "company", "location": [6395, 6402], "entities": [{"type": "Organization", "text": "Cresos", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "(businesspress24) - Creso to launch its first medical cannabis product in Brazil1 November 2018Highlights:- Creso signs an import agreement with MedDepot Brasil for the import and delivery of its first medicinal cannabis product in Brazil- Creso initiates its marketing and sales activities with its Brazilian partner SIN Solution with prescribing physicians- cannaQIX\u00ae50 is Cresos first medicinal cannabis product being made available in Brazil, for the treatment of patients with neuropathic and cancer related painCreso Pharma Limited (ASX:CPH, the Company or Creso) is pleased to announce that it is commenced the importation and sale of its medicinal cannabis product, cannaQIX\u00ae50 to patients in Brazil through its importation representative partner MedDepot Brasil.", "score": 0.772973, "arguments": [{"text": "patients", "location": [468, 476], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [498, 504], "entities": [{"type": "HealthCondition", "text": "cancer"}]}]}, {"type": "locatedAt", "sentence": "(businesspress24) - Creso to launch its first medical cannabis product in Brazil1 November 2018Highlights:- Creso signs an import agreement with MedDepot Brasil for the import and delivery of its first medicinal cannabis product in Brazil- Creso initiates its marketing and sales activities with its Brazilian partner SIN Solution with prescribing physicians- cannaQIX\u00ae50 is Cresos first medicinal cannabis product being made available in Brazil, for the treatment of patients with neuropathic and cancer related painCreso Pharma Limited (ASX:CPH, the Company or Creso) is pleased to announce that it is commenced the importation and sale of its medicinal cannabis product, cannaQIX\u00ae50 to patients in Brazil through its importation representative partner MedDepot Brasil.", "score": 0.631737, "arguments": [{"text": "patients", "location": [689, 697], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "Brazil", "location": [701, 707], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil.For"}]}]}, {"type": "employedBy", "sentence": "(businesspress24) - Creso to launch its first medical cannabis product in Brazil1 November 2018Highlights:- Creso signs an import agreement with MedDepot Brasil for the import and delivery of its first medicinal cannabis product in Brazil- Creso initiates its marketing and sales activities with its Brazilian partner SIN Solution with prescribing physicians- cannaQIX\u00ae50 is Cresos first medicinal cannabis product being made available in Brazil, for the treatment of patients with neuropathic and cancer related painCreso Pharma Limited (ASX:CPH, the Company or Creso) is pleased to announce that it is commenced the importation and sale of its medicinal cannabis product, cannaQIX\u00ae50 to patients in Brazil through its importation representative partner MedDepot Brasil.", "score": 0.549707, "arguments": [{"text": "representative partner", "location": [732, 754], "entities": [{"type": "Person", "text": "years.MedDepot Brasil"}]}, {"text": "its", "location": [716, 719], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}]}, {"type": "hasAttribute", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.722147, "arguments": [{"text": "patients", "location": [801, 809], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "chronic pain", "location": [825, 837], "entities": [{"type": "HealthCondition", "text": "chronic pain"}]}]}, {"type": "hasAttribute", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.715032, "arguments": [{"text": "patients", "location": [801, 809], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer diseases", "location": [901, 916], "entities": [{"type": "HealthCondition", "text": "cancer diseases"}]}]}, {"type": "partOf", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.939401, "arguments": [{"text": "company", "location": [1180, 1187], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}, {"text": "Brazilian", "location": [1170, 1179], "entities": [{"type": "GeopoliticalEntity", "text": "Brazilian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.46323, "arguments": [{"text": "company", "location": [1180, 1187], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}, {"text": "San Paulo", "location": [1197, 1206], "entities": [{"type": "GeopoliticalEntity", "text": "San Paulo"}]}]}], "keywords": [{"text": "SIN Solution", "sentiment": {"score": 0.576234, "label": "positive"}, "relevance": 0.972049}, {"text": "medicinal cannabis product", "sentiment": {"score": 0.616081, "label": "positive"}, "relevance": 0.783418}, {"text": "MedDepot Brasil", "sentiment": {"score": 0.616081, "label": "positive"}, "relevance": 0.574625}, {"text": "Brasil based company", "sentiment": {"score": 0.391839, "label": "positive"}, "relevance": 0.568516}, {"text": "Med Depot Brasil", "sentiment": {"score": 0.373237, "label": "positive"}, "relevance": 0.518748}, {"text": "partner SIN Solution", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.502099}, {"text": "North American group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.493721}, {"text": "health care products", "sentiment": {"score": 0.454725, "label": "positive"}, "relevance": 0.491673}, {"text": "high-profile commercial partners", "sentiment": {"score": 0.59205, "label": "positive"}, "relevance": 0.48807}, {"text": "addition SIN Solution", "sentiment": {"score": 0.59205, "label": "positive"}, "relevance": 0.462592}, {"text": "Brazil based company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.458582}, {"text": "medical cannabis product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.457236}, {"text": "SIN Solution.Cresos Co-founder", "sentiment": {"score": 0.675935, "label": "positive"}, "relevance": 0.428275}, {"text": "years.MedDepot Brasil", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.412317}, {"text": "Brazil- Creso", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.404214}, {"text": "importation representative partner", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.390665}, {"text": "patient delivery agreement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.38853}, {"text": "painCreso Pharma Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.386215}, {"text": "MedDepot Brasil. cannaQIX", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.378565}, {"text": "patient support activities", "sentiment": {"score": 0.298346, "label": "positive"}, "relevance": 0.37184}, {"text": "pharma development company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.371002}, {"text": "CPH ASX Release", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.362367}, {"text": "sales services", "sentiment": {"score": 0.792635, "label": "positive"}, "relevance": 0.362196}, {"text": "proprietary delivery formulation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.358852}, {"text": "SR Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.358276}, {"text": "global distribution", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.357724}, {"text": "Sao Paulo", "sentiment": {"score": 0.298346, "label": "positive"}, "relevance": 0.356494}, {"text": "Director Partner", "sentiment": {"score": 0.792635, "label": "positive"}, "relevance": 0.356265}, {"text": "Latin America", "sentiment": {"score": 0.454725, "label": "positive"}, "relevance": 0.356259}, {"text": "health professionals", "sentiment": {"score": 0.6302, "label": "positive"}, "relevance": 0.355386}, {"text": "Rigueto Director Partner", "sentiment": {"score": 0.909335, "label": "positive"}, "relevance": 0.354598}, {"text": "Cesar Director Partner", "sentiment": {"score": 0.675935, "label": "positive"}, "relevance": 0.352993}, {"text": "Dr. Miri Halperin", "sentiment": {"score": 0.675935, "label": "positive"}, "relevance": 0.352882}, {"text": "strong performance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.352859}, {"text": "life style products", "sentiment": {"score": 0.535113, "label": "positive"}, "relevance": 0.352674}, {"text": "direct patient contacts", "sentiment": {"score": 0.66835, "label": "positive"}, "relevance": 0.350334}, {"text": "standardised pharma-grade formulation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.349481}, {"text": "great unmet need", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.347848}, {"text": "successful launch", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.345844}, {"text": "new evolving area", "sentiment": {"score": 0.909335, "label": "positive"}, "relevance": 0.345505}, {"text": "innovative delivery technologies", "sentiment": {"score": 0.373237, "label": "positive"}, "relevance": 0.345028}, {"text": "buccally formulated cannabidiol", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.342676}, {"text": "Good Manufacturing Practice", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.342268}, {"text": "chronic pain", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.339916}, {"text": "initial product registrations", "sentiment": {"score": 0.823546, "label": "positive"}, "relevance": 0.339706}, {"text": "global medical device", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.338306}]}, "extracted_metadata": {"sha1": "341239e873fdf85b587defdc338aa0a0610c437e", "filename": "1541097419991.zip-81f277ea92d04d958560ba6179c9fa0a.xml", "file_type": "json"}, "external_links": ["https://www.irw-press.at/prcom/images/messages/2018/45069/181101", "http://www.facebook.com/2008/fbml"], "title": "Creso to launch its first medical cannabis product in Brazil", "forum_title": "businesspress24.com"}, {"id": "W8n5Qpes1Bh6zuw_VZ7sh7AEAN-IAl2oBK_wrIrgeNMf-ZXCLyZplpCMF0D18x8c", "result_metadata": {"score": 32.745056}, "author": "Swapna", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Find Market Research", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Years in the future", "relevance": 0.842933, "dbpedia_resource": "http://dbpedia.org/resource/Years_in_the_future"}, {"text": "Marketing research", "relevance": 0.825774, "dbpedia_resource": "http://dbpedia.org/resource/Marketing_research"}, {"text": "Market research", "relevance": 0.822403, "dbpedia_resource": "http://dbpedia.org/resource/Market_research"}, {"text": "Online research community", "relevance": 0.789008, "dbpedia_resource": "http://dbpedia.org/resource/Online_research_community"}], "categories": [{"score": 0.604665, "label": "/health and fitness/disease/cancer"}, {"score": 0.469556, "label": "/health and fitness/disease/cancer/brain tumor"}], "relations": [], "keywords": [{"text": "Reflect Steady Growth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.91203}, {"text": "Kinase Inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.780608}, {"text": "Cancer Treatment Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.553328}, {"text": "Market Research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.306994}]}, "crawl_date": "2018-11-02T08:50:56Z", "url": "https://www.findmarketresearch.org/2018/09/kinase-inhibitors-for-cancer-treatment-market-to-reflect-steady-growth-during-2016-2026/", "host": "findmarketresearch.org", "text": "Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1403 Some of the key participating global players in kinase inhibitors for cancer treatment global market are Pfizer Inc., Boehringer Ingelheim GmbH, Novartis AG, Incyte Corporation, MedImmune, AstraZeneca, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited and others.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-09-27T10:21:00+05:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": -0.640706, "label": "negative"}, "text": "cancer", "relevance": 0.878481, "type": "HealthCondition", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}, {"count": 3, "sentiment": {"score": -0.216194, "label": "negative"}, "text": "North America", "relevance": 0.686702, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 3, "sentiment": {"score": 0.265379, "label": "positive"}, "text": "Western Europe", "relevance": 0.662185, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.620534, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eastern Europe", "relevance": 0.536756, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.521781, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": -0.239557, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.460336, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim GmbH", "relevance": 0.4567, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 1, "sentiment": {"score": -0.361238, "label": "negative"}, "text": "Pfizer Inc.", "relevance": 0.438878, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.426305, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.416148, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Incyte Corporation", "relevance": 0.415737, "type": "Company", "disambiguation": {"subtype": [], "name": "Incyte", "dbpedia_resource": "http://dbpedia.org/resource/Incyte"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MedImmune", "relevance": 0.409107, "type": "Company", "disambiguation": {"subtype": [], "name": "MedImmune", "dbpedia_resource": "http://dbpedia.org/resource/MedImmune"}}, {"count": 1, "sentiment": {"score": -0.216194, "label": "negative"}, "text": "Asia-Pacific", "relevance": 0.395021, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.394256, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.382843, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Co., Ltd.", "relevance": 0.360699, "type": "Company"}], "sentiment": {"document": {"score": -0.634913, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Kinase Inhibitors", "keywords": [{"text": "Kinase Inhibitors"}]}, "sentence": "Kinase Inhibitors are specific enzymes which oppose the process of cell division and growth in cancerous cells.", "object": {"text": "specific enzymes which oppose the process of cell division", "keywords": [{"text": "specific enzymes"}, {"text": "cell division"}, {"text": "process"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "specific enzymes", "keywords": [{"text": "specific enzymes"}]}, "sentence": "Kinase Inhibitors are specific enzymes which oppose the process of cell division and growth in cancerous cells.", "object": {"text": "the process of cell division and growth in cancerous cells", "keywords": [{"text": "cell division"}, {"text": "process"}, {"text": "growth"}], "entities": []}, "action": {"verb": {"text": "oppose", "tense": "present"}, "text": "oppose", "normalized": "oppose"}}, {"subject": {"text": "the signals", "keywords": [{"text": "signals"}]}, "sentence": " It comes handy in treatment of cancer by blocking the signals that notify a cell to divide and grow.", "object": {"text": "a cell", "keywords": [{"text": "cell"}]}, "action": {"verb": {"text": "notify", "tense": "present"}, "text": "notify", "normalized": "notify"}}, {"subject": {"text": "there"}, "sentence": " In last few decades, there has been significant progress made in the development of cancer treatment such as chemotherapy.", "object": {"text": "been significant progress made in the development of cancer treatment such as chemotherapy", "keywords": [{"text": "cancer treatment"}, {"text": "chemotherapy"}, {"text": "development"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "significant progress made in the development of cancer treatment such as chemotherapy", "keywords": [{"text": "significant progress"}, {"text": "chemotherapy"}, {"text": "cancer treatment"}, {"text": "development"}]}, "sentence": " In last few decades, there has been significant progress made in the development of cancer treatment such as chemotherapy.", "action": {"verb": {"text": "be", "tense": "past"}, "text": "has been", "normalized": "have be"}}, {"subject": {"text": "significant progress", "keywords": [{"text": "significant progress"}]}, "sentence": " In last few decades, there has been significant progress made in the development of cancer treatment such as chemotherapy.", "action": {"verb": {"text": "make", "tense": "past"}, "text": "made", "normalized": "make"}}, {"subject": {"text": "these drugs used cancer treatment", "keywords": [{"text": "drugs"}, {"text": "cancer treatment"}]}, "sentence": " However, these drugs used cancer treatment have a restricted therapeutic index, also the result are only unpredictable, partial, brief, palliative as well as uncertain.", "object": {"text": "a restricted therapeutic index", "keywords": [{"text": "therapeutic index"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "kinase inhibitor therapy", "keywords": [{"text": "kinase inhibitor therapy"}]}, "sentence": " In contrast, kinase inhibitor therapy which has recently been introduced is specifically targeted towards cancer molecules and signaling pathways.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "kinase inhibitor therapy", "keywords": [{"text": "kinase inhibitor therapy"}]}, "sentence": " In contrast, kinase inhibitor therapy which has recently been introduced is specifically targeted towards cancer molecules and signaling pathways.", "object": {"text": "introduced"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "kinase inhibitor therapy", "keywords": [{"text": "kinase inhibitor therapy"}]}, "sentence": " In contrast, kinase inhibitor therapy which has recently been introduced is specifically targeted towards cancer molecules and signaling pathways.", "action": {"verb": {"text": "introduce", "tense": "past"}, "text": "introduced", "normalized": "introduce"}}, {"subject": {"text": "kinase inhibitor therapy which has recently been introduced", "keywords": [{"text": "kinase inhibitor therapy"}]}, "sentence": " In contrast, kinase inhibitor therapy which has recently been introduced is specifically targeted towards cancer molecules and signaling pathways.", "object": {"text": "specifically targeted towards cancer molecules", "keywords": [{"text": "cancer molecules"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Such targets", "keywords": [{"text": "targets"}]}, "sentence": " Such targets are normally found in tumor cells, resulting wider therapeutic index and minimum adverse effect.", "object": {"text": "normally found in tumor cells", "keywords": [{"text": "tumor cells"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Such targets", "keywords": [{"text": "targets"}]}, "sentence": " Such targets are normally found in tumor cells, resulting wider therapeutic index and minimum adverse effect.", "action": {"verb": {"text": "find", "tense": "past"}, "text": "are normally found", "normalized": "be normally find"}}, {"subject": {"text": "Significant changes", "keywords": [{"text": "Significant changes"}]}, "sentence": " Significant changes have been made in cancer treatment from last decade and kinase inhibitors therapy signifies to a latest generation of anticancer treatment that are intended to interfere with a particular molecular target, normally a protein with an important role in tumor development or growth.", "object": {"text": "made in cancer treatment", "keywords": [{"text": "cancer treatment"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Significant changes", "keywords": [{"text": "Significant changes"}]}, "sentence": " Significant changes have been made in cancer treatment from last decade and kinase inhibitors therapy signifies to a latest generation of anticancer treatment that are intended to interfere with a particular molecular target, normally a protein with an important role in tumor development or growth.", "action": {"verb": {"text": "make", "tense": "past"}, "text": "have been made", "normalized": "have be make"}}, {"subject": {"text": "to interfere with a particular molecular target, normally a protein with an important role in tumor development or growth", "keywords": [{"text": "particular molecular target"}, {"text": "tumor development"}, {"text": "important role"}, {"text": "protein"}]}, "sentence": " Significant changes have been made in cancer treatment from last decade and kinase inhibitors therapy signifies to a latest generation of anticancer treatment that are intended to interfere with a particular molecular target, normally a protein with an important role in tumor development or growth.", "object": {"text": "anticancer treatment", "keywords": [{"text": "anticancer treatment"}]}, "action": {"verb": {"text": "intend", "tense": "past"}, "text": "intended", "normalized": "intend"}}, {"subject": {"text": "a latest generation of anticancer treatment", "keywords": [{"text": "anticancer treatment"}, {"text": "latest generation"}]}, "sentence": " Significant changes have been made in cancer treatment from last decade and kinase inhibitors therapy signifies to a latest generation of anticancer treatment that are intended to interfere with a particular molecular target, normally a protein with an important role in tumor development or growth.", "object": {"text": "with a particular molecular target, normally a protein with an important role in tumor development or growth", "keywords": [{"text": "particular molecular target"}, {"text": "tumor development"}, {"text": "important role"}, {"text": "protein"}]}, "action": {"verb": {"text": "interfere", "tense": "future"}, "text": "are intended to interfere", "normalized": "be intend to interfere"}}, {"subject": {"text": "the more observed approach", "keywords": [{"text": "observed approach"}]}, "sentence": " This methodology differs from the more observed approach used in orthodox cytotoxic chemotherapy, which has continued to be the backbone of cancer treatment over past several years.", "object": {"text": "in orthodox cytotoxic chemotherapy, which has continued to be the backbone of cancer treatment over past several years", "keywords": [{"text": "orthodox cytotoxic chemotherapy"}, {"text": "cancer treatment"}, {"text": "backbone"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "orthodox cytotoxic chemotherapy", "keywords": [{"text": "orthodox cytotoxic chemotherapy"}]}, "sentence": " This methodology differs from the more observed approach used in orthodox cytotoxic chemotherapy, which has continued to be the backbone of cancer treatment over past several years.", "object": {"text": "continued to be the backbone of cancer treatment over past several years", "keywords": [{"text": "cancer treatment"}, {"text": "backbone"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Kinase inhibitors therapy", "keywords": [{"text": "Kinase inhibitors"}, {"text": "therapy"}]}, "sentence": " Kinase inhibitors therapy has the possibility to eliminate or reduce many of the present difficulties in the area of cytotoxic chemotherapy, such as the causing serious host-cell toxicity.", "object": {"text": "the possibility to eliminate or reduce many of the present difficulties in the area of cytotoxic chemotherapy", "keywords": [{"text": "cytotoxic chemotherapy"}, {"text": "present difficulties"}, {"text": "possibility"}, {"text": "area"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Kinase inhibitors therapy", "keywords": [{"text": "Kinase inhibitors"}, {"text": "therapy"}]}, "sentence": " Kinase inhibitors therapy has the possibility to eliminate or reduce many of the present difficulties in the area of cytotoxic chemotherapy, such as the causing serious host-cell toxicity.", "object": {"text": "many of the present difficulties in the area of cytotoxic chemotherapy, such as the causing serious host-cell toxicity", "keywords": [{"text": "cytotoxic chemotherapy"}, {"text": "present difficulties"}, {"text": "host-cell toxicity"}, {"text": "area"}]}, "action": {"verb": {"text": "eliminate", "tense": "future"}, "text": "to eliminate or reduce", "normalized": "to eliminate or reduce"}}, {"subject": {"text": "Kinase inhibitors therapy", "keywords": [{"text": "Kinase inhibitors"}, {"text": "therapy"}]}, "sentence": " Kinase inhibitors therapy has the possibility to eliminate or reduce many of the present difficulties in the area of cytotoxic chemotherapy, such as the causing serious host-cell toxicity.", "object": {"text": "many of the present difficulties in the area of cytotoxic chemotherapy", "keywords": [{"text": "cytotoxic chemotherapy"}, {"text": "present difficulties"}, {"text": "area"}]}, "action": {"verb": {"text": "reduce", "tense": "present"}, "text": "to eliminate or reduce", "normalized": "to eliminate or reduce"}}, {"subject": {"text": "Presently,kinase inhibitors for cancer treatmentglobal market", "keywords": [{"text": "Presently,kinase inhibitors"}, {"text": "cancer treatmentglobal market"}]}, "sentence": " Presently,kinase inhibitors for cancer treatmentglobal market is driven by some of the factors like technological progression in healthcare area, rise in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease.", "object": {"text": "driven by some of the factors like technological progression", "keywords": [{"text": "technological progression"}, {"text": "factors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by some of the factors like technological progression in healthcare area, rise in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease", "keywords": [{"text": "technological progression"}, {"text": "chronic disease"}, {"text": "healthcare area"}, {"text": "cancer patients"}]}, "sentence": " Presently,kinase inhibitors for cancer treatmentglobal market is driven by some of the factors like technological progression in healthcare area, rise in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease.", "object": {"text": "Presently,kinase inhibitors for cancer treatmentglobal market", "keywords": [{"text": "Presently,kinase inhibitors"}, {"text": "cancer treatmentglobal market"}]}, "action": {"verb": {"text": "drive", "tense": "past"}, "text": "is driven", "normalized": "be drive"}}, {"subject": {"text": "Presently,kinase inhibitors for cancer treatmentglobal market", "keywords": [{"text": "Presently,kinase inhibitors"}, {"text": "cancer treatmentglobal market"}]}, "sentence": " Presently,kinase inhibitors for cancer treatmentglobal market is driven by some of the factors like technological progression in healthcare area, rise in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease.", "object": {"text": "in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease", "keywords": [{"text": "chronic disease"}, {"text": "cancer patients"}, {"text": "prevalence"}, {"text": "incidence"}]}, "action": {"verb": {"text": "rise", "tense": "present"}, "text": "rise", "normalized": "rise"}}, {"subject": {"text": "high cost", "keywords": [{"text": "high cost"}]}, "sentence": " However, high cost associated with latest clinical trials and complex approvals processes are acting as a major obstructions for the growth of kinase inhibitors for cancer treatmentglobal market.", "object": {"text": "with latest clinical trials and complex approvals processes", "keywords": [{"text": "latest clinical trials"}, {"text": "complex approvals"}, {"text": "processes"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "high cost associated with latest clinical trials and complex approvals processes", "keywords": [{"text": "latest clinical trials"}, {"text": "complex approvals"}, {"text": "high cost"}, {"text": "processes"}]}, "sentence": " However, high cost associated with latest clinical trials and complex approvals processes are acting as a major obstructions for the growth of kinase inhibitors for cancer treatmentglobal market.", "object": {"text": "acting as a major obstructions for the growth of kinase inhibitors for cancer treatmentglobal market", "keywords": [{"text": "kinase inhibitors"}, {"text": "major obstructions"}, {"text": "cancer treatmentglobal market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Kinase inhibitors for cancer treatment globalmarketis", "keywords": [{"text": "Kinase inhibitors"}, {"text": "cancer treatment globalmarketis"}]}, "sentence": " Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "object": {"text": "into following types", "keywords": [{"text": "types"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "segmented", "normalized": "segment"}}, {"subject": {"text": "cancer treatmentis", "keywords": [{"text": "cancer treatmentis"}]}, "sentence": " Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "object": {"text": "a healthy CAGR", "keywords": [{"text": "healthy CAGR"}]}, "action": {"verb": {"text": "register", "tense": "future"}, "text": "expected to register", "normalized": "expect to register"}}, {"subject": {"text": "healthy growth rate in the forecast period such asfast technological development, upsurge in the number of incidence of cancer patients,", "keywords": [{"text": "healthy growth rate"}, {"text": "forecast period"}, {"text": "technological development"}, {"text": "upsurge"}]}, "sentence": " There are reasons for healthy growth rate in the forecast period such asfast technological development, upsurge in the number of incidence of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe.", "object": {"text": "in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe", "keywords": [{"text": "adverse effects"}, {"text": "cancer patients"}, {"text": "chemotherapy"}, {"text": "prevalence"}]}, "action": {"verb": {"text": "rise", "tense": "present"}, "text": "rise", "normalized": "rise"}}, {"subject": {"text": "kinase inhibitors for cancer treatment market", "keywords": [{"text": "kinase inhibitors"}, {"text": "cancer treatment market"}]}, "sentence": " Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.", "object": {"text": "segmented into seven key regions", "keywords": [{"text": "key regions"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "kinase inhibitors for cancer treatment market", "keywords": [{"text": "kinase inhibitors"}, {"text": "cancer treatment market"}]}, "sentence": " Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.", "object": {"text": "into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa", "keywords": [{"text": "Asia Pacific Excluding"}, {"text": "key regions"}, {"text": "North America"}, {"text": "Middle East"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "is segmented", "normalized": "be segment"}}, {"subject": {"text": "Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " In terms of region Europe accounts for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients.", "object": {"text": "for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients", "keywords": [{"text": "global kinase inhibitors"}, {"text": "largest market shares"}, {"text": "cancer treatment market"}, {"text": "geriatric population"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "HealthCondition", "text": "cancer", "disambiguation": {"subtype": ["FieldOfStudy", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "MedicalSpecialty", "RiskFactor", "Disease"], "name": "Cancer", "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}}]}, "action": {"verb": {"text": "account", "tense": "present"}, "text": "accounts", "normalized": "account"}}, {"subject": {"text": "geriatric population", "keywords": [{"text": "geriatric population"}]}, "sentence": " In terms of region Europe accounts for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients.", "object": {"text": "with cancer indication.Whereas, North America and Asia-Pacific", "keywords": [{"text": "Asia-Pacific"}, {"text": "cancer indication.Whereas"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "grow", "tense": "present"}, "text": "growing", "normalized": "grow"}}, {"subject": {"text": "North America and Asia-Pacific", "keywords": [{"text": "Asia-Pacific"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " In terms of region Europe accounts for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients.", "action": {"verb": {"text": "project", "tense": "past"}, "text": "is projected showing", "normalized": "be project show"}}, {"subject": {"text": "kinase inhibitors for cancer treatmentin various regions", "keywords": [{"text": "kinase inhibitors"}, {"text": "treatmentin various regions"}, {"text": "cancer"}]}, "sentence": " Thereby, contribute to the growth of global kinase inhibitors for cancer treatmentmarket value.The market for kinase inhibitors for cancer treatmentin various regions is particularly driven by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment.", "object": {"text": "particularly driven by gradually increasing awareness", "keywords": [{"text": "awareness"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment", "keywords": [{"text": "advanced technologies"}, {"text": "cancer patients"}, {"text": "cancer treatment"}, {"text": "incidence"}]}, "sentence": " Thereby, contribute to the growth of global kinase inhibitors for cancer treatmentmarket value.The market for kinase inhibitors for cancer treatmentin various regions is particularly driven by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment.", "object": {"text": "kinase inhibitors for cancer treatmentin various regions", "keywords": [{"text": "kinase inhibitors"}, {"text": "treatmentin various regions"}, {"text": "cancer"}]}, "action": {"verb": {"text": "drive", "tense": "past"}, "text": "is particularly driven", "normalized": "be particularly drive"}}, {"subject": {"text": "Some of the key participating global players in kinase inhibitors for cancer treatment global market", "keywords": [{"text": "kinase inhibitors"}, {"text": "treatment global market"}, {"text": "global players"}, {"text": "cancer"}], "entities": []}, "sentence": " Some of the key participating global players in kinase inhibitors for cancer treatment global market are Pfizer Inc., Boehringer Ingelheim GmbH, Novartis AG, Incyte Corporation, MedImmune, AstraZeneca, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited and others.", "object": {"text": "Pfizer Inc., Boehringer Ingelheim GmbH, Novartis AG, Incyte Corporation, MedImmune, AstraZeneca, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited and others", "keywords": [{"text": "Boehringer Ingelheim GmbH"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "Novartis AG"}, {"text": "Incyte Corporation"}], "entities": [{"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Boehringer Ingelheim GmbH", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Incyte Corporation", "disambiguation": {"subtype": [], "name": "Incyte", "dbpedia_resource": "http://dbpedia.org/resource/Incyte"}}, {"type": "Company", "text": "MedImmune", "disambiguation": {"subtype": ["Organization", "Company"], "name": "MedImmune", "dbpedia_resource": "http://dbpedia.org/resource/MedImmune"}}, {"type": "Company", "text": "Eisai Co., Ltd."}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Cancer", "relevance": 0.986633, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Oncology", "relevance": 0.822186, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Chemotherapy", "relevance": 0.746128, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}, {"text": "Tumor", "relevance": 0.579086, "dbpedia_resource": "http://dbpedia.org/resource/Tumor"}, {"text": "United States", "relevance": 0.509826, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Europe", "relevance": 0.500866, "dbpedia_resource": "http://dbpedia.org/resource/Europe"}, {"text": "Boehringer Ingelheim", "relevance": 0.465216, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}, {"text": "Immune system", "relevance": 0.461547, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Neoplasm", "relevance": 0.454492, "dbpedia_resource": "http://dbpedia.org/resource/Neoplasm"}, {"text": "Eastern Europe", "relevance": 0.428126, "dbpedia_resource": "http://dbpedia.org/resource/Eastern_Europe"}, {"text": "Adverse effect", "relevance": 0.413864, "dbpedia_resource": "http://dbpedia.org/resource/Adverse_effect"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.405835, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Pharmaceutical industry", "relevance": 0.403472, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Epidemiology", "relevance": 0.401509, "dbpedia_resource": "http://dbpedia.org/resource/Epidemiology"}, {"text": "Spain", "relevance": 0.388262, "dbpedia_resource": "http://dbpedia.org/resource/Spain"}, {"text": "Pharmacology", "relevance": 0.381964, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Ingelheim am Rhein", "relevance": 0.37493, "dbpedia_resource": "http://dbpedia.org/resource/Ingelheim_am_Rhein"}, {"text": "North America", "relevance": 0.374434, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Cell cycle", "relevance": 0.364572, "dbpedia_resource": "http://dbpedia.org/resource/Cell_cycle"}, {"text": "Switzerland", "relevance": 0.362599, "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}, {"text": "Novartis", "relevance": 0.343418, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Americas", "relevance": 0.334646, "dbpedia_resource": "http://dbpedia.org/resource/Americas"}, {"text": "Western Europe", "relevance": 0.334501, "dbpedia_resource": "http://dbpedia.org/resource/Western_Europe"}, {"text": "Central Europe", "relevance": 0.322051, "dbpedia_resource": "http://dbpedia.org/resource/Central_Europe"}, {"text": "Cell", "relevance": 0.320264, "dbpedia_resource": "http://dbpedia.org/resource/Cell_(biology)"}, {"text": "Americas", "relevance": 0.319729, "dbpedia_resource": "http://dbpedia.org/resource/Americas_(terminology)"}, {"text": "Cell division", "relevance": 0.316351, "dbpedia_resource": "http://dbpedia.org/resource/Cell_division"}, {"text": "Breast cancer", "relevance": 0.314543, "dbpedia_resource": "http://dbpedia.org/resource/Breast_cancer"}, {"text": "Western world", "relevance": 0.307555, "dbpedia_resource": "http://dbpedia.org/resource/Western_world"}, {"text": "Inhibitor", "relevance": 0.306049, "dbpedia_resource": "http://dbpedia.org/resource/Inhibitor"}, {"text": "Clinical trial", "relevance": 0.305609, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Medicine", "relevance": 0.303295, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Medical statistics", "relevance": 0.302306, "dbpedia_resource": "http://dbpedia.org/resource/Medical_statistics"}, {"text": "Therapeutic effect", "relevance": 0.301071, "dbpedia_resource": "http://dbpedia.org/resource/Therapeutic_effect"}, {"text": "Pfizer", "relevance": 0.300414, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Latin America", "relevance": 0.296585, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}, {"text": "Leukemia", "relevance": 0.296239, "dbpedia_resource": "http://dbpedia.org/resource/Leukemia"}, {"text": "Disease", "relevance": 0.296026, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "World War II", "relevance": 0.295678, "dbpedia_resource": "http://dbpedia.org/resource/World_War_II"}, {"text": "Russia", "relevance": 0.295502, "dbpedia_resource": "http://dbpedia.org/resource/Russia"}], "categories": [{"score": 0.728865, "label": "/health and fitness/disease/cancer"}, {"score": 0.386239, "label": "/health and fitness/disease/cancer/brain tumor"}, {"score": 0.371515, "label": "/health and fitness/therapy"}], "relations": [{"type": "hasAttribute", "sentence": "Enhancedemphasis of pharmaceutical companies on R&D to come up with potential kinase inhibitors for treatment of cancers.", "score": 0.784774, "arguments": [{"text": "inhibitors", "location": [1518, 1528], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancers", "location": [1546, 1553], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "Presently,kinase inhibitors for cancer treatmentglobal market is driven by some of the factors like technological progression in healthcare area, rise in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease.", "score": 0.644799, "arguments": [{"text": "inhibitors", "location": [1642, 1652], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [1657, 1663], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "However, high cost associated with latest clinical trials and complex approvals processes are acting as a major obstructions for the growth of kinase inhibitors for cancer treatmentglobal market.", "score": 0.749969, "arguments": [{"text": "inhibitors", "location": [2026, 2036], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [2041, 2047], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "score": 0.857599, "arguments": [{"text": "inhibitors", "location": [2079, 2089], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [2094, 2100], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "score": 0.685265, "arguments": [{"text": "inhibitors", "location": [2522, 2532], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [2537, 2543], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.", "score": 0.705433, "arguments": [{"text": "inhibitors", "location": [2944, 2954], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [2959, 2965], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "Thereby, contribute to the growth of global kinase inhibitors for cancer treatmentmarket value.", "score": 0.749072, "arguments": [{"text": "inhibitors", "location": [3607, 3617], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [3622, 3628], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "The market for kinase inhibitors for cancer treatmentin various regions is particularly driven by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment.", "score": 0.576114, "arguments": [{"text": "inhibitors", "location": [3673, 3683], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "cancer", "location": [3688, 3694], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "locatedAt", "sentence": "Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.", "score": 0.4926, "arguments": [{"text": "regions", "location": [3011, 3018], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Western Europe", "location": [3066, 3080], "entities": [{"type": "GeopoliticalEntity", "text": "Western Europe"}]}]}, {"type": "locatedAt", "sentence": "Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.", "score": 0.518745, "arguments": [{"text": "Asia", "location": [3082, 3086], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3087, 3094], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "In terms of region Europe accounts for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients.", "score": 0.872703, "arguments": [{"text": "region", "location": [3156, 3162], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Europe", "location": [3163, 3169], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "In terms of region Europe accounts for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients.", "score": 0.829177, "arguments": [{"text": "population", "location": [3343, 3353], "entities": [{"type": "Person", "text": "population"}]}, {"text": "cancer indication.Whereas", "location": [3359, 3384], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "residesIn", "sentence": "The market for kinase inhibitors for cancer treatmentin various regions is particularly driven by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment.", "score": 0.473014, "arguments": [{"text": "inhibitors", "location": [3673, 3683], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "regions", "location": [3715, 3722], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "The market for kinase inhibitors for cancer treatmentin various regions is particularly driven by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment.", "score": 0.549751, "arguments": [{"text": "patients", "location": [3808, 3816], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "regions", "location": [3715, 3722], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "partOfMany", "sentence": "Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1403 Some of the key participating global players in kinase inhibitors for cancer treatment global market are Pfizer Inc., Boehringer Ingelheim GmbH, Novartis AG, Incyte Corporation, MedImmune, AstraZeneca, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited and others.", "score": 0.460917, "arguments": [{"text": "players", "location": [3999, 4006], "entities": [{"type": "Person", "text": "players"}]}, {"text": "inhibitors", "location": [4017, 4027], "entities": [{"type": "Person", "text": "Inhibitors"}]}]}, {"type": "hasAttribute", "sentence": "Presently,kinase inhibitors for cancer treatmentglobal market is driven by some of the factors like technological progression in healthcare area, rise in the prevalence of cancer patients around the globe and rise in the incidence of chronic disease.", "score": 0.812563, "arguments": [{"text": "patients", "location": [1804, 1812], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [1797, 1803], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "There are reasons for healthy growth rate in the forecast period such asfast technological development, upsurge in the number of incidence of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe.", "score": 0.902903, "arguments": [{"text": "patients", "location": [2769, 2777], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [2762, 2768], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "There are reasons for healthy growth rate in the forecast period such asfast technological development, upsurge in the number of incidence of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe.", "score": 0.82648, "arguments": [{"text": "patients", "location": [2877, 2885], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [2870, 2876], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "In terms of region Europe accounts for the largest market shares in global kinase inhibitors for cancer treatment market owing to advancements in medical research, clinical trials, growing geriatric population with cancer indication.Whereas, North America and Asia-Pacific is projected showing a healthy CAGR during the forecast period, 2016-2026 owing to increasing incidence and prevalence of cancer patients.", "score": 0.847158, "arguments": [{"text": "patients", "location": [3546, 3554], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [3539, 3545], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "hasAttribute", "sentence": "The market for kinase inhibitors for cancer treatmentin various regions is particularly driven by gradually increasing awareness, rising incidence of cancer patients and adoption of advanced technologies in cancer treatment.", "score": 0.89156, "arguments": [{"text": "patients", "location": [3808, 3816], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [3801, 3807], "entities": [{"type": "HealthCondition", "text": "cancer indication.Whereas"}]}]}, {"type": "employedBy", "sentence": "Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "score": 0.634289, "arguments": [{"text": "inhibitors", "location": [2231, 2241], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "MEK", "location": [2227, 2230], "entities": [{"type": "Organization", "text": "MEK"}]}]}, {"type": "employedBy", "sentence": "Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "score": 0.531704, "arguments": [{"text": "inhibitors", "location": [2290, 2300], "entities": [{"type": "Person", "text": "Inhibitors"}]}, {"text": "EGFR", "location": [2285, 2289], "entities": [{"type": "Organization", "text": "EGFR"}]}]}, {"type": "locatedAt", "sentence": "Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "score": 0.526167, "arguments": [{"text": "Latin America", "location": [2429, 2442], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}, {"text": "Western Europe", "location": [2444, 2458], "entities": [{"type": "GeopoliticalEntity", "text": "Western Europe"}]}]}, {"type": "locatedAt", "sentence": "Kinase inhibitors for cancer treatment globalmarketis segmented into following types: By Product Type- Angiogenesis inhibitors, m-TOR inhibitors, BRAF and MEK inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), EGFR inhibitors, Others (PI3K Inhibitors, aurora-kinase inhibitors etc); End User- Hospitals, Research Organizations; By Region: North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, MEA The global market for kinase inhibitors for cancer treatmentis expected to register a healthy CAGR during the forecast period.", "score": 0.857623, "arguments": [{"text": "APEJ", "location": [2476, 2480], "entities": [{"type": "GeopoliticalEntity", "text": "APEJ"}]}, {"text": "Japan", "location": [2482, 2487], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "There are reasons for healthy growth rate in the forecast period such asfast technological development, upsurge in the number of incidence of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe.", "score": 0.811686, "arguments": [{"text": "patients", "location": [2877, 2885], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "globe", "location": [2897, 2902], "entities": [{"type": "GeographicFeature", "text": "globe"}]}]}, {"type": "locatedAt", "sentence": "Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.", "score": 0.539305, "arguments": [{"text": "regions", "location": [3011, 3018], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Latin America", "location": [3035, 3048], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "locatedAt", "sentence": "Depending on geographic regions, kinase inhibitors for cancer treatment market is segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, Asia Pacific Excluding Japan, Japan and Middle East & Africa.", "score": 0.621212, "arguments": [{"text": "regions", "location": [3011, 3018], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Eastern Europe", "location": [3050, 3064], "entities": [{"type": "GeopoliticalEntity", "text": "Eastern Europe"}]}]}], "keywords": [{"text": "kinase inhibitors", "sentiment": {"score": -0.40248, "label": "negative"}, "relevance": 0.901779}, {"text": "kinase inhibitors therapy", "sentiment": {"score": -0.509676, "label": "negative"}, "relevance": 0.770664}, {"text": "global kinase inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.696982}, {"text": "cancer treatment", "sentiment": {"score": -0.376333, "label": "negative"}, "relevance": 0.696863}, {"text": "potential kinase inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.692497}, {"text": "Type- Angiogenesis inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.587537}, {"text": "Bcr-Abl tyrosine-kinase inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.586397}, {"text": "kinase inhibitor treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.58614}, {"text": "kinase inhibitor therapy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.583737}, {"text": "Presently,kinase inhibitors", "sentiment": {"score": -0.63858, "label": "negative"}, "relevance": 0.559444}, {"text": "MEK inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558442}, {"text": "m-TOR inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55544}, {"text": "EGFR inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555035}, {"text": "PI3K Inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554901}, {"text": "aurora-kinase inhibitors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55482}, {"text": "cancer treatmentglobal market", "sentiment": {"score": -0.579016, "label": "negative"}, "relevance": 0.551781}, {"text": "cancer patients", "sentiment": {"score": -0.678874, "label": "negative"}, "relevance": 0.551633}, {"text": "cancer treatment market", "sentiment": {"score": -0.255387, "label": "negative"}, "relevance": 0.54854}, {"text": "forecast period", "sentiment": {"score": 0.179933, "label": "positive"}, "relevance": 0.510989}, {"text": "North America", "sentiment": {"score": -0.216194, "label": "negative"}, "relevance": 0.505934}, {"text": "cancer treatment globalmarketis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.504514}, {"text": "cytotoxic chemotherapy", "sentiment": {"score": -0.687333, "label": "negative"}, "relevance": 0.493354}, {"text": "treatment global market", "sentiment": {"score": -0.361238, "label": "negative"}, "relevance": 0.490924}, {"text": "orthodox cytotoxic chemotherapy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.490496}, {"text": "therapeutic index", "sentiment": {"score": -0.282746, "label": "negative"}, "relevance": 0.478625}, {"text": "largest market shares", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.473578}, {"text": "minimum adverse effect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47247}, {"text": "wider therapeutic index", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472141}, {"text": "clinical trials", "sentiment": {"score": -0.395171, "label": "negative"}, "relevance": 0.471985}, {"text": "Boehringer Ingelheim GmbH", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.471716}, {"text": "particular molecular target", "sentiment": {"score": -0.33202, "label": "negative"}, "relevance": 0.471513}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.470928}, {"text": "Western Europe", "sentiment": {"score": 0.265379, "label": "positive"}, "relevance": 0.470872}, {"text": "Eastern Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.470871}, {"text": "healthy growth rate", "sentiment": {"score": 0.423137, "label": "positive"}, "relevance": 0.469835}, {"text": "complex approvals processes", "sentiment": {"score": -0.519452, "label": "negative"}, "relevance": 0.46935}, {"text": "latest clinical trials", "sentiment": {"score": -0.519452, "label": "negative"}, "relevance": 0.469328}, {"text": "healthy CAGR", "sentiment": {"score": -0.243203, "label": "negative"}, "relevance": 0.469082}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": -0.239557, "label": "negative"}, "relevance": 0.467338}, {"text": "Pacific Excluding Japan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.46721}, {"text": "Request Report Sample", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.466819}, {"text": "treatmentin various regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.464139}, {"text": "cancer molecules", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.464128}, {"text": "cancer treatmentis", "sentiment": {"score": -0.270212, "label": "negative"}, "relevance": 0.458972}, {"text": "cancer indication.Whereas", "sentiment": {"score": -0.367127, "label": "negative"}, "relevance": 0.456663}, {"text": "cancer treatmentmarket", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.455951}, {"text": "anticancer treatment", "sentiment": {"score": -0.33202, "label": "negative"}, "relevance": 0.455437}, {"text": "cell division", "sentiment": {"score": -0.39172, "label": "negative"}, "relevance": 0.444377}, {"text": "cancerous cells", "sentiment": {"score": -0.39172, "label": "negative"}, "relevance": 0.444233}, {"text": "specific enzymes", "sentiment": {"score": -0.39172, "label": "negative"}, "relevance": 0.443517}]}, "extracted_metadata": {"sha1": "3f15d2057902e72046480a258a3ad9de45291f9e", "filename": "1541148656971.zip-1aefd831ecdfbf4ddafc660f4678a168.xml", "file_type": "json"}, "external_links": ["http://www.futuremarketinsights.com/reports/sample/rep-gb-1403", "http://www.futuremarketinsights.com/reports/kinase-inhibitors-for-cancer-treatment-market"], "title": "Kinase Inhibitors For Cancer Treatment Market to Reflect Steady Growth During 2016 \u2013 2026 \u2013 Find Market Research", "forum_title": "Research Insights \u2013 Page 214 \u2013 Find Market Research"}, {"id": "aOhjGo1-tqknWGhJp8A72Tf-AFZ9uF-7QBiwD9FdYp_z6P7SqkHUQluY_iPIsnQn", "result_metadata": {"score": 32.69494}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management UK", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.504344, "label": "/finance/investing/brokerages"}, {"score": 0.502277, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.49338, "label": "/finance/bank"}], "relations": [{"type": "agentOf", "sentence": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "score": 0.991221, "arguments": [{"text": "Daiwa Asset Management UK Regulatory", "location": [0, 36], "entities": [{"type": "Organization", "text": "Daiwa Asset Management UK Regulatory", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Announcement", "location": [37, 49], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}], "keywords": [{"text": "Daiwa Asset Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.995973}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.917124}, {"text": "UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.834559}]}, "crawl_date": "2018-11-02T04:36:40Z", "url": "https://www.businesswire.com/news/home/20181003005969/en/Daiwa-Asset-Management-UK-Regulatory-Announcement-Form", "host": "businesswire.com", "text": "Ltd.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-10-04T06:00:00-05:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Co. Ltd", "relevance": 0.732817, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management", "relevance": 0.644186, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Europe", "relevance": 0.625639, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.568962, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.546313, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.250646, "label": "positive"}, "text": "Erich Berner", "relevance": 0.530411, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.502259, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.498119, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.491495, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.491495, "type": "Quantity"}], "sentiment": {"document": {"score": -0.261081, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "3 October 2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " 3 October 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages: N/A", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "increasing/reducing a long/short position", "keywords": [{"text": "long/short position"}]}, "sentence": " Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position", "object": {"text": "e.g. opening/closing a long/short position", "keywords": [{"text": "long/short position"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit - - - - - - - - (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit - - - - - (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " None (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020-7597-7056 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "020-7597-7056 Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "*If the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "a natural person", "keywords": [{"text": "natural person"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a natural person, a telephone number", "keywords": [{"text": "natural person"}, {"text": "telephone number"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "provided to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "provided contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "has been provided", "normalized": "have be provide"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 656705 Time of Receipt (offset from UTC): 20181004T014036+0100 Contacts Daiwa Asset Management", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.989094, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Offer and acceptance", "relevance": 0.528415, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Call option", "relevance": 0.525525, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.507385, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Contract", "relevance": 0.468606, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.426166, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Grammatical number", "relevance": 0.417211, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Bond", "relevance": 0.410217, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.390058, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Option contract", "relevance": 0.388647, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Balance sheet", "relevance": 0.384213, "dbpedia_resource": "http://dbpedia.org/resource/Balance_sheet"}, {"text": "Security", "relevance": 0.379995, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Stock", "relevance": 0.377959, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.366406, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Uniform Commercial Code", "relevance": 0.361257, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Legal person", "relevance": 0.355363, "dbpedia_resource": "http://dbpedia.org/resource/Legal_person"}, {"text": "Security", "relevance": 0.353966, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}], "categories": [{"score": 0.693436, "label": "/real estate/buying and selling homes"}, {"score": 0.486997, "label": "/finance/financial news"}, {"score": 0.317734, "label": "/finance/investing/day trading"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "basedIn", "sentence": "Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 656705 Time of Receipt (offset from UTC): 20181004T014036+0100 Contacts Daiwa Asset Management", "score": 0.434823, "arguments": [{"text": "UTC", "location": [5824, 5827], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [5803, 5810], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "managerOf", "sentence": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Company Limited (the Offeror) (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 3 October 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "score": 0.463222, "arguments": [{"text": "manager", "location": [700, 707], "entities": [{"type": "Person", "text": "manager"}]}, {"text": "Takeda Pharmaceutical Company Limited", "location": [626, 663], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit ORD Sale 2,000 4,746.7629 JPY ORD Purchase 1,900 4,752.4036 JPY ORD Sale 300 4,750.41 JPY ORD Sale 800 4,743.2025 JPY (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit - - - - - (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit -", "score": 0.787954, "arguments": [{"text": "i", "location": [3307, 3308], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3310, 3317], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "- - - - - - - (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit - - - - - (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) - - - - 4.", "score": 0.591687, "arguments": [{"text": "Price", "location": [3933, 3938], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3943, 3947], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4315, 4321], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4332, 4339], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 4 October 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.545365, "arguments": [{"text": "Erich Berner", "location": [5149, 5161], "entities": [{"type": "Person", "text": "Erich Berner"}]}, {"text": "Daiwa Asset Management Europe", "location": [5163, 5192], "entities": [{"type": "Organization", "text": "Daiwa Asset Management Europe", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 4 October 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.842228, "arguments": [{"text": "Rule 8", "location": [5252, 5258], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5266, 5270], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5333, 5357], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5325, 5330], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.", "score": 0.83842, "arguments": [{"text": "Market Surveillance Unit", "location": [5612, 5636], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5604, 5609], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5668, 5673], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5687, 5714], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.989932}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.876853}, {"text": "Daiwa Asset Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.791171}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.713687}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.708797}, {"text": "short positions", "sentiment": {"score": -0.356746, "label": "negative"}, "relevance": 0.643621}, {"text": "JPY ORD Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.615927}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.600097}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.578696}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.56565}, {"text": "reference securities Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555627}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.554864}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549845}, {"text": "JPY ORD Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547325}, {"text": "Short positions Number", "sentiment": {"score": -0.245708, "label": "negative"}, "relevance": 0.540023}, {"text": "relevant security Purchase/sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537695}, {"text": "unit ORD Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534162}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.534017}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531676}, {"text": "Asset Management Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527976}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.527261}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5252}, {"text": "Open Positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522085}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521689}, {"text": "derivative transactions", "sentiment": {"score": -0.408268, "label": "negative"}, "relevance": 0.519389}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518911}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518752}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518535}, {"text": "Contacts Daiwa Asset", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516256}, {"text": "possible cash offer", "sentiment": {"score": 0.408748, "label": "positive"}, "relevance": 0.514454}, {"text": "Supplemental Form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.513116}, {"text": "Expiry date Option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512321}, {"text": "Cash-settled derivative transactions", "sentiment": {"score": -0.403941, "label": "negative"}, "relevance": 0.511834}, {"text": "Stock-settled derivative transactions", "sentiment": {"score": -0.412596, "label": "negative"}, "relevance": 0.51111}, {"text": "e.g. call option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510033}, {"text": "unit Type e.g", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508343}, {"text": "RET Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505952}, {"text": "Asset Management Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505016}, {"text": "Regulatory Information Service", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.504161}, {"text": "Product description e.g", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.503245}, {"text": "long/short position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.502968}, {"text": "Management Category Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.502836}, {"text": "Panel\u2019s Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496055}, {"text": "person", "sentiment": {"score": 0.217529, "label": "positive"}, "relevance": 0.494669}, {"text": "voting rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.493485}, {"text": "Nil", "sentiment": {"score": -0.611983, "label": "negative"}, "relevance": 0.48795}, {"text": "N/A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485519}, {"text": "relevant percentages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.483078}, {"text": "LONDON-\nFORM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474595}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.47376}]}, "extracted_metadata": {"sha1": "b4a03287f445ed4dd52060f5a9d3499e8f71dfe4", "filename": "1541133400239.zip-9100d7b6feb6d6d2b7548b96023989d9.xml", "file_type": "json"}, "title": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "forum_title": "All News | Business Wire"}, {"id": "0BwwNfx1isuAXih6OcE2erduL5D4m1uZMZSqkCqoXaN5RfReit7MYsbf_qd9tvri", "result_metadata": {"score": 32.501987}, "author": "Ver\u00f6ffentlicht von irw", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "medical cannabis", "relevance": 0.33, "type": "Drug"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Creso", "keywords": [{"text": "Creso"}]}, "sentence": "Creso to launch its first medical cannabis product in Brazil", "object": {"text": "its first medical cannabis product in Brazil", "keywords": [{"text": "medical cannabis product"}, {"text": "Brazil"}], "entities": [{"type": "Drug", "text": "medical cannabis"}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "launch", "tense": "future"}, "text": "to launch", "normalized": "to launch"}}], "concepts": [{"text": "Cannabis", "relevance": 0.9044, "dbpedia_resource": "http://dbpedia.org/resource/Cannabis"}, {"text": "Medical cannabis", "relevance": 0.889404, "dbpedia_resource": "http://dbpedia.org/resource/Medical_cannabis"}], "categories": [{"score": 0.508579, "label": "/business and industrial/metals"}, {"score": 0.504629, "label": "/health and fitness/addiction/smoking addiction"}, {"score": 0.486794, "label": "/business and industrial/advertising and marketing"}], "relations": [], "keywords": [{"text": "medical cannabis product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.981421}, {"text": "Brazil", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52898}, {"text": "Creso", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.331517}]}, "crawl_date": "2018-11-01T18:48:14Z", "url": "https://www.firmenpresse.de/pressrelease583389/creso-to-launch-its-first-medical-cannabis-product-in-brazil-br.html", "host": "firmenpresse.de", "text": "SIN Solution has an extensive commercial network, working with a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries including global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brasil and Danone.Forward Looking statements This announcement", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-01T16:11:00Z", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": 0.605148, "label": "positive"}, "text": "SIN Solution", "relevance": 0.798463, "type": "Company"}, {"count": 14, "sentiment": {"score": 0.288524, "label": "positive"}, "text": "Brazil", "relevance": 0.790577, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}, {"count": 8, "sentiment": {"score": 0.33513, "label": "positive"}, "text": "cannabis", "relevance": 0.567993, "type": "Drug"}, {"count": 10, "sentiment": {"score": 0.249881, "label": "positive"}, "text": "Cresos", "relevance": 0.537584, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 6, "sentiment": {"score": 0.417521, "label": "positive"}, "text": "Brasil", "relevance": 0.514118, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 3, "sentiment": {"score": 0.0670005, "label": "positive"}, "text": "MedDepot Brasil", "relevance": 0.502419, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.452269, "label": "positive"}, "text": "Creso", "relevance": 0.401409, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil- Creso", "relevance": 0.395326, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MedDepot Brazil", "relevance": 0.387563, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.0670004, "label": "positive"}, "text": "partner", "relevance": 0.376175, "type": "JobTitle"}, {"count": 3, "sentiment": {"score": 0.298346, "label": "positive"}, "text": "San Paulo", "relevance": 0.360652, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "S\u00e3o Paulo", "dbpedia_resource": "http://dbpedia.org/resource/S\u00e3o_Paulo"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "medical cannabis", "relevance": 0.34898, "type": "Drug"}, {"count": 2, "sentiment": {"score": 0.373237, "label": "positive"}, "text": "Med Depot Brasil", "relevance": 0.329757, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Med Depot Brazil", "relevance": 0.325791, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.383912, "label": "negative"}, "text": "Creso", "relevance": 0.314697, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.294962, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 2, "sentiment": {"score": 0.823546, "label": "positive"}, "text": "Switzerland", "relevance": 0.28827, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "SR Group", "relevance": 0.279793, "type": "Organization"}, {"count": 1, "sentiment": {"score": -0.455791, "label": "negative"}, "text": "painCreso Pharma Limited", "relevance": 0.275183, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.273524, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": 0.454725, "label": "positive"}, "text": "Latin America", "relevance": 0.271697, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Creso Pharma Ltd", "relevance": 0.271141, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "marketing and sales", "relevance": 0.270383, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Miami", "relevance": 0.269605, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Galderma", "relevance": 0.268235, "type": "Company", "disambiguation": {"subtype": [], "name": "Galderma", "dbpedia_resource": "http://dbpedia.org/resource/Galderma"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.264992, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "neurologic diseases", "relevance": 0.261948, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Neurological disorder", "dbpedia_resource": "http://dbpedia.org/resource/Neurological_disorder"}}, {"count": 1, "sentiment": {"score": 0.675935, "label": "positive"}, "text": "Marketing and Sales services", "relevance": 0.246892, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "CBD", "relevance": 0.245491, "type": "Company", "disambiguation": {"subtype": [], "name": "Grupo P\u00e3o de A\u00e7\u00facar", "dbpedia_resource": "http://dbpedia.org/resource/Grupo_P\u00e3o_de_A\u00e7\u00facar"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.243503, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.347459, "label": "positive"}, "text": "Creso Pharma", "relevance": 0.243216, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.909335, "label": "positive"}, "text": "Sergio Rigueto", "relevance": 0.228343, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.383912, "label": "negative"}, "text": "representative", "relevance": 0.227686, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.675935, "label": "positive"}, "text": "Dr. Miri Halperin Wernli", "relevance": 0.225231, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Parana", "relevance": 0.224721, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr. med Aufdermaur AG", "relevance": 0.220704, "type": "Person"}, {"count": 2, "sentiment": {"score": 0.792635, "label": "positive"}, "text": "Partner", "relevance": 0.216936, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.675935, "label": "positive"}, "text": "Alessandra Cesar", "relevance": 0.216126, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Call Center Service", "relevance": 0.214592, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Curitiba", "relevance": 0.213611, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Curitiba", "dbpedia_resource": "http://dbpedia.org/resource/Curitiba"}}, {"count": 2, "sentiment": {"score": 0.792635, "label": "positive"}, "text": "Director", "relevance": 0.211431, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "niacin", "relevance": 0.206363, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0.386625, "label": "positive"}, "text": "cannabidiol", "relevance": 0.205857, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Domaco", "relevance": 0.205, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Domaco", "relevance": 0.204895, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland.", "relevance": 0.199404, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0.675935, "label": "positive"}, "text": "Co-founder and CEO", "relevance": 0.192187, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.384477, "label": "positive"}, "text": "Janeiro", "relevance": 0.181, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3 years", "relevance": 0.181, "type": "Quantity"}], "sentiment": {"document": {"score": 0.666664, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Creso", "keywords": [{"text": "Creso"}], "entities": [{"type": "Location", "text": "Cresos", "disambiguation": {"subtype": ["City"]}}]}, "sentence": "Creso to launch its first medical cannabis product in Brazil ID: 583389", "object": {"text": "its first medical cannabis product in Brazil ID", "keywords": [{"text": "medical cannabis product"}, {"text": "Brazil ID"}], "entities": [{"type": "Drug", "text": "medical cannabis"}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}]}, "action": {"verb": {"text": "launch", "tense": "future"}, "text": "to launch", "normalized": "to launch"}}, {"subject": {"text": "MedDepot Brazil", "keywords": [{"text": "Brazil"}, {"text": "MedDepot"}], "entities": [{"type": "Company", "text": "MedDepot Brazil"}]}, "sentence": " MedDepot Brazil specializes in the importation of medicines that are not commercialized in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient.With its existing relationships with patients, doctors, clinics, hospitals, insurers, pharmacies, distributors, clinical research laboratories and government agencies within Brazil and its knowledge and experience with the relevant laws and regulations in-country, MedDepot Brasil is an ideal strategic partner for Cresos entry into the Brazilian market.", "object": {"text": "in the importation of medicines that are not commercialized in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient.With its existing relationships with patients, doctors, clinics, hospitals, insurers, pharmacies, distributors, clinical research laboratories and government agencies within Brazil and its knowledge and experience with the relevant laws and regulations in-country", "keywords": [{"text": "clinical research laboratories"}, {"text": "initial request"}, {"text": "patient access"}, {"text": "ultimate delivery"}], "entities": [{"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}, {"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}]}, "action": {"verb": {"text": "specialize", "tense": "present"}, "text": "specializes", "normalized": "specialize"}}, {"subject": {"text": "the importation of medicines", "keywords": [{"text": "importation"}, {"text": "medicines"}]}, "sentence": " MedDepot Brazil specializes in the importation of medicines that are not commercialized in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient.With its existing relationships with patients, doctors, clinics, hospitals, insurers, pharmacies, distributors, clinical research laboratories and government agencies within Brazil and its knowledge and experience with the relevant laws and regulations in-country, MedDepot Brasil is an ideal strategic partner for Cresos entry into the Brazilian market.", "object": {"text": "not commercialized in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient.With its existing relationships with patients, doctors, clinics, hospitals, insurers, pharmacies, distributors, clinical research laboratories and government agencies within Brazil and its knowledge and experience with the relevant laws and regulations in-country, MedDepot Brasil is an ideal strategic partner for Cresos entry into the Brazilian market", "keywords": [{"text": "ideal strategic partner"}, {"text": "clinical research laboratories"}, {"text": "MedDepot Brasil"}, {"text": "initial request"}], "entities": [{"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}, {"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}, {"type": "Company", "text": "MedDepot Brasil"}, {"type": "JobTitle", "text": "partner"}, {"type": "Company", "text": "Creso"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "patient", "keywords": [{"text": "patient"}]}, "sentence": " MedDepot Brazil specializes in the importation of medicines that are not commercialized in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient.With its existing relationships with patients, doctors, clinics, hospitals, insurers, pharmacies, distributors, clinical research laboratories and government agencies within Brazil and its knowledge and experience with the relevant laws and regulations in-country, MedDepot Brasil is an ideal strategic partner for Cresos entry into the Brazilian market.", "object": {"text": "access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient.With its existing relationships with patients, doctors, clinics, hospitals, insurers, pharmacies, distributors, clinical research laboratories and government agencies within Brazil and its knowledge and experience with the relevant laws and regulations in-country, MedDepot Brasil", "keywords": [{"text": "clinical research laboratories"}, {"text": "initial request"}, {"text": "MedDepot Brasil"}, {"text": "ultimate delivery"}], "entities": [{"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}, {"type": "Company", "text": "MedDepot Brasil"}]}, "action": {"verb": {"text": "facilitate", "tense": "present"}, "text": "facilitating", "normalized": "facilitate"}}, {"subject": {"text": "the initial request", "keywords": [{"text": "initial request"}]}, "sentence": " MedDepot Brazil specializes in the importation of medicines that are not commercialized in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient.With its existing relationships with patients, doctors, clinics, hospitals, insurers, pharmacies, distributors, clinical research laboratories and government agencies within Brazil and its knowledge and experience with the relevant laws and regulations in-country, MedDepot Brasil is an ideal strategic partner for Cresos entry into the Brazilian market.", "object": {"text": "to the ultimate delivery in the hands of the patient.With its existing relationships with patients", "keywords": [{"text": "ultimate delivery"}, {"text": "hands"}, {"text": "relationships"}, {"text": "patients"}]}, "action": {"verb": {"text": "monitor", "tense": "present"}, "text": "monitoring", "normalized": "monitor"}}, {"subject": {"text": "by Cresos established partnership with SIN Solution, who will engage in the sales and marketing of Cresos products through its well established Call Center Service", "keywords": [{"text": "SIN Solution"}, {"text": "Cresos products"}, {"text": "partnership"}, {"text": "sales"}], "entities": [{"type": "Company", "text": "Cresos"}, {"type": "Company", "text": "SIN Solution"}, {"type": "Company", "text": "Creso"}, {"type": "Organization", "text": "Call Center Service"}]}, "sentence": " Sales and marketing efforts in Brazil will be supported by Cresos established partnership with SIN Solution, who will engage in the sales and marketing of Cresos products through its well established Call Center Service.", "object": {"text": "Sales and marketing efforts in Brazil", "keywords": [{"text": "marketing efforts"}, {"text": "Brazil"}, {"text": "Sales"}], "entities": [{"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}]}, "action": {"verb": {"text": "support", "tense": "future"}, "text": "will be supported", "normalized": "will be support"}}, {"subject": {"text": "Cresos", "keywords": [{"text": "Cresos"}], "entities": [{"type": "Company", "text": "Cresos"}]}, "sentence": " Sales and marketing efforts in Brazil will be supported by Cresos established partnership with SIN Solution, who will engage in the sales and marketing of Cresos products through its well established Call Center Service.", "object": {"text": "partnership", "keywords": [{"text": "partnership"}]}, "action": {"verb": {"text": "establish", "tense": "future"}, "text": "established", "normalized": "establish"}}, {"subject": {"text": "SIN Solution", "keywords": [{"text": "SIN Solution"}], "entities": [{"type": "Company", "text": "SIN Solution"}]}, "sentence": " SIN Solution is a Brazil based company that specialised in the market-access sales, doctors and patients support for health care products in Brazil and across Latin America.", "object": {"text": "a Brazil based company that specialised in the market-access sales, doctors and patients support for health care products in Brazil and across Latin America", "keywords": [{"text": "Brazil based company"}, {"text": "health care products"}, {"text": "market-access sales"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}, {"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a Brazil based company", "keywords": [{"text": "Brazil based company"}], "entities": [{"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}]}, "sentence": " SIN Solution is a Brazil based company that specialised in the market-access sales, doctors and patients support for health care products in Brazil and across Latin America.", "action": {"verb": {"text": "specialise", "tense": "past"}, "text": "specialised", "normalized": "specialise"}}, {"subject": {"text": "It"}, "sentence": " It has direct access to more than 350,000 health professionals and over 200,000 patients.In addition SIN Solution works with a number of high-profile commercial partners in Brazil and beyond, including Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brazil and Danone.The first focus of its marketing, sales and patient support activities will be in the big agglomerations of Sao Paulo, Rio de Janeiro, Curitiba (Parana) with a total population of over 22 million people.", "object": {"text": "direct access to more than 350,000 health professionals and over 200,000 patients.In", "keywords": [{"text": "direct access"}, {"text": "health professionals"}, {"text": "patients.In"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache", "keywords": [{"text": "Galderma"}, {"text": "GSK"}, {"text": "Takeda"}, {"text": "Ache"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "GSK"}, {"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Novartis", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Galderma", "disambiguation": {"subtype": [], "name": "Galderma", "dbpedia_resource": "http://dbpedia.org/resource/Galderma"}}]}, "sentence": " It has direct access to more than 350,000 health professionals and over 200,000 patients.In addition SIN Solution works with a number of high-profile commercial partners in Brazil and beyond, including Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brazil and Danone.The first focus of its marketing, sales and patient support activities will be in the big agglomerations of Sao Paulo, Rio de Janeiro, Curitiba (Parana) with a total population of over 22 million people.", "object": {"text": "Brazil", "keywords": [{"text": "Brazil"}], "entities": [{"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}]}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "do", "normalized": "do"}}, {"subject": {"text": "sales and patient support activities", "keywords": [{"text": "patient support activities"}, {"text": "sales"}]}, "sentence": " It has direct access to more than 350,000 health professionals and over 200,000 patients.In addition SIN Solution works with a number of high-profile commercial partners in Brazil and beyond, including Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brazil and Danone.The first focus of its marketing, sales and patient support activities will be in the big agglomerations of Sao Paulo, Rio de Janeiro, Curitiba (Parana) with a total population of over 22 million people.", "object": {"text": "in the big agglomerations of Sao Paulo, Rio de Janeiro, Curitiba (Parana)", "keywords": [{"text": "Sao Paulo"}, {"text": "big agglomerations"}, {"text": "Parana"}, {"text": "Curitiba"}], "entities": [{"type": "Location", "text": "San Paulo", "disambiguation": {"subtype": ["City"], "name": "S\u00e3o Paulo", "dbpedia_resource": "http://dbpedia.org/resource/S\u00e3o_Paulo"}}, {"type": "Location", "text": "Janeiro", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "Curitiba", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Curitiba", "dbpedia_resource": "http://dbpedia.org/resource/Curitiba"}}, {"type": "Location", "text": "Parana", "disambiguation": {"subtype": ["Region"]}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "Main addressees", "keywords": [{"text": "Main addressees"}]}, "sentence": " Main addressees are doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution is in a good position to provide the marketing / sales services combined with the needed doctors and patients support in this new evolving area says Sergio Rigueto Director Partner of SIN Solution.", "object": {"text": "doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution", "keywords": [{"text": "50000.SIN Solution"}, {"text": "neurology"}, {"text": "oncology"}, {"text": "doctors"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "an expected number of patients over 50000.SIN Solution", "keywords": [{"text": "expected number"}, {"text": "50000.SIN Solution"}, {"text": "patients"}]}, "sentence": " Main addressees are doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution is in a good position to provide the marketing / sales services combined with the needed doctors and patients support in this new evolving area says Sergio Rigueto Director Partner of SIN Solution.", "object": {"text": "in a good position", "keywords": [{"text": "good position"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution", "keywords": [{"text": "50000.SIN Solution"}, {"text": "neurology"}, {"text": "oncology"}, {"text": "doctors"}]}, "sentence": " Main addressees are doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution is in a good position to provide the marketing / sales services combined with the needed doctors and patients support in this new evolving area says Sergio Rigueto Director Partner of SIN Solution.", "object": {"text": "the marketing / sales services combined with the needed doctors and patients support in this new evolving area", "keywords": [{"text": "new evolving area"}, {"text": "marketing / sales"}, {"text": "patients support"}, {"text": "doctors"}], "entities": [{"type": "JobTitle", "text": "Marketing and Sales services"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "Sergio Rigueto Director Partner of SIN Solution", "keywords": [{"text": "Sergio Rigueto Director"}, {"text": "SIN"}, {"text": "Partner"}], "entities": [{"type": "Person", "text": "Sergio Rigueto"}, {"type": "JobTitle", "text": "Director"}, {"type": "JobTitle", "text": "Partner"}, {"type": "Company", "text": "SIN Solution"}]}, "sentence": " Main addressees are doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution is in a good position to provide the marketing / sales services combined with the needed doctors and patients support in this new evolving area says Sergio Rigueto Director Partner of SIN Solution.", "object": {"text": "Main addressees are doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution is in a good position to provide the marketing / sales services combined with the needed doctors and patients support in this new evolving area", "keywords": [{"text": "new evolving area"}, {"text": "good position"}, {"text": "Main addressees"}, {"text": "50000.SIN Solution"}], "entities": [{"type": "JobTitle", "text": "Marketing and Sales services"}]}, "action": {"verb": {"text": "say", "tense": "present"}, "text": "says", "normalized": "say"}}, {"subject": {"text": "SIN Solution", "keywords": [{"text": "SIN Solution"}], "entities": [{"type": "Company", "text": "SIN Solution"}]}, "sentence": " The Marketing and Sales services combined with doctors and patients support which SIN Solution can provide are very innovative and provide an added value to all stakeholders involved says Alessandra Cesar Director Partner of SIN Solution.Cresos Co-founder and CEO Dr. Miri Halperin Wernli, said: We are very excited about the launch of our first medicinal cannabis product in Brazil through our partnerships with MedDepot Brasil and SIN Solution.", "object": {"text": "very innovative"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Alessandra Cesar Director Partner of SIN Solution.Cresos Co-founder and CEO Dr. Miri Halperin Wernli", "keywords": [{"text": "Dr. Miri Halperin"}, {"text": "Alessandra Cesar Director"}, {"text": "SIN Solution.Cresos Co-founder"}, {"text": "CEO"}], "entities": [{"type": "Person", "text": "Alessandra Cesar"}, {"type": "JobTitle", "text": "Director"}, {"type": "JobTitle", "text": "Partner"}, {"type": "JobTitle", "text": "Co-founder and CEO"}, {"type": "Person", "text": "Dr. Miri Halperin Wernli"}]}, "sentence": " The Marketing and Sales services combined with doctors and patients support which SIN Solution can provide are very innovative and provide an added value to all stakeholders involved says Alessandra Cesar Director Partner of SIN Solution.Cresos Co-founder and CEO Dr. Miri Halperin Wernli, said: We are very excited about the launch of our first medicinal cannabis product in Brazil through our partnerships with MedDepot Brasil and SIN Solution.", "object": {"text": "The Marketing and Sales services combined with doctors and patients support which SIN Solution can provide are very innovative and provide an added value to all stakeholders involved", "keywords": [{"text": "SIN Solution"}, {"text": "Sales services"}, {"text": "stakeholders"}, {"text": "doctors"}], "entities": [{"type": "JobTitle", "text": "Marketing and Sales services"}, {"type": "Company", "text": "SIN Solution"}]}, "action": {"verb": {"text": "say", "tense": "present"}, "text": "says", "normalized": "say"}}, {"subject": {"text": "We"}, "sentence": " The Marketing and Sales services combined with doctors and patients support which SIN Solution can provide are very innovative and provide an added value to all stakeholders involved says Alessandra Cesar Director Partner of SIN Solution.Cresos Co-founder and CEO Dr. Miri Halperin Wernli, said: We are very excited about the launch of our first medicinal cannabis product in Brazil through our partnerships with MedDepot Brasil and SIN Solution.", "object": {"text": "very excited about the launch of our first medicinal cannabis product in Brazil", "keywords": [{"text": "medicinal cannabis product"}, {"text": "launch"}, {"text": "Brazil"}], "entities": [{"type": "Drug", "text": "cannabis"}, {"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "We"}, "sentence": " We see that there is a great unmet need in the areas of neuropathic pain and pains related to cancer and other neurologic diseases in Brazil and we believe both MedDepot Brasil and SIN Solution are well placed to ensure our successful launch in the region.", "object": {"text": "that there is a great unmet need in the areas of neuropathic pain and pains related to cancer and other neurologic diseases in Brazil and we believe both MedDepot Brasil and SIN Solution are well placed to ensure our successful launch in the region", "keywords": [{"text": "great unmet need"}, {"text": "neuropathic pain"}, {"text": "neurologic diseases"}, {"text": "MedDepot Brasil"}], "entities": [{"type": "HealthCondition", "text": "neurologic diseases", "disambiguation": {"subtype": [], "name": "Neurological disorder", "dbpedia_resource": "http://dbpedia.org/resource/Neurological_disorder"}}, {"type": "Location", "text": "SIN Solution", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}, {"type": "Company", "text": "SIN Solution"}]}, "action": {"verb": {"text": "see", "tense": "present"}, "text": "see", "normalized": "see"}}, {"subject": {"text": "both MedDepot Brasil and SIN Solution", "keywords": [{"text": "MedDepot Brasil"}, {"text": "SIN Solution"}], "entities": [{"type": "Company", "text": "SIN Solution"}]}, "sentence": " We see that there is a great unmet need in the areas of neuropathic pain and pains related to cancer and other neurologic diseases in Brazil and we believe both MedDepot Brasil and SIN Solution are well placed to ensure our successful launch in the region.", "object": {"text": "our successful launch in the region", "keywords": [{"text": "successful launch"}, {"text": "region"}]}, "action": {"verb": {"text": "ensure", "tense": "future"}, "text": "to ensure", "normalized": "to ensure"}}, {"subject": {"text": "the active ingredients", "keywords": [{"text": "active ingredients"}]}, "sentence": " By being dissolved in the mouth, the active ingredients enter the blood stream directly, avoiding this first pass through the liver.The standardized, user-friendly strength and formulation allows precise dosage control, ensuring a reliable and stable effect.", "object": {"text": "the blood stream", "keywords": [{"text": "blood stream"}]}, "action": {"verb": {"text": "enter", "tense": "present"}, "text": "enter", "normalized": "enter"}}, {"subject": {"text": "user-friendly strength and formulation", "keywords": [{"text": "user-friendly strength"}, {"text": "formulation"}]}, "sentence": " By being dissolved in the mouth, the active ingredients enter the blood stream directly, avoiding this first pass through the liver.The standardized, user-friendly strength and formulation allows precise dosage control, ensuring a reliable and stable effect.", "object": {"text": "precise dosage control, ensuring a reliable and stable effect", "keywords": [{"text": "precise dosage control"}, {"text": "stable effect"}]}, "action": {"verb": {"text": "allow", "tense": "present"}, "text": "allows", "normalized": "allow"}}, {"subject": {"text": "The cannaQIX\u00ae range", "keywords": [{"text": "cannaQIX\u00ae range"}]}, "sentence": " The cannaQIX\u00ae range has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Cresos partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality with a Swiss Made label.", "object": {"text": "to Good Manufacturing Practice standards", "keywords": [{"text": "Good Manufacturing Practice"}, {"text": "standards"}]}, "action": {"verb": {"text": "develop", "tense": "past"}, "text": "has been developed", "normalized": "have be develop"}}, {"subject": {"text": "by Cresos partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco)", "keywords": [{"text": "pharma development company"}, {"text": "Swiss-based food"}, {"text": "Cresos partner"}, {"text": "Aufdermaur AG"}], "entities": [{"type": "JobTitle", "text": "partner"}, {"type": "Location", "text": "Domaco", "disambiguation": {"subtype": ["City"]}}, {"type": "Person", "text": "Dr. med Aufdermaur AG"}, {"type": "Company", "text": "Domaco"}]}, "sentence": " The cannaQIX\u00ae range has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Cresos partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality with a Swiss Made label.", "object": {"text": "The cannaQIX\u00ae range", "keywords": [{"text": "cannaQIX\u00ae range"}]}, "action": {"verb": {"text": "produce", "tense": "past"}, "text": "is produced", "normalized": "be produce"}}, {"subject": {"text": "END -About Creso Pharma Ltd (www.cresopharma.com)Creso Pharma", "keywords": [{"text": ")Creso Pharma"}], "entities": [{"type": "Company", "text": "Creso Pharma Ltd"}, {"type": "Company", "text": "Creso Pharma"}]}, "sentence": " - END -About Creso Pharma Ltd (www.cresopharma.com)Creso Pharma brings the best of cannabis to better the lives of people and animals.", "object": {"text": "the best of cannabis", "keywords": [{"text": "cannabis"}], "entities": [{"type": "Drug", "text": "cannabis"}]}, "action": {"verb": {"text": "bring", "tense": "present"}, "text": "brings", "normalized": "bring"}}, {"subject": {"text": "It"}, "sentence": " It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products.", "object": {"text": "pharmaceutical expertise and methodological rigor to the cannabis world", "keywords": [{"text": "methodological rigor"}, {"text": "cannabis world"}, {"text": "pharmaceutical expertise"}], "entities": [{"type": "Drug", "text": "cannabis"}]}, "action": {"verb": {"text": "bring", "tense": "present"}, "text": "brings", "normalized": "bring"}}, {"subject": {"text": "for the highest quality", "keywords": [{"text": "highest quality"}]}, "sentence": " It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products.", "action": {"verb": {"text": "strive", "tense": "present"}, "text": "strives", "normalized": "strive"}}, {"subject": {"text": "It"}, "sentence": " It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.", "object": {"text": "cannabis and hemp derived therapeutic, nutraceutical,", "keywords": [{"text": "cannabis"}, {"text": "hemp"}], "entities": [{"type": "Drug", "text": "cannabis"}]}, "action": {"verb": {"text": "develop", "tense": "present"}, "text": "develops", "normalized": "develop"}}, {"subject": {"text": "Creso", "keywords": [{"text": "Creso"}], "entities": [{"type": "Location", "text": "Cresos", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland.", "object": {"text": "GMP development and manufacturing standards", "keywords": [{"text": "GMP development"}, {"text": "manufacturing standards"}]}, "action": {"verb": {"text": "use", "tense": "present"}, "text": "uses", "normalized": "use"}}, {"subject": {"text": "It"}, "sentence": " It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines.", "object": {"text": "worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.About Med Depot Brasil", "keywords": [{"text": "Med Depot Brasil"}, {"text": "proprietary innovative delivery"}, {"text": "worldwide rights"}, {"text": "bioavailability"}], "entities": [{"type": "Company", "text": "Med Depot Brasil"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the bioavailability and absorption of cannabinoids.About Med Depot Brasil", "keywords": [{"text": "Med Depot Brasil"}, {"text": "bioavailability"}, {"text": "absorption"}], "entities": [{"type": "Company", "text": "Med Depot Brasil"}]}, "sentence": " It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines.", "object": {"text": "proprietary innovative delivery technologies", "keywords": [{"text": "delivery technologies"}]}, "action": {"verb": {"text": "enhance", "tense": "present"}, "text": "enhance", "normalized": "enhance"}}, {"subject": {"text": "technologies which enhance the bioavailability and absorption of cannabinoids.About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil", "keywords": [{"text": "Med Depot Brasil"}, {"text": "bioavailability"}, {"text": "absorption"}, {"text": "technologies"}], "entities": [{"type": "Company", "text": "Med Depot Brasil"}, {"type": "Company", "text": "Med Depot Brasil"}]}, "sentence": " It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines.", "object": {"text": "a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines", "keywords": [{"text": "Brasil based company"}, {"text": "North American group"}, {"text": "SR Group"}, {"text": "strong performance"}], "entities": [{"type": "Location", "text": "MedDepot Brasil", "disambiguation": {"subtype": ["City"]}}, {"type": "Organization", "text": "SR Group"}, {"type": "Location", "text": "Miami", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "It"}, "sentence": " It is based in Sao Paulo, Brasil.", "action": {"verb": {"text": "base", "tense": "past"}, "text": "is based", "normalized": "be base"}}, {"subject": {"text": "It"}, "sentence": " It has a potent structure with global access and expertise to take care of all steps involving the purchase of imported medicines, monitoring from the request to the delivery in the hands of the patient.About SIN Solution (www.sinsolution.com)SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America.", "object": {"text": "a potent structure with global access and expertise to take care of all steps involving the purchase of imported medicines, monitoring from the request to the delivery in the hands of the patient.About SIN Solution (www.sinsolution.com)SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America", "keywords": [{"text": "Brasil based company"}, {"text": "health care products"}, {"text": "potent structure"}, {"text": "global access"}], "entities": [{"type": "Company", "text": "SIN Solution"}, {"type": "Location", "text": "Brasil", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "MedDepot Brasil", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "care", "keywords": [{"text": "care"}]}, "sentence": " It has a potent structure with global access and expertise to take care of all steps involving the purchase of imported medicines, monitoring from the request to the delivery in the hands of the patient.About SIN Solution (www.sinsolution.com)SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America.", "object": {"text": "of all steps involving the purchase of imported medicines", "keywords": [{"text": "medicines"}, {"text": "steps"}, {"text": "purchase"}]}, "action": {"verb": {"text": "take", "tense": "future"}, "text": "to take", "normalized": "to take"}}, {"subject": {"text": "the purchase of imported medicines", "keywords": [{"text": "medicines"}, {"text": "purchase"}]}, "sentence": " It has a potent structure with global access and expertise to take care of all steps involving the purchase of imported medicines, monitoring from the request to the delivery in the hands of the patient.About SIN Solution (www.sinsolution.com)SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America.", "object": {"text": "all steps", "keywords": [{"text": "steps"}]}, "action": {"verb": {"text": "involve", "tense": "present"}, "text": "involving", "normalized": "involve"}}, {"subject": {"text": "a Brasil based company", "keywords": [{"text": "Brasil based company"}], "entities": [{"type": "Location", "text": "Brasil", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " It has a potent structure with global access and expertise to take care of all steps involving the purchase of imported medicines, monitoring from the request to the delivery in the hands of the patient.About SIN Solution (www.sinsolution.com)SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America.", "object": {"text": "in the market-access, sale and distribution services of health care products in Brasil and across Latin America", "keywords": [{"text": "health care products"}, {"text": "distribution services"}, {"text": "Latin America"}, {"text": "Brasil"}], "entities": [{"type": "Location", "text": "MedDepot Brasil", "disambiguation": {"subtype": ["City"]}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "specialise", "tense": "past"}, "text": "specialised", "normalized": "specialise"}}, {"subject": {"text": "It"}, "sentence": " It has access to more than 350,000 health professionals and over 200,000 direct patient contacts in the region.", "object": {"text": "access to more than 350,000 health professionals and over 200,000 direct patient contacts in the region", "keywords": [{"text": "direct patient contacts"}, {"text": "health professionals"}, {"text": "access"}, {"text": "region"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "SIN Solution", "keywords": [{"text": "SIN Solution"}], "entities": [{"type": "Company", "text": "SIN Solution"}]}, "sentence": " SIN Solution has an extensive commercial network, working with a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries including global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brasil and Danone.Forward Looking statements This announcement contains forward-looking statements with respect to Creso, and their respective operations, strategy, investments, financial performance and condition.", "object": {"text": "an extensive commercial network, working with a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries including global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma", "keywords": [{"text": "high-profile commercial partners"}, {"text": "global medical device"}, {"text": "extensive commercial network"}, {"text": "various consumer goods"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "GSK"}, {"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Novartis", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Galderma", "disambiguation": {"subtype": [], "name": "Galderma", "dbpedia_resource": "http://dbpedia.org/resource/Galderma"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache", "keywords": [{"text": "global medical device"}, {"text": "various consumer goods"}, {"text": "Galderma"}, {"text": "GSK"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "GSK"}, {"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Novartis", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Galderma", "disambiguation": {"subtype": [], "name": "Galderma", "dbpedia_resource": "http://dbpedia.org/resource/Galderma"}}]}, "sentence": " SIN Solution has an extensive commercial network, working with a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries including global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brasil and Danone.Forward Looking statements This announcement contains forward-looking statements with respect to Creso, and their respective operations, strategy, investments, financial performance and condition.", "object": {"text": "a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries", "keywords": [{"text": "high-profile commercial partners"}, {"text": "food manufacturing"}, {"text": "pharmaceutical industries"}, {"text": "number"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "high-profile commercial partners across the food manufacturing and pharmaceutical industries including global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache", "keywords": [{"text": "high-profile commercial partners"}, {"text": "global medical device"}, {"text": "various consumer goods"}, {"text": "food manufacturing"}], "entities": [{"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "GSK"}, {"type": "Person", "text": "Takeda"}, {"type": "Company", "text": "Novartis", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Galderma", "disambiguation": {"subtype": [], "name": "Galderma", "dbpedia_resource": "http://dbpedia.org/resource/Galderma"}}]}, "sentence": " SIN Solution has an extensive commercial network, working with a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries including global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brasil and Danone.Forward Looking statements This announcement contains forward-looking statements with respect to Creso, and their respective operations, strategy, investments, financial performance and condition.", "object": {"text": "Brasil", "keywords": [{"text": "Brasil"}], "entities": [{"type": "Company", "text": "MedDepot Brasil"}]}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "do", "normalized": "do"}}, {"subject": {"text": "Brasil and Danone.Forward Looking statements This announcement", "keywords": [{"text": "Danone.Forward Looking statements"}, {"text": "Brasil"}, {"text": "announcement"}], "entities": [{"type": "Company", "text": "MedDepot Brasil"}]}, "sentence": " SIN Solution has an extensive commercial network, working with a number of high-profile commercial partners across the food manufacturing and pharmaceutical industries including global medical device, pharmaceutical and various consumer goods manufacturers Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brasil and Danone.Forward Looking statements This announcement contains forward-looking statements with respect to Creso, and their respective operations, strategy, investments, financial performance and condition.", "object": {"text": "forward-looking statements with respect to Creso, and their respective operations, strategy, investments, financial performance and condition", "keywords": [{"text": "forward-looking statements"}, {"text": "respective operations"}, {"text": "financial performance"}, {"text": "investments"}], "entities": [{"type": "Person", "text": "Creso"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "contains", "normalized": "contain"}}, {"subject": {"text": "These statements", "keywords": [{"text": "statements"}]}, "sentence": " These statements generally can be identified by use of forward-looking words such as \"may\", \"will\", \"expect\", \"estimate\", \"anticipate\", \"intends\", \"believe\" or \"continue\" or the negative thereof or similar variations.", "object": {"text": "identified by use of forward-looking words such as \"may\"", "keywords": [{"text": "forward-looking words"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "by use of forward-looking words", "keywords": [{"text": "forward-looking words"}]}, "sentence": " These statements generally can be identified by use of forward-looking words such as \"may\", \"will\", \"expect\", \"estimate\", \"anticipate\", \"intends\", \"believe\" or \"continue\" or the negative thereof or similar variations.", "object": {"text": "These statements", "keywords": [{"text": "statements"}]}, "action": {"verb": {"text": "identify", "tense": "future"}, "text": "can be identified", "normalized": "can be identify"}}, {"subject": {"text": "by such statements", "keywords": [{"text": "statements"}]}, "sentence": " The actual results and performance of Creso could differ materially from those expressed or implied by such statements.", "object": {"text": "those"}, "action": {"verb": {"text": "imply", "tense": "past"}, "text": "implied", "normalized": "imply"}}, {"subject": {"text": "Such statements", "keywords": [{"text": "statements"}]}, "sentence": " Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations.", "object": {"text": "qualified in their entirety by the inherent risks and uncertainties surrounding future expectations", "keywords": [{"text": "inherent risks"}, {"text": "future expectations"}, {"text": "entirety"}, {"text": "uncertainties"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Such statements", "keywords": [{"text": "statements"}]}, "sentence": " Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations.", "object": {"text": "in their entirety by the inherent risks and uncertainties surrounding future expectations", "keywords": [{"text": "inherent risks"}, {"text": "future expectations"}, {"text": "entirety"}, {"text": "uncertainties"}]}, "action": {"verb": {"text": "qualify", "tense": "past"}, "text": "are qualified", "normalized": "be qualify"}}, {"subject": {"text": "Some important factors", "keywords": [{"text": "important factors"}]}, "sentence": " Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.", "object": {"text": "actual results to differ materially from expectations", "keywords": [{"text": "actual results"}, {"text": "expectations"}]}, "action": {"verb": {"text": "cause", "tense": "future"}, "text": "could cause", "normalized": "could cause"}}, {"subject": {"text": "general economic and market factors, competition and government regulation", "keywords": [{"text": "market factors"}, {"text": "government regulation"}, {"text": "competition"}]}, "sentence": " Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.", "object": {"text": "Some important factors that could cause actual results to differ materially from expectations", "keywords": [{"text": "actual results"}, {"text": "important factors"}, {"text": "expectations"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}], "concepts": [{"text": "S\u00e3o Paulo", "relevance": 0.949361, "dbpedia_resource": "http://dbpedia.org/resource/S\u00e3o_Paulo"}, {"text": "Medical cannabis", "relevance": 0.759482, "dbpedia_resource": "http://dbpedia.org/resource/Medical_cannabis"}, {"text": "Neuropathic pain", "relevance": 0.729671, "dbpedia_resource": "http://dbpedia.org/resource/Neuropathic_pain"}, {"text": "Brazil", "relevance": 0.67319, "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}, {"text": "Latin America", "relevance": 0.657791, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}, {"text": "Cannabis", "relevance": 0.631837, "dbpedia_resource": "http://dbpedia.org/resource/Cannabis"}, {"text": "Medicine", "relevance": 0.615248, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Rio de Janeiro", "relevance": 0.542587, "dbpedia_resource": "http://dbpedia.org/resource/Rio_de_Janeiro"}, {"text": "Tetrahydrocannabinol", "relevance": 0.536954, "dbpedia_resource": "http://dbpedia.org/resource/Tetrahydrocannabinol"}, {"text": "Chemotherapy", "relevance": 0.508032, "dbpedia_resource": "http://dbpedia.org/resource/Chemotherapy"}], "categories": [{"score": 0.885753, "label": "/health and fitness/disease/chronic pain"}], "relations": [{"type": "employedBy", "sentence": "Creso to launch its first medical cannabis product in Brazil ID: 583389 Creso to launch its first medical cannabis product in Brazil1 November 2018Highlights:- Creso signs an import agreement with MedDepot Brasil for the import and delivery of its first medicinal cannabis product in Brazil- Creso initiates its marketing and sales activities with its Brazilian partner SIN Solution with prescribing physicians- cannaQIX\u00ae50 is Cresos first medicinal cannabis product being made available in Brazil, for the treatment of patients with neuropathic and cancer related painCreso Pharma Limited (ASX:CPH, the Company or Creso) is pleased to announce that it is commenced the importation and sale of its medicinal cannabis product, cannaQIX\u00ae50 to patients in Brazil through its importation representative partner MedDepot Brasil.", "score": 0.762517, "arguments": [{"text": "partner", "location": [362, 369], "entities": [{"type": "Person", "text": "SIN Solution.Cresos Co-founder"}]}, {"text": "Brazilian", "location": [352, 361], "entities": [{"type": "GeopoliticalEntity", "text": "Brazilian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.879785, "arguments": [{"text": "San Paulo", "location": [1249, 1258], "entities": [{"type": "GeopoliticalEntity", "text": "San Paulo"}]}, {"text": "Brazil", "location": [1260, 1266], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil.For"}]}]}, {"type": "basedIn", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.908333, "arguments": [{"text": "group", "location": [1321, 1326], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}, {"text": "North American", "location": [1306, 1320], "entities": [{"type": "GeopoliticalEntity", "text": "North American"}]}]}, {"type": "basedIn", "sentence": "About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines.", "score": 0.953007, "arguments": [{"text": "group", "location": [6396, 6401], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}, {"text": "North American", "location": [6381, 6395], "entities": [{"type": "GeopoliticalEntity", "text": "North American"}]}]}, {"type": "basedIn", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.452349, "arguments": [{"text": "group", "location": [1321, 1326], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}, {"text": "headquarters", "location": [1332, 1344], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "basedIn", "sentence": "About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines.", "score": 0.367274, "arguments": [{"text": "group", "location": [6396, 6401], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}, {"text": "headquarters", "location": [6407, 6419], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "locatedAt", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.970479, "arguments": [{"text": "headquarters", "location": [1332, 1344], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "Miami", "location": [1348, 1353], "entities": [{"type": "GeopoliticalEntity", "text": "Miami"}]}]}, {"type": "locatedAt", "sentence": "About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines.", "score": 0.959579, "arguments": [{"text": "headquarters", "location": [6407, 6419], "entities": [{"type": "Facility", "text": "headquarters"}]}, {"text": "Miami", "location": [6423, 6428], "entities": [{"type": "GeopoliticalEntity", "text": "Miami"}]}]}, {"type": "managerOf", "sentence": "MedDepot Brazil specializes in the importation of medicines that are not commercialized in Brazil, facilitating patient access to imported medicines at all stages in the process, from monitoring the initial request to the ultimate delivery in the hands of the patient.", "score": 0.719954, "arguments": [{"text": "MedDepot", "location": [1419, 1427], "entities": [{"type": "Person", "text": "years.MedDepot Brasil"}]}, {"text": "Brazil", "location": [1428, 1434], "entities": [{"type": "GeopoliticalEntity", "text": "Brazilian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "With its existing relationships with patients, doctors, clinics, hospitals, insurers, pharmacies, distributors, clinical research laboratories and government agencies within Brazil and its knowledge and experience with the relevant laws and regulations in-country, MedDepot Brasil is an ideal strategic partner for Cresos entry into the Brazilian market.", "score": 0.966431, "arguments": [{"text": "agencies", "location": [1845, 1853], "entities": [{"type": "Organization", "text": "agencies", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "government", "location": [1834, 1844], "entities": [{"type": "GeopoliticalEntity", "text": "Brazilian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "With its existing relationships with patients, doctors, clinics, hospitals, insurers, pharmacies, distributors, clinical research laboratories and government agencies within Brazil and its knowledge and experience with the relevant laws and regulations in-country, MedDepot Brasil is an ideal strategic partner for Cresos entry into the Brazilian market.", "score": 0.829538, "arguments": [{"text": "partner", "location": [1990, 1997], "entities": [{"type": "Person", "text": "years.MedDepot Brasil"}]}, {"text": "Cresos", "location": [2002, 2008], "entities": [{"type": "Organization", "text": "Cresos", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "About Med Depot Brasil (www.meddepotbrasil.com)Med Depot Brasil is a Brasil based company associated with the SR Group, a North American group with headquarters in Miami and strong performance in the global distribution of medicines.", "score": 0.332158, "arguments": [{"text": "Brasil", "location": [6328, 6334], "entities": [{"type": "Person", "text": "years.MedDepot Brasil"}]}, {"text": "company", "location": [6341, 6348], "entities": [{"type": "Organization", "text": "Cresos", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "About SIN Solution (www.sinsolution.com)SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America.", "score": 0.600491, "arguments": [{"text": "Brasil", "location": [6788, 6794], "entities": [{"type": "Person", "text": "years.MedDepot Brasil"}]}, {"text": "company", "location": [6801, 6808], "entities": [{"type": "Organization", "text": "Cresos", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Sales and marketing efforts in Brazil will be supported by Cresos established partnership with SIN Solution, who will engage in the sales and marketing of Cresos products through its well established Call Center Service.", "score": 0.721117, "arguments": [{"text": "Call Center Service", "location": [2242, 2261], "entities": [{"type": "Organization", "text": "Call Center Service"}]}, {"text": "its", "location": [2221, 2224], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}]}, {"type": "basedIn", "sentence": "SIN Solution is a Brazil based company that specialised in the market-access sales, doctors and patients support for health care products in Brazil and across Latin America.", "score": 0.953456, "arguments": [{"text": "company", "location": [2294, 2301], "entities": [{"type": "Organization", "text": "pharmacies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Brazil", "location": [2281, 2287], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil.For"}]}]}, {"type": "partOfMany", "sentence": "In addition SIN Solution works with a number of high-profile commercial partners in Brazil and beyond, including Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brazil and Danone.The first focus of its marketing, sales and patient support activities will be in the big agglomerations of Sao Paulo, Rio de Janeiro, Curitiba (Parana) with a total population of over 22 million people.", "score": 0.374847, "arguments": [{"text": "SIN Solution", "location": [2538, 2550], "entities": [{"type": "Person", "text": "SIN Solution.Cresos Co-founder"}]}, {"text": "partners", "location": [2598, 2606], "entities": [{"type": "Person", "text": "partners"}]}]}, {"type": "hasAttribute", "sentence": "Creso to launch its first medical cannabis product in Brazil ID: 583389 Creso to launch its first medical cannabis product in Brazil1 November 2018Highlights:- Creso signs an import agreement with MedDepot Brasil for the import and delivery of its first medicinal cannabis product in Brazil- Creso initiates its marketing and sales activities with its Brazilian partner SIN Solution with prescribing physicians- cannaQIX\u00ae50 is Cresos first medicinal cannabis product being made available in Brazil, for the treatment of patients with neuropathic and cancer related painCreso Pharma Limited (ASX:CPH, the Company or Creso) is pleased to announce that it is commenced the importation and sale of its medicinal cannabis product, cannaQIX\u00ae50 to patients in Brazil through its importation representative partner MedDepot Brasil.", "score": 0.913587, "arguments": [{"text": "patients", "location": [520, 528], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "neuropathic", "location": [534, 545], "entities": [{"type": "HealthCondition", "text": "neuropathic pain"}]}]}, {"type": "locatedAt", "sentence": "In addition SIN Solution works with a number of high-profile commercial partners in Brazil and beyond, including Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brazil and Danone.The first focus of its marketing, sales and patient support activities will be in the big agglomerations of Sao Paulo, Rio de Janeiro, Curitiba (Parana) with a total population of over 22 million people.", "score": 0.960441, "arguments": [{"text": "Sao Paulo", "location": [2835, 2844], "entities": [{"type": "GeopoliticalEntity", "text": "Sao Paulo"}]}, {"text": "Rio de Janeiro", "location": [2846, 2860], "entities": [{"type": "GeopoliticalEntity", "text": "Rio de Janeiro"}]}]}, {"type": "locatedAt", "sentence": "In addition SIN Solution works with a number of high-profile commercial partners in Brazil and beyond, including Johnson & Johnson, GSK, Takeda, Shire, Novartis and Galderma, Ache do Brazil and Danone.The first focus of its marketing, sales and patient support activities will be in the big agglomerations of Sao Paulo, Rio de Janeiro, Curitiba (Parana) with a total population of over 22 million people.", "score": 0.518204, "arguments": [{"text": "Curitiba", "location": [2862, 2870], "entities": [{"type": "GeopoliticalEntity", "text": "Curitiba"}]}, {"text": "Parana", "location": [2872, 2878], "entities": [{"type": "GeopoliticalEntity", "text": "Parana"}]}]}, {"type": "agentOf", "sentence": "Main addressees are doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution is in a good position to provide the marketing / sales services combined with the needed doctors and patients support in this new evolving area says Sergio Rigueto Director Partner of SIN Solution.", "score": 0.677898, "arguments": [{"text": "Sergio Rigueto", "location": [3193, 3207], "entities": [{"type": "Person", "text": "Sergio Rigueto"}]}, {"text": "says", "location": [3188, 3192], "entities": [{"type": "EventCommunication", "text": "says"}]}]}, {"type": "colleague", "sentence": "Main addressees are doctors in oncology and neurology and an expected number of patients over 50000.SIN Solution is in a good position to provide the marketing / sales services combined with the needed doctors and patients support in this new evolving area says Sergio Rigueto Director Partner of SIN Solution.", "score": 0.239357, "arguments": [{"text": "Director Partner", "location": [3208, 3224], "entities": [{"type": "Person", "text": "Sergio Rigueto"}]}, {"text": "SIN Solution", "location": [3228, 3240], "entities": [{"type": "Person", "text": "SIN Solution.Cresos Co-founder"}]}]}, {"type": "agentOf", "sentence": "The Marketing and Sales services combined with doctors and patients support which SIN Solution can provide are very innovative and provide an added value to all stakeholders involved says Alessandra Cesar Director Partner of SIN Solution.Cresos Co-founder and CEO Dr. Miri Halperin Wernli, said: We are very excited about the launch of our first medicinal cannabis product in Brazil through our partnerships with MedDepot Brasil and SIN Solution.", "score": 0.481614, "arguments": [{"text": "stakeholders", "location": [3403, 3415], "entities": [{"type": "Person", "text": "stakeholders"}]}, {"text": "says", "location": [3425, 3429], "entities": [{"type": "EventCommunication", "text": "says"}]}]}, {"type": "agentOf", "sentence": "The Marketing and Sales services combined with doctors and patients support which SIN Solution can provide are very innovative and provide an added value to all stakeholders involved says Alessandra Cesar Director Partner of SIN Solution.Cresos Co-founder and CEO Dr. Miri Halperin Wernli, said: We are very excited about the launch of our first medicinal cannabis product in Brazil through our partnerships with MedDepot Brasil and SIN Solution.", "score": 0.902434, "arguments": [{"text": "Miri Halperin Wernli", "location": [3510, 3530], "entities": [{"type": "Person", "text": "Miri Halperin Wernli"}]}, {"text": "said", "location": [3532, 3536], "entities": [{"type": "EventCommunication", "text": "says"}]}]}, {"type": "locatedAt", "sentence": "The LatAm market is key for Creso, and a successful launch of its products in Brazil will put the Company in a prime position to expand its products to surrounding LatAm countries.", "score": 0.465472, "arguments": [{"text": "its", "location": [4008, 4011], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}, {"text": "Brazil", "location": [4024, 4030], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil.For"}]}]}, {"type": "hasAttribute", "sentence": "About cannaQIX\u00ae 50cannaQIX\u00ae50 is Cresos proprietary buccally formulated cannabidiol (CBD) lozenge which is designed to support the management of chronic pain.", "score": 0.733295, "arguments": [{"text": "cannaQIX\u00ae 50cannaQIX\u00ae", "location": [4132, 4153], "entities": [{"type": "Person", "text": "cannaQIX\u00ae 50cannaQIX\u00ae"}]}, {"text": "chronic pain", "location": [4271, 4283], "entities": [{"type": "HealthCondition", "text": "chronic pain"}]}]}, {"type": "employedBy", "sentence": "The cannaQIX\u00ae range has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Cresos partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality with a Swiss Made label.", "score": 0.737548, "arguments": [{"text": "partner", "location": [5361, 5368], "entities": [{"type": "Person", "text": "partner"}]}, {"text": "Cresos", "location": [5354, 5360], "entities": [{"type": "Organization", "text": "Cresos", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "The cannaQIX\u00ae range has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Cresos partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality with a Swiss Made label.", "score": 0.356287, "arguments": [{"text": "Aufdermaur AG", "location": [5435, 5448], "entities": [{"type": "Person", "text": "Aufdermaur AG"}]}, {"text": "Domaco", "location": [5450, 5456], "entities": [{"type": "Organization", "text": "Domaco"}]}]}, {"type": "hasAttribute", "sentence": "Creso to launch its first medical cannabis product in Brazil ID: 583389 Creso to launch its first medical cannabis product in Brazil1 November 2018Highlights:- Creso signs an import agreement with MedDepot Brasil for the import and delivery of its first medicinal cannabis product in Brazil- Creso initiates its marketing and sales activities with its Brazilian partner SIN Solution with prescribing physicians- cannaQIX\u00ae50 is Cresos first medicinal cannabis product being made available in Brazil, for the treatment of patients with neuropathic and cancer related painCreso Pharma Limited (ASX:CPH, the Company or Creso) is pleased to announce that it is commenced the importation and sale of its medicinal cannabis product, cannaQIX\u00ae50 to patients in Brazil through its importation representative partner MedDepot Brasil.", "score": 0.772973, "arguments": [{"text": "patients", "location": [520, 528], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer", "location": [550, 556], "entities": [{"type": "HealthCondition", "text": "cancer"}]}]}, {"type": "locatedAt", "sentence": "It is based in Sao Paulo, Brasil.", "score": 0.395328, "arguments": [{"text": "Brasil", "location": [6519, 6525], "entities": [{"type": "Person", "text": "years.MedDepot Brasil"}]}, {"text": "Sao Paulo", "location": [6508, 6517], "entities": [{"type": "GeopoliticalEntity", "text": "Sao Paulo"}]}]}, {"type": "employedBy", "sentence": "About SIN Solution (www.sinsolution.com)SIN Solution is a Brasil based company that specialised in the market-access, sale and distribution services of health care products in Brasil and across Latin America.", "score": 0.291738, "arguments": [{"text": "SIN Solution", "location": [6770, 6782], "entities": [{"type": "Person", "text": "SIN Solution.Cresos Co-founder"}]}, {"text": "company", "location": [6801, 6808], "entities": [{"type": "Organization", "text": "Cresos", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Creso to launch its first medical cannabis product in Brazil ID: 583389 Creso to launch its first medical cannabis product in Brazil1 November 2018Highlights:- Creso signs an import agreement with MedDepot Brasil for the import and delivery of its first medicinal cannabis product in Brazil- Creso initiates its marketing and sales activities with its Brazilian partner SIN Solution with prescribing physicians- cannaQIX\u00ae50 is Cresos first medicinal cannabis product being made available in Brazil, for the treatment of patients with neuropathic and cancer related painCreso Pharma Limited (ASX:CPH, the Company or Creso) is pleased to announce that it is commenced the importation and sale of its medicinal cannabis product, cannaQIX\u00ae50 to patients in Brazil through its importation representative partner MedDepot Brasil.", "score": 0.631737, "arguments": [{"text": "patients", "location": [741, 749], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "Brazil", "location": [753, 759], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil.For"}]}]}, {"type": "employedBy", "sentence": "Creso to launch its first medical cannabis product in Brazil ID: 583389 Creso to launch its first medical cannabis product in Brazil1 November 2018Highlights:- Creso signs an import agreement with MedDepot Brasil for the import and delivery of its first medicinal cannabis product in Brazil- Creso initiates its marketing and sales activities with its Brazilian partner SIN Solution with prescribing physicians- cannaQIX\u00ae50 is Cresos first medicinal cannabis product being made available in Brazil, for the treatment of patients with neuropathic and cancer related painCreso Pharma Limited (ASX:CPH, the Company or Creso) is pleased to announce that it is commenced the importation and sale of its medicinal cannabis product, cannaQIX\u00ae50 to patients in Brazil through its importation representative partner MedDepot Brasil.", "score": 0.549707, "arguments": [{"text": "representative partner", "location": [784, 806], "entities": [{"type": "Person", "text": "years.MedDepot Brasil"}]}, {"text": "its", "location": [768, 771], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}]}, {"type": "hasAttribute", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.722147, "arguments": [{"text": "patients", "location": [853, 861], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "chronic pain", "location": [877, 889], "entities": [{"type": "HealthCondition", "text": "chronic pain"}]}]}, {"type": "hasAttribute", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.715032, "arguments": [{"text": "patients", "location": [853, 861], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "cancer diseases", "location": [953, 968], "entities": [{"type": "HealthCondition", "text": "cancer diseases"}]}]}, {"type": "partOf", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.939401, "arguments": [{"text": "company", "location": [1232, 1239], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}, {"text": "Brazilian", "location": [1222, 1231], "entities": [{"type": "GeopoliticalEntity", "text": "Brazilian", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "cannaQIX 50\u00ae is designed for patients suffering from chronic pain and in particular with chronic pain related to neuropathic and cancer diseases and is classified as medicinal cannabis under medical prescription in Brazil.For this purpose Creso signed an importation and direct to patient delivery agreement with MedDepot Brasil, with a contracted term of 3 years.MedDepot Brasil is an established Brazilian company based in San Paulo, Brazil and is associated with the SR Group, a North American group with headquarters in Miami with strong performance in the global distribution of medicines.", "score": 0.46323, "arguments": [{"text": "company", "location": [1232, 1239], "entities": [{"type": "Organization", "text": "www.cresopharma.com"}]}, {"text": "San Paulo", "location": [1249, 1258], "entities": [{"type": "GeopoliticalEntity", "text": "San Paulo"}]}]}], "keywords": [{"text": "SIN Solution", "sentiment": {"score": 0.576237, "label": "positive"}, "relevance": 0.924903}, {"text": "medicinal cannabis product", "sentiment": {"score": 0.616081, "label": "positive"}, "relevance": 0.816197}, {"text": "MedDepot Brasil", "sentiment": {"score": 0.566997, "label": "positive"}, "relevance": 0.759076}, {"text": "Brasil based company", "sentiment": {"score": 0.391839, "label": "positive"}, "relevance": 0.62852}, {"text": "medical cannabis product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.619336}, {"text": "Med Depot Brasil", "sentiment": {"score": 0.373237, "label": "positive"}, "relevance": 0.58751}, {"text": "North American group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563611}, {"text": "partner SIN Solution", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.55954}, {"text": "health care products", "sentiment": {"score": 0.454725, "label": "positive"}, "relevance": 0.556738}, {"text": "high-profile commercial partners", "sentiment": {"score": 0.59205, "label": "positive"}, "relevance": 0.552517}, {"text": "Brazil", "sentiment": {"score": 0.213614, "label": "positive"}, "relevance": 0.549568}, {"text": "Brazil based company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533427}, {"text": "addition SIN Solution", "sentiment": {"score": 0.59205, "label": "positive"}, "relevance": 0.523916}, {"text": "Brazil- Creso", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.500313}, {"text": "SIN Solution.Cresos Co-founder", "sentiment": {"score": 0.675935, "label": "positive"}, "relevance": 0.494456}, {"text": "years.MedDepot Brasil", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.487952}, {"text": "partner MedDepot Brasil.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.468977}, {"text": "patient delivery agreement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.462146}, {"text": "painCreso Pharma Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.461101}, {"text": "Brazil ID", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.459624}, {"text": "pharma development company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.45142}, {"text": "patient support activities", "sentiment": {"score": 0.298346, "label": "positive"}, "relevance": 0.449175}, {"text": "ideal strategic partner", "sentiment": {"score": 0.517912, "label": "positive"}, "relevance": 0.446871}, {"text": "CPH ASX Release", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.442312}, {"text": "global distribution", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.441711}, {"text": "SR Group", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.441123}, {"text": "Rigueto Director Partner", "sentiment": {"score": 0.909335, "label": "positive"}, "relevance": 0.439624}, {"text": "proprietary delivery formulation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.439386}, {"text": "Sao Paulo", "sentiment": {"score": 0.298346, "label": "positive"}, "relevance": 0.438196}, {"text": "life style products", "sentiment": {"score": 0.535113, "label": "positive"}, "relevance": 0.438114}, {"text": "Cesar Director Partner", "sentiment": {"score": 0.675935, "label": "positive"}, "relevance": 0.437993}, {"text": "clinical research laboratories", "sentiment": {"score": 0.55306, "label": "positive"}, "relevance": 0.437521}, {"text": "Latin America", "sentiment": {"score": 0.454725, "label": "positive"}, "relevance": 0.437283}, {"text": "health professionals", "sentiment": {"score": 0.6302, "label": "positive"}, "relevance": 0.436875}, {"text": "strong performance", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.43562}, {"text": "Danone.Forward Looking statements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.435131}, {"text": "Dr. Miri Halperin", "sentiment": {"score": 0.675935, "label": "positive"}, "relevance": 0.434727}, {"text": "forward-looking statements", "sentiment": {"score": -0.461301, "label": "negative"}, "relevance": 0.433758}, {"text": "forward looking statements", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.433401}, {"text": "standardised pharma-grade formulation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.431638}, {"text": "innovative delivery technologies", "sentiment": {"score": 0.373237, "label": "positive"}, "relevance": 0.431634}, {"text": "great unmet need", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.431163}, {"text": "sales services", "sentiment": {"score": 0.792635, "label": "positive"}, "relevance": 0.430366}, {"text": "new evolving area", "sentiment": {"score": 0.909335, "label": "positive"}, "relevance": 0.428796}, {"text": "initial product registrations", "sentiment": {"score": 0.823546, "label": "positive"}, "relevance": 0.428318}, {"text": "Good Manufacturing Practice", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.427942}]}, "extracted_metadata": {"sha1": "377f00bc49c72bb97c790d73e4b214783e789d9f", "filename": "1541098094455.zip-6c4f92a89317ec19af58c011d338b9e9.xml", "file_type": "json"}, "external_links": ["https://www.irw-press.at/prcom/images/messages/2018/45069/181101"], "title": "Creso to launch its first medical cannabis product in Brazil", "forum_title": "firmenpresse"}, {"id": "uPpanPDun2Pca48bQGdm6WAAkmE03TISzHN5rM_AaDg_I20_00sIMwXQnAh08IHD", "result_metadata": {"score": 31.878313}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management UK", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.92115, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.504344, "label": "/finance/investing/brokerages"}, {"score": 0.502277, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.49338, "label": "/finance/bank"}], "relations": [{"type": "agentOf", "sentence": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "score": 0.991221, "arguments": [{"text": "Daiwa Asset Management UK Regulatory", "location": [0, 36], "entities": [{"type": "Organization", "text": "Daiwa Asset Management UK Regulatory", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Announcement", "location": [37, 49], "entities": [{"type": "EventCommunication", "text": "Announcement"}]}]}], "keywords": [{"text": "Daiwa Asset Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.995973}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.917124}, {"text": "UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.834559}]}, "crawl_date": "2018-11-01T15:39:34Z", "url": "https://www.businesswire.com/news/home/20181101005416/en/Daiwa-Asset-Management-UK-Regulatory-Announcement-Form", "host": "businesswire.com", "text": "Ltd.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-01T07:15:00-05:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Co. Ltd", "relevance": 0.728644, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management", "relevance": 0.640588, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiwa Asset Management Europe", "relevance": 0.621995, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.567978, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.546175, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.250646, "label": "positive"}, "text": "Erich Berner", "relevance": 0.529577, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.502283, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.497964, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.491168, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.491168, "type": "Quantity"}], "sentiment": {"document": {"score": -0.261081, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "31 October 2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " 31 October 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages: N/A", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "increasing/reducing a long/short position", "keywords": [{"text": "long/short position"}]}, "sentence": " Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position", "object": {"text": "e.g. opening/closing a long/short position", "keywords": [{"text": "long/short position"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit - - - - - - - - (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit - - - - - (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " None (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020-7597-7056 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "020-7597-7056 Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "*If the discloser", "keywords": [{"text": "discloser"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "a natural person", "keywords": [{"text": "natural person"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a natural person, a telephone number", "keywords": [{"text": "natural person"}, {"text": "telephone number"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "provided to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "provided contact information", "keywords": [{"text": "contact information"}]}, "sentence": " *If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel\u2019s Market Surveillance Unit.", "object": {"text": "to the Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "has been provided", "normalized": "have be provide"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 658589 Time of Receipt (offset from UTC): 20181101T065456+0000 Contacts Daiwa Asset Management", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.982887, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Offer and acceptance", "relevance": 0.518262, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Call option", "relevance": 0.517903, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.500202, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Contract", "relevance": 0.462804, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.420378, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Grammatical number", "relevance": 0.411862, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Bond", "relevance": 0.404602, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.389992, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Option contract", "relevance": 0.385301, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Balance sheet", "relevance": 0.382526, "dbpedia_resource": "http://dbpedia.org/resource/Balance_sheet"}, {"text": "Security", "relevance": 0.379966, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Stock", "relevance": 0.373176, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.358464, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Uniform Commercial Code", "relevance": 0.356757, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Legal person", "relevance": 0.355287, "dbpedia_resource": "http://dbpedia.org/resource/Legal_person"}], "categories": [{"score": 0.698236, "label": "/real estate/buying and selling homes"}, {"score": 0.491522, "label": "/finance/financial news"}, {"score": 0.308958, "label": "/finance/investing/day trading"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "basedIn", "sentence": "Short Name: Daiwa Asset Management Category Code: RET Sequence Number: 658589 Time of Receipt (offset from UTC): 20181101T065456+0000 Contacts Daiwa Asset Management", "score": 0.434823, "arguments": [{"text": "UTC", "location": [5887, 5890], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [5866, 5873], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}, {"type": "managerOf", "sentence": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Company Limited (the Offeror) (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 31 October 2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "score": 0.463222, "arguments": [{"text": "manager", "location": [700, 707], "entities": [{"type": "Person", "text": "manager"}]}, {"text": "Takeda Pharmaceutical Company Limited", "location": [626, 663], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "(a) Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit ORD Sale 2,000 4473 JPY ORD Purchase 6,000 4473 JPY ORD Purchase 2,000 4570.8683 JPY ORD Purchase 1,300 4572.2858 JPY ORD Sale 30,000 4494.9456 JPY ORD Purchase 6,600 4523.14 JPY (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit - - - - - (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American,", "score": 0.787954, "arguments": [{"text": "i", "location": [3369, 3370], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3372, 3379], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "European etc. Expiry date Option money paid/ received per unit - - - - - - - - (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit - - - - - (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) - - - - 4.", "score": 0.591687, "arguments": [{"text": "Price", "location": [3995, 4000], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [4005, 4009], "entities": [{"type": "Organization", "text": "ORD Sale"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4377, 4383], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4394, 4401], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 1 November 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.545365, "arguments": [{"text": "Erich Berner", "location": [5212, 5224], "entities": [{"type": "Person", "text": "Erich Berner"}]}, {"text": "Daiwa Asset Management Europe", "location": [5226, 5255], "entities": [{"type": "Organization", "text": "Daiwa Asset Management Europe", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 1 November 2018 Contact name: Erich Berner (Daiwa Asset Management Europe) Telephone number*: 020-7597-7056 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.842228, "arguments": [{"text": "Rule 8", "location": [5315, 5321], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5329, 5333], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5396, 5420], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5388, 5393], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.", "score": 0.83842, "arguments": [{"text": "Market Surveillance Unit", "location": [5675, 5699], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5667, 5672], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5731, 5736], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5750, 5777], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "relevant securities", "sentiment": {"score": 0.229926, "label": "positive"}, "relevance": 0.990942}, {"text": "relevant security", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.879326}, {"text": "Daiwa Asset Management", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.791911}, {"text": "JPY ORD Purchase", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.770349}, {"text": "security Product description", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.714215}, {"text": "relevant security Product", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.708778}, {"text": "short positions", "sentiment": {"score": -0.356746, "label": "negative"}, "relevance": 0.643673}, {"text": "Product description e.g.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.600309}, {"text": "Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.578914}, {"text": "JPY ORD Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.575924}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563731}, {"text": "reference securities Price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.553836}, {"text": "new securities", "sentiment": {"score": 0.582177, "label": "positive"}, "relevance": 0.553372}, {"text": "securities Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547932}, {"text": "unit ORD Sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.546923}, {"text": "Short positions Number", "sentiment": {"score": -0.245708, "label": "negative"}, "relevance": 0.538828}, {"text": "relevant security Purchase/sale", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537068}, {"text": "stock-settled derivative positions", "sentiment": {"score": -0.27481, "label": "negative"}, "relevance": 0.532832}, {"text": "relevant security Nature", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530841}, {"text": "class", "sentiment": {"score": -0.251285, "label": "negative"}, "relevance": 0.529011}, {"text": "Asset Management Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527825}, {"text": "PUBLIC OPENING POSITION", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524785}, {"text": "additional class", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521718}, {"text": "Open Positions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521525}, {"text": "derivative transactions", "sentiment": {"score": -0.408268, "label": "negative"}, "relevance": 0.519272}, {"text": "Takeda Pharmaceutical Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519003}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518807}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518728}, {"text": "Contacts Daiwa Asset", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515733}, {"text": "possible cash offer", "sentiment": {"score": 0.408748, "label": "positive"}, "relevance": 0.514396}, {"text": "Supplemental Form", "sentiment": {"score": 0.425721, "label": "positive"}, "relevance": 0.513258}, {"text": "Expiry date Option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51175}, {"text": "Cash-settled derivative transactions", "sentiment": {"score": -0.403941, "label": "negative"}, "relevance": 0.511423}, {"text": "Stock-settled derivative transactions", "sentiment": {"score": -0.412596, "label": "negative"}, "relevance": 0.510656}, {"text": "e.g. call option", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509728}, {"text": "unit Type e.g", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508102}, {"text": "RET Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.505831}, {"text": "Asset Management Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.504896}, {"text": "Regulatory Information Service", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.504201}, {"text": "Product description e.g", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.50307}, {"text": "long/short position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.502749}, {"text": "Management Category Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.502677}, {"text": "Panel\u2019s Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496265}, {"text": "person", "sentiment": {"score": 0.217529, "label": "positive"}, "relevance": 0.495224}, {"text": "voting rights", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.493604}, {"text": "Nil", "sentiment": {"score": -0.611983, "label": "negative"}, "relevance": 0.487874}, {"text": "N/A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.485154}, {"text": "relevant percentages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.482627}, {"text": "LONDON-\nFORM", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.474499}, {"text": "Takeover Code", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.473573}]}, "extracted_metadata": {"sha1": "c59e31393bc3e7876c9903f08fc51b1186f46af8", "filename": "1541086774941.zip-259a8ce5ac7a44a327726d50b051caa3.xml", "file_type": "json"}, "title": "Daiwa Asset Management UK Regulatory Announcement: Form 8.3 - Takeda Pharmaceutical Company Limited", "forum_title": "All News | Business Wire"}]}